nct_id,phase,completion_date,limitations_and_caveats,why_stopped,result_group_id,#AE_probability,#AE_Subjects,#Total_Subjects,time_frame,AEdescription,Treatment,Treatment_description
NCT00001962,Phase 2,9/1/10,NA,DSMB recommended closing the study and publishing the results,577971,0.09,9,100,NA,NA,Daclizumab Hematologic Response,"daclizumab, 1 mg/kg of body weight, will be given for a total of 5 intravenous infusions. The subjects diagnosed with moderate aplastic anemia, pure red cell aplasia, Diamond Blackfan anemia, relapse and refractory severe aplastic anemia will receive treatment. The subjects will be seen and receive the daclizumab infusion biweekly during the treatment period. The Diamond Blackfan anemia arm was closed due to lack of accrual."
NCT00003910,Phase 2,3/1/12,NA,NA,577603,0.5,8,16,Assessed every 30 days while on treatment and for 30 days after the end of treatment.,"Here we look at all patients, all 59, whereas we excluded the ineligible patients from the baseline tables etc (n=55) as is standard to do in our final reports for ECOG.",Cyclophosphamide,step 2 patients who received CY
NCT00003910,Phase 2,3/1/12,NA,NA,577604,0.949152542,56,59,Assessed every 30 days while on treatment and for 30 days after the end of treatment.,"Here we look at all patients, all 59, whereas we excluded the ineligible patients from the baseline tables etc (n=55) as is standard to do in our final reports for ECOG.",Methotrexate,MTX given orally at 10 mg/m2 in divided doses once weekly. Prednisone was given orally at 1 mg/kg per day for 30 days and then tapered off in the subsequent 24 days. Patients not responding to MTX after 4 months received Cy orally at 100 mg daily in step two with the same prednisone schedule.
NCT00012298,Phase 1/Phase 2,4/1/10,NA,Trial completed prematurely.,576729,0.363636364,4,11,NA,NA,"Treatment: Trial 1, Dose Level 1",0.2 mCi/kg Yttrium (Y-90 ibritumomab tiuxetan (IDEC-90Y2B8) IV over 10 minutes on day 8
NCT00012298,Phase 1/Phase 2,4/1/10,NA,Trial completed prematurely.,576724,0.166666667,1,6,NA,NA,"Treatment: Trial 3, Dose Level 6","50 micrograms/kg Interleukin-11 SC when PLT counts less than 150,000."
NCT00012298,Phase 1/Phase 2,4/1/10,NA,Trial completed prematurely.,576728,0.714285714,5,7,NA,NA,"Treatment: Trial 1, Dose Level 2",0.3 mCi/kg Yttrium (Y-90 ibritumomab tiuxetan (IDEC-90Y2B8) IV over 10 minutes on day 8
NCT00012298,Phase 1/Phase 2,4/1/10,NA,Trial completed prematurely.,576723,0.153846154,6,39,NA,NA,Treatment : Phase II (Dose Level 6),"50 micrograms/kg Interleukin-11 SC when PLT counts less than 150,000."
NCT00012298,Phase 1/Phase 2,4/1/10,NA,Trial completed prematurely.,576726,0.5,2,4,NA,NA,"Treatment: Trial 2, Dose Level 4","50 micrograms/kg Interleukin-11 SC when PLT counts less than 75,000."
NCT00012298,Phase 1/Phase 2,4/1/10,NA,Trial completed prematurely.,576727,0.444444444,4,9,NA,NA,"Treatment: Trial 2, Dose Level 3","50 micrograms/kg Interleukin-11 SC when PLT counts less than 75,000."
NCT00012298,Phase 1/Phase 2,4/1/10,NA,Trial completed prematurely.,576725,0.2,1,5,NA,NA,"Treatment: Trial 3, Dose Level 5","50 micrograms/kg Interleukin-11 SC when PLT counts less than 150,000."
NCT00015847,Phase 2,5/1/11,Early termination; 12 month follow-up was not carried out.,NA,576639,0.32,8,25,NA,NA,Imatinib Mesylate,Once daily oral administration of STI571 (imatinib mesylate) at a dose of 400 mg or 600mg for 12 months.
NCT00022490,Phase 2,7/1/11,"Study was terminated, therefore the 12 month response data was not analyzed.",NA,576522,0.541666667,13,24,NA,NA,Cytarabine/ Imatinib Mesylate,"Cytarabine: Once daily subcutaneous injection of Ara-C (Cytarabine) at a dose of 20 mg (10 mg or 5 mg if they have been dose reduced) per square meter of calculated body surface area, on days 15-28 of each sequential 28 day cycleImatinib Mesylate: Once daily oral administration of STI571 (Imatinib Mesylate) at a dose of 400 mg for 12 months"
NCT00058214,Phase 2,1/1/09,"Study was terminated early after the first stage of a two-stage design, allowing for early termination for discouraging results.",Did not meet interim stopping criteria for continuation to the second stage.,572329,0.04,1,25,Adverse events were collected over a 60 month period.,Other Adverse Events include all events that were not severe adverse events regardless of grade or relation to treatment.,Treatment (Perifosine),"Patients receive oral perifosine 100 mg once daily on days 1-28. On day 1 of course 1 only, patients receive 2 doses of oral perifosine at 450 mg. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease by PSA alone may receive up to 3 additional courses of therapy after documentation of progression.perifosine: Given orallylaboratory biomarker analysis: Correlative studies"
NCT00069329,Phase 1/Phase 2,4/1/10,Data reported is on 26 patients who completed their 3 year assessment and 20 of these patients also completed their 5 year assessment.,data submitted for Food and Drug Administration (FDA) approval,570983,0.418604651,18,43,NA,NA,NOMID,Patients who met the criteria for NOMID and treated with escalating doses of anakinra 1-5 mg/kg/day to achieve laboratory and organ inflammation remission.
NCT00072189,Phase 2,3/1/10,"Study was terminated early after the first stage of a two-stage design, allowing for early termination for discouraging results",Early termination for discouraging results,570452,0.411764706,7,17,Collected over a period of 24 months.,Other Adverse Events include all events that were not severe adverse events regardless of grade or relation to treatment.,Arm 1,"Patients receive UCN-01 IV at 90 mg/m2 over 3 hours on cycle 1, reduced to 45 mg/m2 over 3 hours for subsequent cycles. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.7-hydroxystaurosporine: Given IVlaboratory biomarker analysis: Correlative studiespharmacological study: Correlative studies"
NCT01365130,Phase 2,8/1/13,NA,As of 12/12/12 study closed to enrollment because study was determined to be ineffective.,149981,0.384615385,5,13,NA,NA,Real Drug,"patients will receive Jevtana 25mg/m2, IV every 21 days until disease progression or unacceptable toxicityjevtana: Cabazitaxel 25mg/m2, IV every 21 days until progression"
NCT00073008,Phase 2,7/1/08,"Based on interim analysis and predefined stopping rules for futility, the study was discontinued due to lack of efficacy. At that time, no additional participants were added; enrolled participants could continue on treatment, following the protocol.","Based on interim analysis at the end of Stage 1, and predefined stopping rules for futility,   further enrollment was stopped due to lack of efficacy",570394,0.257575758,17,66,NA,NA,Lapatinib 500 mg BID,Oral lapatinib 500 mg twice daily (BID)
NCT00076804,Phase 2,9/1/08,"Intervention was stopped at 12 months, transition phase did not ensure that participants developed a set of adherence strategies to replace DOT-ART. Low incidence of AIDS-defining illness and death limit our ability to make final conclusions",DSMB stopped trial for futility,569529,0.138686131,19,137,Adverse Event data was collected throughout the duration of the study. It was assessed at each clinic visit and if the subject presented between visits.,NA,Peer Supporter,Use of a patient nominated peer supporter who sill observe the morning dose of ARVs
NCT00076804,Phase 2,9/1/08,"Intervention was stopped at 12 months, transition phase did not ensure that participants developed a set of adherence strategies to replace DOT-ART. Low incidence of AIDS-defining illness and death limit our ability to make final conclusions",DSMB stopped trial for futility,569528,0.211678832,29,137,Adverse Event data was collected throughout the duration of the study. It was assessed at each clinic visit and if the subject presented between visits.,NA,Self Administration,Self administration of ARVs
NCT00084487,Phase 2,4/1/08,NA,NA,568097,0.35,7,20,"Adverse events were collected while patients were on study, up to four years.",NA,Treatment (Rebeccamycin Analogue),"Patients receive rebeccamycin analogue IV over 1 hour on days 1-5. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.becatecarin : Given IV"
NCT00088881,Phase 2,3/1/11,NA,NA,567176,0.821428571,46,56,Assessed every 3 weeks while on treatment and for 30 days after the end of treatment,NA,Step 2 - Zevalin‰ã¢ Radioimmunotherapy,"Beginning no more than 9 weeks after the last course of R-CHOP, patients receive rituximab IV on day 1 followed by indium In 111 ibritumomab tiuxetan IV over 10 minutes for imaging studies. Patients then receive rituximab IV followed by yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day 8."
NCT00088881,Phase 2,3/1/11,NA,NA,567177,0.709677419,44,62,Assessed every 3 weeks while on treatment and for 30 days after the end of treatment,NA,Step 1 - R-CHOP,"Patients receive R-CHOP every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) after 2 courses receive 2 additional courses. Patients achieving a partial response, uncertain CR, or stable disease receive 4 additional courses. Patients are evaluated 3 weeks after the last course of therapy. Patients with progressive disease go off study."
NCT00089076,Phase 1/Phase 2,10/1/09,NA,NA,567145,0.444444444,8,18,NA,NA,MDX-010,Patients receive anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody (MDX-010) IV over 90 minutes on day 1. Treatment repeats every 28 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity.
NCT00089544,Phase 2,12/1/12,This study closed early due to unacceptably high rate of thromboembolic events in Cohort A and due to low accrual in Cohort B. For this reason efficacy endpoints other than response to pre-operative therapy were not reported.,NA,567006,0.428571429,3,7,NA,"Per the protocol, toxicity data was collected via CTCAE3.0 then mapped to CTCAE 4.0 for reporting on this website. Subjects experiencing more than one of a given SAE are counted only once for that SAE. Subjects experiencing more than one of a given Other (Not Including Serious) AE are counted only once for that Other (Not Including Serious) AE.","Cohort B (Thalidomide, Radiation, Surgery)","Patients receive oral thalidomide once daily beginning on day 1 and continuing until 1 week before surgery. Patients undergo radiotherapy once daily, 5 days a week, on weeks 1-5. Patients undergo surgical resection between days 77 and 91. Beginning 2 weeks after surgery, patients receive oral thalidomide once daily for 6 months in the absence of unacceptable toxicity."
NCT00089544,Phase 2,12/1/12,This study closed early due to unacceptably high rate of thromboembolic events in Cohort A and due to low accrual in Cohort B. For this reason efficacy endpoints other than response to pre-operative therapy were not reported.,NA,567007,0.6,9,15,NA,"Per the protocol, toxicity data was collected via CTCAE3.0 then mapped to CTCAE 4.0 for reporting on this website. Subjects experiencing more than one of a given SAE are counted only once for that SAE. Subjects experiencing more than one of a given Other (Not Including Serious) AE are counted only once for that Other (Not Including Serious) AE.","Cohort A (Chemotherapy, Radiation, Thalidomide, Surgery)","Patients receive doxorubicin, ifosfamide, and dacarbazine IV continuously on days 1-3, 22-24, and 43-45. Patients receive G-CSF subcutaneously beginning on days 4, 25, and 46 and continuing until blood counts recover. Patients undergo radiotherapy once daily on days 7-11, 14-18, 21, 28-32, 35-39, and 42. Patients receive oral thalidomide once daily on days 7-21 and 28-42. Patients undergo surgical resection between days 84 and 98. Beginning 2 weeks after surgery, patients receive oral thalidomide once daily for 12 months in the absence of unacceptable toxicity."
NCT00090779,Phase 2,5/1/11,NA,The DSMB concluded that the findings regarding the primary analysis would persist and that no   additional study goals would be achieved by continuing the study.,566207,0.015151515,1,66,5 years since randomization,NA,IT Arm,IT arm participants received emtricitabine/tenofovir disoproxil fumarate once daily and lopinavir/ritonavir twice daily
NCT00095576,Phase 2,9/1/09,"The DSMB (Data & Safety Monitoring Board) reviewed interim data which demonstrated that the investigational vaccine was not effective, and all vaccinations were halted. Long term follow up was available for participants in V520-030.",NA,563923,0.011371237,17,1495,NA,NA,Placebo,"Participants randomized to receive three 1.0-ml intramuscular (IM) injections of placebo to MRKAd5 HIV-1 gag/pol/nef at Day 1, Week 4, and Week 26."
NCT00095576,Phase 2,9/1/09,"The DSMB (Data & Safety Monitoring Board) reviewed interim data which demonstrated that the investigational vaccine was not effective, and all vaccinations were halted. Long term follow up was available for participants in V520-030.",NA,563924,0.012803235,19,1484,NA,NA,Trivalent MRKAd5 HIV-1 Gag/Pol/Nef,"Participants randomized to receive three 1.0-ml intramuscular (IM) injections of Merck Trivalent Adenovirus Serotype 5 HIV-1 gag/pol/nef (MRKAd5 HIV-1 gag/pol/nef) Vaccine at a dose of 1.5x10^10 adenovirus genomes (Ad vg) per dose at Day 1, Week 4, and Week 26."
NCT00098371,Phase 2,11/1/12,NA,CTEP Initiated Action.,563156,0.0625,4,64,NA,NCI Common Toxicity Criteria of Adverse Events (version 3) and modified NCI Common Toxicity Criteria guidelines for evaluating hematologic toxicity for leukemia was used to grade adverse events for patients. Adverse events are reported across all grades.,Treatment (Alvocidib),"Patients receive flavopiridol IV over 30 minutes followed by a 4-hour infusion on days 1, 8, 15, and 22. Treatment repeats every 42 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving at least a partial remission (PR) and whose PR lasts for > 6 months after completion of treatment may receive 6 additional courses of flavopiridol."
NCT00109772,Phase 2,4/1/08,NA,Interim analysis showed the primary outcome was not reached,559291,0.137931034,12,87,"Day 1 up to week 158, covering both the double-blind treatment and extension periods.","If multiple SAEs were reported within a given preferred term, only one event was counted per subject.",Lenalidomide,10 mg/day lenalidomide orally for up to 12 weeks in the double-blind treatment period. Participants who completed double-blind treatment had the option of continuing on lenalidomide in the open-label extension period for as long as benefit was derived from the drug or until study closure.
NCT00109772,Phase 2,4/1/08,NA,Interim analysis showed the primary outcome was not reached,559290,0.172043011,16,93,"Day 1 up to week 158, covering both the double-blind treatment and extension periods.","If multiple SAEs were reported within a given preferred term, only one event was counted per subject.",Placebo to Lenalidomide,Placebo orally for up to 12 weeks in the double-blind treatment period. Participants who completed double-blind treatment had the option of crossing over to lenalidomide 10mg in the open-label extension period for as long as benefit was derived from the drug or until study closure.
NCT00111917,Phase 1/Phase 2,1/1/09,"Although our goal was 20 CBD subjects, only 11 subjects were enrolled, 8:3 in the infliximab:placebo treatment arms as the study was stopped by the sponsor due to slow recruitment.",Not enough patients meeting criteria to enroll in the time period,558710,0.333333333,1,3,through week 40,adverse events reported through week 40,Group 2 - Placebo,Placebo infusion received
NCT00111917,Phase 1/Phase 2,1/1/09,"Although our goal was 20 CBD subjects, only 11 subjects were enrolled, 8:3 in the infliximab:placebo treatment arms as the study was stopped by the sponsor due to slow recruitment.",Not enough patients meeting criteria to enroll in the time period,558711,0.375,3,8,through week 40,adverse events reported through week 40,Group 1 - Infliximab,Infliximab infusion received
NCT00112905,Phase 2,3/1/08,NA,NA,557944,0.555555556,15,27,Assessed every 8 weeks,NA,TCC Cohort,"Only eligible and treated patients are included in the analysis.BAY 43-9006 was administered at a dose of 400 mg orally twice daily (total daily dose 800 mg) for eight weeks as one cycle. Patients swallowed the tablets whole with approximately 250 ml (8 oz.) of water each morning and evening (i.e., 12-hourly), with or without food. If Bay 43-9006 was taken with meals, patients were instructed to take BAY 43-9006 tosylate with a moderate to low-fat meal, as a high fat meal caused a decrease in absorption in previous studies."
NCT00113022,Phase 2,2/1/07,NA,Terminated due to concerns about adverse events in separate study.,557485,0.2,1,5,NA,NA,Org 24448,"Blinded, active experimental compound. Dosing starts at 250 mg once per day for one week, then 250 mg twice per day for one week, then 500 mg twice per day. After 4 weeks with insufficient response, the dose may be increased to 750 mg twice per day. The titration schedule may be delayed if the subject is experiencing adverse effects. The subject may be increased or decreased at the discretion of the investigator. The minimum dose allowed for the study is 250 mg once per day."
NCT00126568,Phase 2,9/1/11,The study met the pre-specified criteria for enrollment of all planned 32 patients. However due to poor accrual the study was halted.,NA,553895,0.4,8,20,Adverse events were collected weekly for the duration that the patients started on treatment to end of study.,NA,BAY 43-9006,BAY 43-9006 (sorafenib) will be administered on a fixed daily oral dosing schedule of 400 mg twice daily. A cycle of therapy will be considered 28 days (4 weeks / 1 month).
NCT00132002,Phase 2,1/1/08,"Study was terminated early after the first stage of a two-stage design, allowing for early termination for discouraging results",Early termination for discouraging results,551671,0.214285714,3,14,Adverse events occured over a period of 1 year and 7 months.,Other Adverse Events include all events that were not severe adverse events regardless of grade or relation to treatment.,Arm 1,"Vorinostat, 200 mg orally twice daily, was administered for the first 14 days of each 21 day cycle. Treatment was continued unless either disease progression was determined, the patient requested to be withdrawn from the study, or excessive toxicity was noted."
NCT00132730,Phase 2,8/1/05,"The extension studies were terminated based on data from the completed base study suggesting that MK-0873, at doses up to 2.5 mg per day, demonstrated no benefits versus placebo in lung function or symptoms in participants with COPD.",NA,551567,0.05362776,17,317,Up to 14 weeks in the Base Study; up to 14 weeks in study EXT1; up to 80 weeks in study EXT2,NA,MK-0873 2.5 mg EXT 1,Participants receive MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)
NCT00132730,Phase 2,8/1/05,"The extension studies were terminated based on data from the completed base study suggesting that MK-0873, at doses up to 2.5 mg per day, demonstrated no benefits versus placebo in lung function or symptoms in participants with COPD.",NA,551570,0.074324324,11,148,Up to 14 weeks in the Base Study; up to 14 weeks in study EXT1; up to 80 weeks in study EXT2,NA,MK-0873 1.25 mg Base Study,"Participants receive placebo tablets once daily for 3 weeks in Period I (Base), and MK-0873 1.25 mg tablets once daily for 12 weeks in Period II (Base)"
NCT00132730,Phase 2,8/1/05,"The extension studies were terminated based on data from the completed base study suggesting that MK-0873, at doses up to 2.5 mg per day, demonstrated no benefits versus placebo in lung function or symptoms in participants with COPD.",NA,551568,0.039215686,6,153,Up to 14 weeks in the Base Study; up to 14 weeks in study EXT1; up to 80 weeks in study EXT2,NA,Placebo Base Study,"Participants receive placebo tablets once daily for 3 weeks in Period I (Base), placebo tablets once daily for 12 weeks in Period II (Base) and placebo tablets once daily for 12 weeks in Period III (EXT1)"
NCT00132730,Phase 2,8/1/05,"The extension studies were terminated based on data from the completed base study suggesting that MK-0873, at doses up to 2.5 mg per day, demonstrated no benefits versus placebo in lung function or symptoms in participants with COPD.",NA,551571,0.066666667,10,150,Up to 14 weeks in the Base Study; up to 14 weeks in study EXT1; up to 80 weeks in study EXT2,NA,MK-0873 0.75 mg Base Study,"Participants receive placebo tablets once daily for 3 weeks in Period I (Base), and MK-0873 0.75 mg tablets once daily for 12 weeks in Period II (Base)"
NCT00132730,Phase 2,8/1/05,"The extension studies were terminated based on data from the completed base study suggesting that MK-0873, at doses up to 2.5 mg per day, demonstrated no benefits versus placebo in lung function or symptoms in participants with COPD.",NA,551569,0.065359477,10,153,Up to 14 weeks in the Base Study; up to 14 weeks in study EXT1; up to 80 weeks in study EXT2,NA,MK-0873 2.5 mg Base Study,"Participants receive placebo tablets once daily for 3 weeks in Period I (Base), MK-0873 2.5 mg tablets once daily for 12 weeks in Period II (Base) and MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)"
NCT00132730,Phase 2,8/1/05,"The extension studies were terminated based on data from the completed base study suggesting that MK-0873, at doses up to 2.5 mg per day, demonstrated no benefits versus placebo in lung function or symptoms in participants with COPD.",NA,551566,0.037383178,4,107,Up to 14 weeks in the Base Study; up to 14 weeks in study EXT1; up to 80 weeks in study EXT2,NA,Placebo EXT 1,Participants receive placebo tablets once daily for 12 weeks in Period III (EXT1)
NCT00132730,Phase 2,8/1/05,"The extension studies were terminated based on data from the completed base study suggesting that MK-0873, at doses up to 2.5 mg per day, demonstrated no benefits versus placebo in lung function or symptoms in participants with COPD.",NA,551564,0.070422535,5,71,Up to 14 weeks in the Base Study; up to 14 weeks in study EXT1; up to 80 weeks in study EXT2,NA,Usual Care EXT2,"Participants receive usual care (inhaled short- or long-acting beta-agonists, inhaled corticosteroids, or short- or long-acting anticholinergics) for 28 weeks in Periods IV and V (EXT2)"
NCT00138424,Phase 1/Phase 2,4/1/11,The study closed early due to failure to enroll in a timely manner.,NA,550478,0.2,1,5,SAEs were reported within one business day of awareness of the event by completing Serious Adverse Event Report. Events were reported from start of study drug use to end of study..,NA,Cohort I - Placebo,"One dose (0.25 mg/kg/week-days 0, 7, 21, 35, 49)"
NCT00138424,Phase 1/Phase 2,4/1/11,The study closed early due to failure to enroll in a timely manner.,NA,550476,0.333333333,1,3,SAEs were reported within one business day of awareness of the event by completing Serious Adverse Event Report. Events were reported from start of study drug use to end of study..,NA,Cohort II - Placebo,"One dose (0.5 mg/kg/week-days 0, 7, 21, 35, 49)"
NCT00142168,Phase 2,4/1/08,"Due to toxicity, study was terminated.",Toxicity,549209,0.6875,11,16,NA,NA,Lenalidomide and Rituximab,Intended therapy consisted of 48 weeks of lenalidomide (25 mg/d for 3 weeks and then 1 week off) along with rituximab (375 mg/m(2)/wk) dosed on weeks 2 to 5 and 13 to 16.
NCT00157248,Phase 2,NA,NA,NA,545841,0.433333333,39,90,5 years,"All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.",300 mg Once Daily,Number of Participants treated at any time with 300 mg of Dabigatran etexilate once daily
NCT00157248,Phase 2,NA,NA,NA,545842,0.429775281,153,356,5 years,"All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.",150 mg Twice Daily,Number of Participants treated at any time with 150 mg of Dabigatran etexilate twice daily
NCT00157248,Phase 2,NA,NA,NA,545840,0.130434783,21,161,5 years,"All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.",300 mg Twice Daily,Number of Participants treated at any time with 300 mg of Dabigatran etexilate twice daily
NCT00157248,Phase 2,NA,NA,NA,545843,0.196078431,20,102,5 years,"All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.",150 mg Once Daily,Number of Participants treated at any time with 150 mg of Dabigatran etexilate once daily
NCT00157248,Phase 2,NA,NA,NA,545844,0.076190476,8,105,5 years,"All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.",50 mg Twice Daily,Number of Participants treated at any time with 50 mg of Dabigatran etexilate twice daily
NCT00176644,Phase 2,12/1/08,NA,Treatment ineffective,542431,0.217391304,5,23,3 years and 6 months,NA,Transdermal Estradiol,"Transdermal Estradiol : application of 4 transdermal estradiol patches, each patch releases a dose of 0.1 mg/day for a total dose of 0.4 mg/day. All four patches will be changed every 7 days. This continuous weekly schedule will be followed until the patient goes off-study.The patch will be applied to a clean, dry, intact area of the lower abdomen or the upper quadrant of the buttock. The sites should be rotated weekly. If a patch falls off during the 7 days, a new patch will be applied for the remainder of the 7 day period. At the end of the 7 days all four patches will be changed."
NCT00185679,Phase 2,2/1/10,NA,This study was superseded by the subsequent study IRB-15919 (NCT01050764),541276,0.230769231,3,13,SAEs reported through Day 100 post-transplant.,Non-serious adverse events not reported,Haploidentical Allogeneic Transplant Using CliniMACS System,"The CliniMACS cell selection system (Miltenyi Biotec) will be used to enrich hematopoietic stem cells from related, haploidentical, HLA-matched donors, who matched on the A,B,C and DRB1, DQ loci.CliniMACS System: The CliniMACS System is a cell selection device consisting of the following components:Computer-controlled instrument;Sterile disposable tubing set (PVC tubing, filters and bags connected to two separation columns containing an iron/plastic matrix)Anti-CD34 antibody reagent (murine monoclonal antibody chemically coupled to a magnetic particle)Wash buffer"
NCT00210626,Phase 2,6/1/08,The study was stopped early due to slow enrollment. Four subjects were randomized but withdrew prior to hospital entry and no data were collected,NA,537325,0.177083333,17,96,NA,NA,PROCRIT,"40,000 IU/mL/week for maximum of 12 weeks"
NCT00210626,Phase 2,6/1/08,The study was stopped early due to slow enrollment. Four subjects were randomized but withdrew prior to hospital entry and no data were collected,NA,537324,0.217391304,20,92,NA,NA,Placebo,Placebo given at equivalent volume (1 mL) as Procrit
NCT00215657,Phase 2,3/1/06,NA,The doses were not effective in maintaining testosterone suppression,536890,NA,4,NA,NA,NA,Degarelix 120mg (40mg/mL),Degarelix 120 mg (40 mg/mL)
NCT00215657,Phase 2,3/1/06,NA,The doses were not effective in maintaining testosterone suppression,536888,NA,7,NA,NA,NA,Degarelix 200mg (40mg/mL),Degarelix 200 mg (40 mg/mL)
NCT00215657,Phase 2,3/1/06,NA,The doses were not effective in maintaining testosterone suppression,536891,NA,8,NA,NA,NA,Degarelix 120mg (20mg/mL),Degarelix 120 mg (20 mg/mL)
NCT00215657,Phase 2,3/1/06,NA,The doses were not effective in maintaining testosterone suppression,536887,NA,8,NA,NA,NA,Degarelix 200mg (60mg/mL),Degarelix 200 mg (60 mg/mL)
NCT00215657,Phase 2,3/1/06,NA,The doses were not effective in maintaining testosterone suppression,536889,NA,3,NA,NA,NA,Degarelix 160mg (40mg/mL),Degarelix 160 mg (40 mg/mL)
NCT00215657,Phase 2,3/1/06,NA,The doses were not effective in maintaining testosterone suppression,536886,NA,5,NA,NA,NA,Degarelix 240mg (40mg/mL),Degarelix 240 mg (40 mg/mL)
NCT00215657,Phase 2,3/1/06,NA,The doses were not effective in maintaining testosterone suppression,536885,NA,3,NA,NA,NA,Degarelix 240mg (60mg/mL),Degarelix 240 mg (60 mg/mL)
NCT00215657,Phase 2,3/1/06,NA,The doses were not effective in maintaining testosterone suppression,536884,NA,9,NA,NA,NA,Degarelix 320mg (60mg/mL),Degarelix 320 mg (60 mg/mL)
NCT00217464,Phase 2,3/1/10,NA,Closed for futility,536625,0.058823529,1,17,NA,NA,Fulvestrant,"Patients receive fulvestrant intramuscularly on days 0, 14, and 28. Treatment repeats once a month in the absence of disease progression or unacceptable toxicity.fulvestrant: intramuscularly"
NCT00239720,Phase 2,6/1/08,"This study was put on voluntary clinical hold after a serious adverse event occurred. After a review of the data, the team decided to close the study to further enrollment. Due to limited participants, no formal statistical analyses were performed",FDA Clinical Hold,533718,0.333333333,1,3,Baseline to end of study (up to 24 months post baseline visit),"This study graded the severity of adverse events experienced by the study participant according to criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events Version 3.0 (June 10, 2003)",hOKT3gamma1 (Ala-Ala),Escalating dose of hOKT3gamma1 (Ala-Ala) given intravenously over 5 days of each 28 day cycle
NCT00240162,Phase 2,12/1/08,"In November 2008, it was reported that the drug might have carcinogenic potential in animal models. At that time, the remaining three patients were taken off study.",investigator letter from drug manufacturer stating animal studies showed increased risk of   cancer which was an unknown adverse event,533651,0.142857143,3,21,Adverse events were collected from the start of treatment up through 30 days following the end of treatment.,NA,PTK787/ZK 222584,"Initially patients will receive a dose of 500mg (2, 250mg tablets) in the morning and 250mg (1, 250mg tablet) in the afternoon for 2 weeks (cycle 1, days 1-14), then 500mg (2, 250mg tablets) bid for 2 weeks (cycle 1, days 15-28) and finally 750mg (3, 250mg tablets) in the morning and 500mg (2, 250mg tablets) in the afternoon for the remainder of treatment duration (cycle 2, day 1 and onwards). Each 28 days of drug administration will constitute one cycle of therapy."
NCT00245128,Phase 2,10/1/11,Early termination/results were never analyzed due to negative study results from other similar studies.,"Per PI, results from another similar study were published prior to study analysis. Negative   study results were published therefore analysis was not completed",532779,1,10,10,NA,NA,Imatinib Mesylate (Gleevec),Once daily oral administration of Imatinib Mesylate at a dose of 600mg for 12 months.
NCT00249002,Phase 2,11/1/07,NA,Terminated due to pipeline prioritization,531951,0.666666667,6,9,"AEs collected up to 30 days after the last ABI-007 dose administration (Week 21), except for cardiovascular side effects or other events at the investigator‰Ûªs discretion, which would be reported whenever they occur.",NA,ABI-007,"ABI-007 35 mg/m^2 given intravenously (IV) into the arteriovenous (AV) graft within 96 hours after angioplasty, followed by repeat treatment during weeks 5, 13 and 21"
NCT00073008,Phase 2,7/1/08,"Based on interim analysis and predefined stopping rules for futility, the study was discontinued due to lack of efficacy. At that time, no additional participants were added; enrolled participants could continue on treatment, following the protocol.","Based on interim analysis at the end of Stage 1, and predefined stopping rules for futility,   further enrollment was stopped due to lack of efficacy",570395,0.230769231,15,65,NA,NA,Lapatinib 1500 mg QD,Oral lapatinib 1500 mg once daily (QD)
NCT00262951,Phase 2,8/1/11,NA,Closed at a planned interim analysis by meeting a predefined toxicity endpoint,528232,0.52173913,12,23,Adverse events were assessed during study treatment and for 1 month following study treatment (for up to 10 months).,NA,Pancreatic Adenocarcinoma Patients,"Pancreatic Adenocarcinoma Patients treated with chemotherapy regimen and radiation (and or surgery). Patients were given one cycle of continuous infusion 5-FU (175 mg/m^2/day for 38 days), weekly cisplatin 30 mg/m^2 over 1 hour, and IFN-alpha-2b (3 million units given subcutaneously on days 1, 3, and 5 of each week for 5å_ weeks) with radiation therapy (5040 cGy total, in 28 fractions, at 180 cGy/fraction daily, Monday ‰ÛÒFriday, for 5å_ weeks) followed by two cycles of bolus 5-FU alone (500 mg/m^2 weekly * 6, followed by 2 weeks of rest)."
NCT00266812,Phase 2,1/1/08,NA,Patient target could not be reached within the planned timeframe.,526841,0.307692308,4,13,NA,NA,Radiotherapy Alone,"2 regimens are allowed: a) 20 fractions of 2 Gray each, on days 1 to 5, 8 to 12, 15 to 19, and 22 to 26; b) 10 fractions of 3 Gray each, administered on days 1 to 5 and 8 to 12."
NCT00266812,Phase 2,1/1/08,NA,Patient target could not be reached within the planned timeframe.,526842,0.444444444,8,18,NA,NA,Chemotherapy With Temozolomide and Radiotherapy,"Oral temozolomide 75mg/m2/day for 14 days, during radiation treatment, and later on temozolomide 100mg/m2/day at 14 days on/14 days off, until unacceptable toxicity or evidence of disease progression for up to 6 cycles from initial treatment. Radiotherapy (as in Intervention 2)."
NCT00268437,Phase 2,3/1/15,NA,"Trial closed early because, during an interim analysis, the primary endpoint fell short.",526385,0.222222222,6,27,NA,NA,Pemetrexed/Carboplatin,"Pemetrexed+Carboplatin+Radiation carboplatin: carboplatin is to be given on days 1 and 22 of the 5 å_ weeks of radiation treatment.Pemetrexed: Pemetrexed is to be given on days 1 and 22 of the 5 å_ weeks of radiation treatment.Radiation therapy: Radiation therapy begins day 1 and continues for 5 å_ weeks (45 Gy in 22-25 fractions of 1.8 Gy to extended field; 50.4 Gy in 28 fractions within boost field).Conventional surgery"
NCT00272961,Phase 2,8/1/08,Results for ‰Û÷change from standing to sitting SBP and DBP‰Ûª and ‰Û÷change from pre-dose to post-dose SBP and DBP‰Ûª are reported only at Week 10 as per changes in planned analysis because of early termination of the study and clinical development program.,See termination reason in detailed description.,525450,0.1,1,10,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",TBC3711 100 mg,"Participants who received placebo matched to TBC3711 tablet orally once daily in 2-week Placebo Run-in Phase, received TBC3711 50 mg tablet and 3 matching placebo tablets orally once daily for 1 week followed by 2 TBC3711 50 mg tablets (equivalent to TBC3711 100 mg) and 2 matching placebo tablets orally once daily for 9 weeks in 10-week Treatment Phase."
NCT00272961,Phase 2,8/1/08,Results for ‰Û÷change from standing to sitting SBP and DBP‰Ûª and ‰Û÷change from pre-dose to post-dose SBP and DBP‰Ûª are reported only at Week 10 as per changes in planned analysis because of early termination of the study and clinical development program.,See termination reason in detailed description.,525451,0.090909091,1,11,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",TBC3711 50 mg,"Participants who received placebo matched to TBC3711 tablet orally once daily in 2-week Placebo Run-in Phase, received TBC3711 50 mg tablet and 3 matching placebo tablets orally once daily in 10-week Treatment Phase."
NCT01428219,Phase 2,9/1/15,NA,Closed due to slowing enrollment and negative results of a phase III trial using cabozantinib.,136555,0.64,16,25,NA,NA,Cabozantinib (XL184),"Cabozantinib is available in capsule form. The dose is 60 mg daily by mouth. Subjects with disease progression at 6 weeks who do not have significant toxicities may remain on therapy for an additional six weeks until a progression is confirmed. Further study drug administration beyond 12 weeks will be at the discretion of the investigator provided that the subject does not have disease progression, does not have unacceptable side effects, does not withdraw from study, or does not have a medical condition or illness that renders the subject unacceptable to receive further study drug."
NCT00281528,Phase 2,3/1/11,NA,sufficient mature data to complete a final analysis,523817,0.405063291,32,79,Up to 54 months,NA,130 mg/m^2 ABI-007 Weekly,130 mg/m^2 of ABI-007 every week and 10 mg/kg bevacizumab every 2 weeks
NCT00281528,Phase 2,3/1/11,NA,sufficient mature data to complete a final analysis,523819,0.293333333,22,75,Up to 54 months,NA,260 mg/m^2 ABI-007 Every 3 Weeks,260 mg/m^2 of ABI-007 every 3 weeks and 15 mg/kg bevacizumab every 3 weeks.
NCT00281528,Phase 2,3/1/11,NA,sufficient mature data to complete a final analysis,523818,0.296296296,16,54,Up to 54 months,NA,260 mg/m^2 ABI-007 Every 2 Weeks,260 mg/m^2 of ABI-007 every two weeks and 10 mg/kg bevacizumab every 2 weeks
NCT00281879,Phase 2,3/1/08,Early termination,NA,523379,0.85,17,20,NA,NA,BEAM Regimen,"On the day of your admission, you will start to take a drug called allopurinol which helps to protect your kidneys as your body works to discharge cells killed off by your chemotherapy and TBI. Chemotherapy will begin on Day -6 with carmustine (BCNU), followed by etoposide (VP-16), cytosine arabinoside (ARA-C), and melphalan. This conditioning regimen is known as the BEAM regimen. The dose of this therapy is high enough to kill cancer cells but will also kill all of your normal blood forming cells. Subjects undergoing the BEAM regimen will not have total body irradiation (TBI)."
NCT00281879,Phase 2,3/1/08,Early termination,NA,523381,0.7890625,101,128,NA,NA,Cyclophosphamide (Cytoxan) and Total Body Irradiation (TBI),"On admission day, you will start to take a drug called allopurinol which helps to protect your kidneys as your body works to discharge cells killed off by your chemotherapy and TBI. Allopurinol tablets will be given to you by mouth up to three times a day for 7 days. You will begin radiation therapy to your entire body at the start of your transplant treatment. This procedure is called TBI (total body irradiation). Radiation will be given to you 2 times a day for 3 or 4 days. After the radiation treatment, you will receive two doses of cyclophosphamide by vein (through a small plastic tube leading into the bloodstream). Each dose takes about 2 hours to administer. When you are given cyclophosphamide, you will also be given a medication called MESNA to help protect your bladder from damage. After you have completed the cyclophosphamide you will rest one day without any anti-cancer therapy."
NCT00281879,Phase 2,3/1/08,Early termination,NA,523374,1,1,1,NA,NA,"Cyclophosphamide, Etoposide (VP16) and TBI (Pediatric Only)","On the day after your admission, you will start receiving radiation therapy (TBI). Radiation will be given to you 2 times a day for 3 days. On the next day, you will then begin your chemotherapy with a drug called etoposide. This medicine will be given to you by an infusion into your bloodstream through a small tube in the vein of your arm for one day. After the etoposide treatment, on the next day you will receive cyclophosphamide (also known as Cytoxan) for 2 days. When you are given cyclophosphamide, you will also be given a medication called MESNA to help protect your bladder from damage. After you have completed the cyclophosphamide you will rest one day without any anti-cancer therapy. This allows your body time to remove and inactivate the chemotherapy. After a day of rest, you will be given your donor‰Ûªs cells."
NCT00281879,Phase 2,3/1/08,Early termination,NA,523376,0.666666667,6,9,NA,NA,ATG For Cord Blood Transplants,"If you are undergoing a pre-transplant conditioning regimen prior to undergoing a cord blood transplant, you will receive a drug called ATG to improve your chances of engraftment and decrease your risk of graft versus host disease. You may receive ATG 3 times during your transplant regimen on days ‰ÛÒ3 through days ‰ÛÒ1 in addition to your pre-transplant conditioning therapy. Methylprednisolone will also be given during each dose of ATG to help reduce any reactions during infusion."
NCT00281879,Phase 2,3/1/08,Early termination,NA,523380,0.694444444,25,36,NA,NA,Busulfan and Cyclophosphamide (Cytoxan),"On admission day, you will start to take a drug called Dilantin, which is used to help prevent seizures while you receive your chemotherapy drugs. You will also start to take a drug called allopurinol,which helps to protect your kidneys as your body works to discharge cells killed off by your chemotherapy and TBI. Allopurinol tablets will be given to you by mouth up to three times a day for 7 days. You will begin the therapy with a drug called busulfan. This medicine is take by mouth four times per day for four days. After the oral busulfan treatment, you will receive two doses of cyclophosphamide over 2 hours by vein (through a small tube leading into the bloodstream). When you are given cyclophosphamide, you will also be given a medication called MESNA to help protect your bladder from damage. Subjects undergoing the Busulfan and Cyclophosphamide regimen will not have total body irradiation (TBI)."
NCT00281879,Phase 2,3/1/08,Early termination,NA,523377,0.833333333,5,6,NA,NA,"Busulfan, Cyclophosphamide, and Fludarabine (Pediatric Only)","On the day of your admission you will start to take a drug called Dilantin which is used to help prevent seizures while you receive your chemotherapy drugs. You will also start to take a drug called allopurinol which helps to protect your kidneys as your body works to discharge cells killed off by your chemotherapy and TBI. On the next day, you will then begin your conditioning therapy with a drug called busulfan. This medicine will be given to you by an infusion into your bloodstream through a small tube in the vein of your arm four times per day for four days. After the busulfan treatment, you will receive 4 doses each of two drugs, cyclophosphamide (also known as Cytoxan) and fludarabine, over 2 hours into your vein."
NCT00295880,Phase 1/Phase 2,8/1/08,"This study was terminated early based on interim statistical analysis that indicated time to engraftment will not be improved compared to historical controls. While safe, lack of faster marrow recovery supports early discontinuation.",Time to engraftment would not be improved compared to historical controls.,518911,0.416666667,5,12,NA,NA,Umbilical Cord Blood Transplant Patients,Patients with high-risk hematologic malignancy transplanted with umbilical cord blood via direct marrow injection.
NCT00313612,Phase 2,12/1/12,NA,NA,513135,0.736842105,14,19,NA,NA,Treatment Stratum I (Oxaliplatin Plus Topotecan),"Patients receive oxaliplatin IV over 2 hours on days 1 and 15 and topotecan IV continuously on days 1-14. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed at 30 days.oxaliplatin: Given IVtopotecan: Given IV"
NCT00313612,Phase 2,12/1/12,NA,NA,513134,0.631578947,12,19,NA,NA,Treatment Stratum II (Oxaliplatin Plus Topotecan),"Patients receive oxaliplatin IV over 2 hours on days 1 and 15 and topotecan IV continuously on days 1-14. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed at 30 days.oxaliplatin: Given IVtopotecan: Given IV"
NCT00322881,Phase 2,4/1/10,This study terminated early due to 3 deaths on study and consequently results are limited.,Early closure based on audit by study investigators after 3 patients died on study.,510015,0.416666667,5,12,"The planned treatment regimen was of fixed duration: 6 cycles of therapy, up to approximately 4.5 months given the cycle length of 21 days.","Serious AEs were defined as events with treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAE (v3).Other AEs were defined as events with treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAE (v3).",Carboplatin/Paclitaxel,"Paclitaxel: Chemotherapy will be given per standard treatment practices for 6 cycles (18 weeks)Carboplatin: Chemotherapy will be given per standard treatment practices for 6 cycles (18 weeks)"
NCT00323362,Phase 2,10/1/08,NA,Toxicity,509917,0.588235294,10,17,2 years,NA,Gemcitabine Hydrochloride and Imatinib Mesylate,"gemcitabine hydrochloride : 1000 mg/m2 given intravenously at a FDR of 10 mg/m2/min on Days 3 and 10, every 21 days.imatinib mesylate : 400 mg/day orally, given Days 1-5 and 8-12 every 21 days"
NCT00324740,Phase 1/Phase 2,5/1/14,NA,NA,509138,0.916666667,11,12,NA,NA,Treatment (Vorinostat and Isotretinoin),"Patients receive oral vorinostat (SAHA) twice daily and oral isotretinoin twice daily on days 3-5, 10-12, 17-19, and 24-26. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.vorinostat: Given orallyisotretinoin: Given orally"
NCT00325078,Phase 1/Phase 2,6/1/12,"Due to limited subject participation and lack of sustained clinical benefits (1 year), there is insufficient complete data to generate meaningful statistics for the outcome measures. Instead, this data are reported as a case series.",Insufficient patient participation,509067,0.25,2,8,NA,The adverse events reported only relate to events occurring following study drug (TNFa inhibitors) treatment. Group 3 subjects who volunteered for endoscopy/gut biopsies are terminated at completion of the procedure. Baseline infections in endoscopy volunteers are not reported as adverse events.,Treatment Group,"This group comprises patients with Chronic granulomatous disease (CGD) complicated by significant inflammatory bowel disease (IBD). The subjects are treated with a TNFa inhibitor at standard recommended doses for treatment of Crohn‰Ûªs disease. Infliximab is administered as intravenous infusions at 5mg/kg on weeks 0, 2 and 6 for induction and every 6-8 weeks at 5-10mg/kg for maintenance. Adalimumab is administered at 160mg, 60mg, 40mg, 40mg on weeks 0, 2, 4 and 6 via subcutaneous injection.Endoscopies and gastrointestinal mucosal biopsies are obtained before treatment, following induction, and again at completion of treatment."
NCT00343512,Phase 2,3/1/11,"All adverse events have been included in the other adverse event section. They are not differentiated by causality (eg. related to disease, con-meds).",closed due to competing neoadjuvant studies for a small patient population,503214,0.28125,9,32,NA,NA,Therapeutic Intervention,Docetaxel 75 mg/m2 IV (1-hour infusion) on day 1 of each cycle (cycle = 2 weeks) x 4 cycles
NCT00346151,Phase 2,2/1/10,The trial was stopped early due to meeting an acute rejection threshold of three acute rejections based on local pathology reads in the first five participants enrolled.,Stopping rule-acute rejection threshold-was met based on local biopsy results,502814,0.8,4,5,NA,NA,Immunosuppression Withdrawal,"Daclizumab, antithymocyte globulin, sirolimus, or belatacept dosing with the intention of immunosuppression withdrawal"
NCT00346632,Phase 1,4/1/08,NA,Terminated due to suboptimal dosing schedule,502722,1,4,4,NA,NA,Arm A - 300 mg/Day,KW2449-001 300 mg/day (Treatment Arm A)
NCT00346632,Phase 1,4/1/08,NA,Terminated due to suboptimal dosing schedule,502718,0.5,2,4,NA,NA,Arm B - 25 mg/Day,KW2449-001 25 mg/day (Treatment Arm B)
NCT00346632,Phase 1,4/1/08,NA,Terminated due to suboptimal dosing schedule,502720,0.6,3,5,NA,NA,Arm A - 500 mg/Day,KW2449-001 500 mg/day (Treatment Arm A)
NCT00346632,Phase 1,4/1/08,NA,Terminated due to suboptimal dosing schedule,502726,0.666666667,2,3,NA,NA,Arm A - 25 mg/Day,KW2449-001 25 mg/day (Treatment Arm A)
NCT00346632,Phase 1,4/1/08,NA,Terminated due to suboptimal dosing schedule,502721,0.5,1,2,NA,NA,Arm A - 400 mg/Day,KW2449-001 400 mg/day (Treatment Arm A)
NCT00346632,Phase 1,4/1/08,NA,Terminated due to suboptimal dosing schedule,502719,0.730769231,19,26,NA,NA,Arm A - Total,Total Patients in Treatment Arm A
NCT00346632,Phase 1,4/1/08,NA,Terminated due to suboptimal dosing schedule,502723,0.666666667,2,3,NA,NA,Arm A - 200 mg/Day,KW2449-001 200 mg/day (Treatment Arm A)
NCT00346632,Phase 1,4/1/08,NA,Terminated due to suboptimal dosing schedule,502716,1,3,3,NA,NA,Arm B - 100 mg/Day,KW2449-001 100 mg/day (Treatment Arm B)
NCT00346632,Phase 1,4/1/08,NA,Terminated due to suboptimal dosing schedule,502717,0.75,3,4,NA,NA,Arm B - 50 mg/Day,KW2449-001 50 mg/day (Treatment Arm B)
NCT00346632,Phase 1,4/1/08,NA,Terminated due to suboptimal dosing schedule,502725,0.666666667,2,3,NA,NA,Arm A - 50 mg/Day,KW2449-001 50 mg/day (Treatment Arm A)
NCT00346632,Phase 1,4/1/08,NA,Terminated due to suboptimal dosing schedule,502724,0.833333333,5,6,NA,NA,Arm A - 100 mg/Day,KW2449-001 100 mg/day (Treatment Arm A)
NCT00346632,Phase 1,4/1/08,NA,Terminated due to suboptimal dosing schedule,502715,0.727272727,8,11,NA,NA,Arm B - Total,Total Patients in Treatment Arm B
NCT00350623,Phase 2,5/1/08,"An interim analysis of a related study, V520-023 (NCT00095576), showed that the vaccine used in V520-027 (NCT00350623) was not efficacious; therefore, vaccinations in V520-027 were stopped and only a high level summary of safety data was performed.",NA,501499,0.029411765,2,68,Non-Serious and Serious AEs were collected for 14 days following each vaccination.,"In addition, SAEs that occurred outside the time period specified above were collected if they were either a death or an SAE that was considered possibly, probably, or definitely vaccine related.",MRKAd5 HIV-1 Gag/Pol/Nef 1.5 x 10^10 Ad5 vg/Dose,"MRKAd5 HIV-1 gag/pol/nef 1.5 x 10^10 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26."
NCT00352690,Phase 2,6/1/08,(3) grade 5 serious adverse events occurred and led to the study closing early for the safety of participants.,Safety of patients,501072,0.625,5,8,Adverse events were collected from the start of treatment through 30 days after completion of treatment (approximately 114 days),NA,Cohort 1 (First 12 Eligible Patients),"Paclitaxel poliglumex 135 mg/m2 IV on day 1 of each 21 day cycle for a total of 2 cycles.Carboplatin AUC=5 IV over 30 minutes on day 1 of each 21 day cycle for a total of 2 cycles.Thoracic radiation therapy starting day 1 consisting of 66 Gy delivered in 2 Gy daily fractions.Paclitaxel poliglumex 175 mg/m2 IV beginning 3-5 weeks after completion of radiation therapy on day 1 every 21 days for a total of 2 cycles.Carboplatin AUC=6 IV beginning 3-5 weeks after completion of radiation therapy on day 1 every 21 days for a total of 2 cycles."
NCT00354107,Phase 1/Phase 2,1/1/10,Number of participants analyzed = 4. One patient was not evaluable for response.,NA,500393,0.2,1,5,NA,NA,"Treatment (Monoclonal Antibody Therapy, Chemotherapy)","Patients receive monoclonal antibody SGN-30 (dosage 12mg/kg) IV alone on day 1 in weeks 1-8. Beginning in week 5, patients receive ICE chemotherapy comprising ifosfamide IV (dosage 3g/m2) x 3 days over 2 hours on days 1-3, carboplatin IV (635mg/m2) over 1 hour on day 1, and etoposide IV (dosage 100/m2) over 1 hour on days 1-3. Treatment with ICE repeats every 3 weeks for 6 courses** in the absence of unacceptable toxicity. Patients also receive intrathecal therapy (dosage dependent on age) comprising methotrexate, cytarabine, and hydrocortisone once on day 29 (week 5).Cohorts of 3-6 patients receive a pre-determined dose of monoclonal antibody SGN-30 with possible dose de-escalation to 1 dose level below (dosage 8mg/kg) in the event of ‰ä´ 2 of 6 patients experience dose-limiting toxicity (DLT). The dose at which ‰ä_ 1 of 6 patients experience DLT will be used in a phase II study."
NCT00361257,Phase 2,1/1/10,"Originally, 100 participants were expected to enroll. As of the early termination notice, 107 participants were randomized, yet not all subjects could complete the 24 week assessment.",This study was terminated early due to futility.,497676,0.134615385,7,52,Up to 48 weeks since the randomization.,NA,Minocycline,100 mg orally every 12 hours
NCT00361257,Phase 2,1/1/10,"Originally, 100 participants were expected to enroll. As of the early termination notice, 107 participants were randomized, yet not all subjects could complete the 24 week assessment.",This study was terminated early due to futility.,497675,0.054545455,3,55,Up to 48 weeks since the randomization.,NA,Matching Placebo,Placebo taken orally every 12 hours
NCT00363883,Phase 2,12/1/10,"Study was terminated early after the first stage of a two-stage design, allowing for early termination for discouraging results.",Trial stopped early for futility,496714,0.428571429,6,14,Adverse events were collected over a period of 1 year and 5 months.,Other Adverse Events include all events that were not severe adverse events regardless of grade or relation to treatment.,Treatment (Vorinostat),"Patients receive oral vorinostat (SAHA) twice daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.vorinostat: Given orallylaboratory biomarker analysis: Correlative studies"
NCT00372489,Phase 2,11/1/09,Early termination of study due to generation of controlled long-term data in Phase 3 studies. Amended dosing guidelines during the trial to reflect label changes for ESAs; the primary outcome was assessed after the dosing guideline change.,Due to more robust long-term data generated in other active-controlled studies,493537,0.716049383,58,81,NA,NA,Peginesatide,Participants received the same initial peginesatide dose as was administered at the end of the previous peginesatide treatment study (NCT00228449) in which the participant was enrolled. The median first dose at study start was 0.087 milligram per kilogram (mg/kg) with an interquartile range of 0.064 to 0.123 mg/kg. Each participant was to receive peginesatide as an injection administered intravenously once every 4 weeks for approximately 54 months in this trial.
NCT00376805,Phase 2,1/1/10,NA,Withdrawn due to toxicity,492514,1,6,6,All adverse events were collected up to patients' death (within 1 year of treatment).,NA,NK Cells With or Without Total Body Irradiation,"Patients receiving natural killer cell infusion, fludarabine and cyclosphosphamide preparatory regimen, and with or without total body irradiation for treatment of metastatic breast cancer."
NCT00378573,Phase 2,9/1/08,Due to early termination of the study only 17/90 subjects enrolled. Efficacy analysis of Progression Free Survival and Overall Survival were not performed. Efficacy results limited to a descriptive summary of best overall response for each subject.,Incidence of GI Perforation,491917,0.529411765,9,17,Adverse Events were collected from time of subject consent until 30 days after the completion of the last dose of study drug,NA,"Docetaxel, Gemcitabine and Bevacizumab",Combination therapy administered as follows: gemcitabine 1000 mg/m2 IV over 0.5 hour on Days 1 and 8; docetaxel 75 mg/m2 IV over 1 hour on Day 8; and bevacizumab 15 mg/kg IV on Day 1. Maintenance bevacizumab therapy was administered as 15 mg/kg IV on Day 1.
NCT00383071,Phase 2,12/1/14,NA,Not possible to achieve original goal of sufficient volume of high titer plasma to   manufacturer a high titer IVIG for human trials.,490402,0.04,1,25,NA,NA,90 mcg,90 mcg every 28 days x 4 doses
NCT00383071,Phase 2,12/1/14,NA,Not possible to achieve original goal of sufficient volume of high titer plasma to   manufacturer a high titer IVIG for human trials.,490404,0.04,1,25,NA,NA,180 mcg,180 mcg every 28 days x 4 doses
NCT00383071,Phase 2,12/1/14,NA,Not possible to achieve original goal of sufficient volume of high titer plasma to   manufacturer a high titer IVIG for human trials.,490403,0.039215686,2,51,NA,NA,180 mcg Cohort 4,180 mcg every 28 days x 2 doses
NCT00383565,Phase 2,4/1/11,NA,NA,489815,0.666666667,6,9,3 years and 9 months,NA,FR901228,"13 mg/m^2 FR901228 by vein (IV) over 4 hours on days 1, 8, and 15"
NCT00387153,Phase 1,10/1/06,NA,Last subject enrolled experienced bradycardia; study was terminated by Sponsor.,488302,0.375,3,8,NA,NA,MPC-2130 Group 1,Group 1 will be dosed at 10 mg/ml administered via IV over a 1-2 hour period.
NCT00387426,Phase 2,2/1/09,NA,NA,488502,0.5,7,14,2 years,NA,Sunitinib,37.5 mg orally daily for 6-week cycle
NCT00393380,Phase 2,3/1/12,The study was closed prematurely due to early mortality and lack of efficacy.,Study stopped because of toxicity concerns.,486729,0.615384615,8,13,2 years,NA,Parathyroid Hormone (Teriparatide),Parathyroid hormone after double umbilical cord blood transplant.
NCT00395083,Phase 2,9/1/10,NA,The DMC detected an imbalance in safety outcomes between the two groups.,485708,0.435406699,91,209,NA,Non-serious adverse events were not collected for this study.,Comprehensive Care Management Program,"The comprehensive group will receive an initial, intense education program with development of an action plan, and regular telephone contacts by a case manager in addition to standardized COPD care.COPD Self-management Education: The comprehensive self-management intervention incorporates self-management education, development of an action plan, and case management. The intervention is designed using the social cognitive theory with the Precede-Proceed Model which has guided other successful patient education programs."
NCT00395083,Phase 2,9/1/10,NA,The DMC detected an imbalance in safety outcomes between the two groups.,485709,0.451612903,98,217,NA,Non-serious adverse events were not collected for this study.,Usual Care,"Patients allocated to the control arm will receive standardized care that incorporates guide-line based recommendations including influenza vaccination, a short-acting bronchodilator, and either a long-acting bronchodilator or inhaled corticosteroid inhaler."
NCT00396812,Phase 1/Phase 2,7/1/09,The trial terminated early due to rituximab‰Ûªs risk-benefit ratio for individuals with early active Rheumatoid Arthritis. Mechanistic samples were not processed and corresponding endpoints were not assessed. Only descriptive statistics are presented.,The perceived risk-benefit ratio for individuals with early active RA,484693,0.25,1,4,"From the start of steroid taper, when applicable, and otherwise, from 1.)time of the 1st invasive screening procedure (knee arthroscopy) until participant study completion (Wk 48) or 2.)30 days after a participant prematurely withdraws from the study.","This study graded the severity of adverse events experienced by the study participant according to criteria set forth in the National Cancer Institute's Common Terminology Criteria for Adverse Events Version 3.0 (June 10, 2003).",Rituximab,"Participants to receive an intravenous infusion of rituximab (1 gram ) fourteen days apart, at baseline (Day 0) and at Week 2. Concomitant treatments to be administered at a dose and frequency prescribed per protocol include methotrexate (MTX) and folic or folinic acid."
NCT00397878,Phase 2,11/1/11,NA,NA,484330,0.9,9,10,"Adverse events collected while participant was receiving treatment and up to 30 days after the last dose of treatment. Total study period was from January 10, 2007 to February 25, 2009.",NA,Treatment (Saracatinib),Oral AZD0530 175 mg once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
NCT00400205,Phase 2,9/1/09,NA,Safety reasons,483566,0.428571429,6,14,3 years,NA,TPF Induction Therapy for Head and Neck Cancer,Patients with locally advanced squamous cell carcinoma of the head and neck received three cycles of induction therapy with TPF followed by local therapy consisting of surgical resection in addition to possible radiation therapy with or without concurrent chemotherapy.
NCT00400764,Phase 1/Phase 2,NA,"The Sponsor terminated the study on 5 May 2010, prior to the completion of the 36-month follow-up (FU) period, based on the primary analysis results. All patients were off-study or in survival FU (the treatment period was completed).",NA,483491,0.166666667,1,6,Adverse events occurring on or after the first treatment through Study Termination (up to approximately 13 months for phase Ib and up to approximately 33 months for phase II) are summarized.,Evaluation is on all Treated Patients.,Phase Ib - Dulanermin 8 mg/kg,"Participants received 8.0 mg/kg/day dose of dulanermin, administered by intravenous (IV) infusion for 5 consecutive days at the start of each 21-day treatment cycle for up to four cycles. Participants also received rituximab administered by IV infusion at 375 mg/m^2 weekly for up to eight doses."
NCT00400764,Phase 1/Phase 2,NA,"The Sponsor terminated the study on 5 May 2010, prior to the completion of the 36-month follow-up (FU) period, based on the primary analysis results. All patients were off-study or in survival FU (the treatment period was completed).",NA,483489,0.153846154,4,26,Adverse events occurring on or after the first treatment through Study Termination (up to approximately 13 months for phase Ib and up to approximately 33 months for phase II) are summarized.,Evaluation is on all Treated Patients.,Phase II - Combination Therapy,"Participants received 8.0 mg/kg/day dose of dulanermin, administered by intravenous (IV) infusion for 5 consecutive days at the start of each 21-day treatment cycle for up to four cycles. Participants also received rituximab administered by IV infusion at 375 mg/m^2 weekly for up to eight doses."
NCT00400764,Phase 1/Phase 2,NA,"The Sponsor terminated the study on 5 May 2010, prior to the completion of the 36-month follow-up (FU) period, based on the primary analysis results. All patients were off-study or in survival FU (the treatment period was completed).",NA,483490,0.045454545,1,22,Adverse events occurring on or after the first treatment through Study Termination (up to approximately 13 months for phase Ib and up to approximately 33 months for phase II) are summarized.,Evaluation is on all Treated Patients.,Phase II - Rituximab,Participants received rituximab administered by intravenous (IV) infusion at 375 mg/m^2 weekly for up to eight doses.
NCT00400764,Phase 1/Phase 2,NA,"The Sponsor terminated the study on 5 May 2010, prior to the completion of the 36-month follow-up (FU) period, based on the primary analysis results. All patients were off-study or in survival FU (the treatment period was completed).",NA,483492,0.166666667,1,6,Adverse events occurring on or after the first treatment through Study Termination (up to approximately 13 months for phase Ib and up to approximately 33 months for phase II) are summarized.,Evaluation is on all Treated Patients.,Phase Ib - Dulanermin 4 mg/kg,"Participants received 4.0 mg/kg/day dose of dulanermin, administered by intravenous (IV) infusion for 5 consecutive days at the start of each 21-day treatment cycle for up to four cycles. Participants also received rituximab administered by IV infusion at 375 mg/m^2 weekly for up to eight doses."
NCT00401401,Phase 1/Phase 2,10/1/10,"All adverse events were collected during the 8 week treatment period and for additional 4 weeks. Serious adverse events were collected for the extended follow-up period of up to 3 years.The planned parallell group of the study was cancelled.",MTD was established and patients completed 16 months safety f-up and response assessments. It   is considered of limited value to follow patients for 3 years.,483301,0.833333333,5,6,NA,NA,Zalutumumab 4 mg/kg,Zalutumumab 8 weekly infusions
NCT00401401,Phase 1/Phase 2,10/1/10,"All adverse events were collected during the 8 week treatment period and for additional 4 weeks. Serious adverse events were collected for the extended follow-up period of up to 3 years.The planned parallell group of the study was cancelled.",MTD was established and patients completed 16 months safety f-up and response assessments. It   is considered of limited value to follow patients for 3 years.,483299,0.833333333,5,6,NA,NA,Zalutumumab 12 mg/kg,Zalutumumab 8 weekly infusions
NCT00401401,Phase 1/Phase 2,10/1/10,"All adverse events were collected during the 8 week treatment period and for additional 4 weeks. Serious adverse events were collected for the extended follow-up period of up to 3 years.The planned parallell group of the study was cancelled.",MTD was established and patients completed 16 months safety f-up and response assessments. It   is considered of limited value to follow patients for 3 years.,483298,0.916666667,11,12,NA,NA,Zalutumumab 16 mg/kg,Zalutumumab 8 weekly infusions
NCT00401401,Phase 1/Phase 2,10/1/10,"All adverse events were collected during the 8 week treatment period and for additional 4 weeks. Serious adverse events were collected for the extended follow-up period of up to 3 years.The planned parallell group of the study was cancelled.",MTD was established and patients completed 16 months safety f-up and response assessments. It   is considered of limited value to follow patients for 3 years.,483300,1,6,6,NA,NA,Zalutumumab 8 mg/kg,Zalutumumab 8 weeky infusions
NCT00402883,Phase 2,1/1/09,NA,Terminated due to bevacizumab and chemoradiotherapy toxicity,482531,1,5,5,NA,NA,Intervention,"Induction treatment included: carboplatin AUC=5, pemetrexed 500 mg/m2, and bevacizumab 15 mg/kg each administered intravenously weeks 1 and 4. Radiation was administered concurrently at a dose of 1.8 Gy/d weeks 1 to 7 to a total of 61.2 Gy per institutional guidelines. Consolidative therapy, following an 8-week break from chemoradiotherapy, included carboplatin AUC=6, pemetrexed 500 mg/m2, and bevacizumab 15 mg/kg each administered intravenously on week 16, repeated weeks 19 and 22. Folic acid (350 to 1,000 ug or equivalent) supplementation was administered orally beginning 1 to 2 weeks before the first dose of pemetrexed and continued daily until the patient discontinued study therapy. Vitamin B12(1,000ug) was administered by intramuscular injection 1 to 2 weeks before the first dose of study therapy and repeated every 9 weeks until the patient discontinued therapy."
NCT00412841,Phase 2,1/1/08,NA,NA,478911,0.619047619,13,21,NA,NA,Placebo,Placebo
NCT00412841,Phase 2,1/1/08,NA,NA,478912,0.181818182,4,22,NA,NA,Atorvastatin,Atorvastatin 40mg
NCT00413959,Phase 2,1/1/11,NA,NA,478025,0.166666667,2,12,NA,NA,"Velcade, Rituximab,Cyclophosphamide & Decadron","Velcade 375 mg/m^2 given intravenously on days 1, 8, 15 and 22 during the first cycle then on day 1 of each subsequent cycle."
NCT00414726,Phase 2,6/1/09,Early termination leading to small numbers of subjects analyzed.,Imbalance in deaths favoring control arm; deaths not attributed to treatment by the blinded   external medical monitor.,477722,0.558139535,24,43,"AEs were collected until the final visit at 3 months (range, 75-110 days). All deaths until day 110 were included.","Total 24 deaths: 7 RA, 17 NBO. The blinded external medical monitor did not adjudicte any death as definitely or probably related to therapy. One death in each arm was adjudicated as possibly related to therapy; 6 deaths in the Room Air arm and 16 deaths in the NBO arm, were adjudicated as unlikely or unrelated to therapy.",Normobaric Oxygen,"Oxygen, inhaled at 30-45L/min via a facemask for 8 hours"
NCT00414726,Phase 2,6/1/09,Early termination leading to small numbers of subjects analyzed.,Imbalance in deaths favoring control arm; deaths not attributed to treatment by the blinded   external medical monitor.,477721,0.487804878,20,41,"AEs were collected until the final visit at 3 months (range, 75-110 days). All deaths until day 110 were included.","Total 24 deaths: 7 RA, 17 NBO. The blinded external medical monitor did not adjudicte any death as definitely or probably related to therapy. One death in each arm was adjudicated as possibly related to therapy; 6 deaths in the Room Air arm and 16 deaths in the NBO arm, were adjudicated as unlikely or unrelated to therapy.",Room Air,"Room Air, inhaled at 30-45L/min via a facemask for 8 hours"
NCT00417248,Phase 1/Phase 2,4/1/08,NA,Negative sorafenib results from ESCAPE trial and safety concerns of regimen,477237,0.375,3,8,"Duration of OnStudy time, up to two 28 day cycles.",NA,Cisplatin/Etoposide/Radiotherapy Followed by Sorafenib,"Cisplatin/Etoposide/Radiotherapy followed by Sorafenib in patients with inoperable stage III non-small cell lung cancerCisplatin: Cisplatin 50 mg/m2 IV, days 1 and 8 of 28 day cycleEtoposide: Etoposide 50 mg/m2 IV, days 1-5 of 28 day cycleRadiotherapy: Concurrent chest radiation (planned dose is 5940 cGy with an additional, optional boost of 1080 cGy to a total allowed dose of 7020 cGy)Sorafenib: Maintenance therapy of Sorafenib 400 mg PO BID, to begin a minimum of 6 and maximum of 9 weeks from completion of chemo-radiotherapy until PD, intolerable toxicity, or up to 6 months"
NCT00419120,Phase 2,4/1/11,NA,36 months follow up without change to profile. No further studies planned.,476926,0.545454545,6,11,NA,Adverse events are reported for 11 subjects who were enrolled in the study. One patient withdrew prior to implantation with the neo-bladder construct and is included in the safety population but not in the all implanted population used for efficacy analysis.,Safety Population,All patients undergoing screeing and meeting inclusion/exclusion criteria
NCT00422201,Phase 2,4/1/12,"As a consequence of the premature study end, analyses performed were primarily descriptive due to the reduced number of enrolled and completed patients.",NA,475267,0.529411765,9,17,Adverse events were collected from enrollment to the end of the study,"Number of patients at risk corresponds to the number of patients who have received study treatment. Among the 18 patients enrolled, 17 received study treament and are considered in the set of population at risk.",Mifepristone,"Single arm. Study medication was to be administered at a total daily dose of 600 mg (given as one 200 mg tablet tid, per os) starting on the day of inclusion.This dose was to be maintained during the whole study except in case of suspicion of adrenal insufficiency, in which case the dose was temporally stopped for 2 to 3 days and restarted at a lower dose of 400 mg daily until the end of the study."
NCT00423150,Phase 2,6/1/09,"Due to low response rate for colorectal cancer in interim analyses, low enrollment in head & neck and non-small cell lung cancer groups due to low methylation rates, and low overall response rate in esophageal cancer group, the study was terminated.",NA,474774,0.430232558,37,86,NA,Other adverse events: these non-serious events are treatment-emergent.,Temozolomide,"Temozolomide capsules 150 mg/m^2 daily on a 7-day on/7-day off schedule for each 28-day cycle. Temozolomide is the only treatment group, and and all participants received the same dosing regimen."
NCT00424294,Phase 2,2/1/08,The study was terminated early because it was determined that the dual therapy with CP-195543 and celecoxib had poor tolerability and a high discontinuation rate.,See Detailed Description field,474124,0.028571429,1,35,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study. All causality treatment-emergent SAEs and Other AEs were reported.",Placebo and Celecoxib,Placebo matched to CP-195543 capsule orally twice daily along with celecoxib capsule 200 milligram (mg) orally twice daily for 12 weeks. A stable dose of methotrexate greater than or equal to (>=) 10 milligram per week (mg/week) and less than or equal to (<=) 25 mg/week via oral or parenteral route was continued as background therapy.
NCT00424294,Phase 2,2/1/08,The study was terminated early because it was determined that the dual therapy with CP-195543 and celecoxib had poor tolerability and a high discontinuation rate.,See Detailed Description field,474123,0.058823529,2,34,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study. All causality treatment-emergent SAEs and Other AEs were reported.",CP-195543 and Celecoxib,CP-195543 capsule 400 mg orally twice daily along with celecoxib capsule 200 mg orally twice daily for 12 weeks. A stable dose of methotrexate >=10 mg/week and <=25 mg/week via oral or parenteral route was continued as background therapy.
NCT00427011,Phase 2,4/1/08,"Due to early termination, a limited number of subjects (n=26) were screened for inclusion in the study and only 25 subjects were analyzed. The majority of subjects did not reach the scheduled Week 56 assessment.",Study stopped due to lack of efficacy.,472807,0.08,2,25,NA,NA,Perampanel,"Subjects entered this open-label extension study from the double-blind core study (E2007 A001 214), and included the placebo subjects. During the titration phase (lasting 12 weeks), subjects started on perampanel 2mg once daily for 2 weeks, 4 mg for 2 weeks, 6 mg for 2 weeks and finally, 8 mg until the end of the trial. Subjects remained on the same dose or had their dose reduced to their previously tolerated dose. Subjects were allowed to reduce the dose one or two steps, but only one step was allowed at a visit. Those subjects requiring more than two dose reductions were withdrawn. Subjects who did not tolerate the 2mg dose were discontinued from the study."
NCT00441168,Phase 2,1/1/08,"Due to a substantial decline in the use of the VAD regimen as standard of care, recruitment of the study was halted at 30 subjects. It was not possible to statistically evaluate any long term efficacy parameter.",TRIAL STOPPED due to a change in standard of care and the required patient numbers could no   longer be achieved,467484,0.375,6,16,"For up to 6 to 8 cycles, consisting of 28 days each, and for up to a 1-year follow-up period",NA,VAD Treatment,vincristine: 0.4mg IV push on days 1 to 4; adriamycin: 9mg/må_ IV push on days 1 to 4; dexamethasone: 40 mg daily days 1- 4/9-12/17-20 - cycle 1 / days 1-4/17-20 - subsequent cycle
NCT00441168,Phase 2,1/1/08,"Due to a substantial decline in the use of the VAD regimen as standard of care, recruitment of the study was halted at 30 subjects. It was not possible to statistically evaluate any long term efficacy parameter.",TRIAL STOPPED due to a change in standard of care and the required patient numbers could no   longer be achieved,467483,0.384615385,5,13,"For up to 6 to 8 cycles, consisting of 28 days each, and for up to a 1-year follow-up period",NA,PAD Treatment,"bortezomib: 1.3 mg/må_ intravenous (IV) bolus on days 1, 4, 8, and 11; adriamycin: 9mg/må_ IV push on days 1 to 4; dexamethasone: 40 mg daily days 1- 4/9-12/17-20 - cycle 1 / days 1-4/17-20 - subsequent cycle"
NCT00441701,Phase 2,10/1/08,NA,NA,467190,0.045454545,1,22,Up to 30 days after last dose of study drug (Up to 16 weeks),Part 2 was not conducted under this protocol.,Part 1: Navarixin 10 mg,Cohort 2: Participants receive navarixin 10 mg (one 10 mg capsule and two placebo capsules) QD for up to 12 weeks
NCT00441701,Phase 2,10/1/08,NA,NA,467188,0.121212121,4,33,Up to 30 days after last dose of study drug (Up to 16 weeks),Part 2 was not conducted under this protocol.,Part 1: Placebo to Navarixin (Pooled),Pooled Placebo Cohorts: Participants receive placebo to navarixin (three capsules) QD for up to 12 weeks
NCT00441701,Phase 2,10/1/08,NA,NA,467191,0.045454545,1,22,Up to 30 days after last dose of study drug (Up to 16 weeks),Part 2 was not conducted under this protocol.,Part 1: Navarixin 3 mg,Cohort 1: Participants receive navarixin 3 mg (three 1 mg capsules) QD for up to 12 weeks
NCT00441701,Phase 2,10/1/08,NA,NA,467189,0.045454545,1,22,Up to 30 days after last dose of study drug (Up to 16 weeks),Part 2 was not conducted under this protocol.,Part 1: Navarixin 30 mg,Cohort 3: Participants receive navarixin 30 mg (three 10 mg capsules) QD for up to 12 weeks
NCT00442598,Phase 2,4/1/08,NA,NA,466644,0.3,3,10,NA,NA,Glufosfamide q7 Days Low,"1-hour infusion of glufosfamide at a dose of 1,660 mg/m2 on Days 1, 8 and 15 of a 21-day cycleGlufosfamide"
NCT00442598,Phase 2,4/1/08,NA,NA,466645,0.285714286,2,7,NA,NA,Glufosfamide q21 Days,"1-hour infusion of glufosfamide at a dose of 5,000 mg/m2 on Day 1 of a 21-day cycleGlufosfamide"
NCT00447122,Phase 2,8/1/08,NA,NA,464755,0.034482759,1,29,NA,NA,Treatment,"lapatinib, 1,500 mg/day, and Gemcitabine, 1 gm/m2/week for 3 weeks followed by 1 week off, until disease progression"
NCT00447226,Phase 2,9/1/09,Study terminated prematurely: preliminary assessment (prompted by low screening/enrollment rates) showed primary objective of tumor response rate not met. Also unable to test primary treatment comparison after randomization following SD at 12 wks.,The study had failed to meet the primary objective of tumor response rate at 12 weeks from   first dose.,464751,0.125,4,32,"All adverse events (AEs) and serious adverse events (SAEs), regardless of relationship to lapatinib, were collected from the first dose until 5 days after the last dose of study medications (up to 84.1 weeks).","The AEs and SAEs presented below represent data collected from all participants, whether taking open-label lapatinib or whether randomized to lapatinib/placebo. The SAE of cerebral hemorrhage was reported 2 days after the last dose of study drug was taken and was thus not an on-treatment event.",All Participants,"All participants treated in the open-label phase (1500 mg lapatinib, orally once a day), including those subsequently randomized to lapatinib (1500 mg, orally once a day) or matching placebo"
NCT00448864,Phase 2,8/1/08,NA,Experience gained from this study is sufficient to design and facilitate the follow-on study.,464291,0.346153846,9,26,NA,NA,Ecallantide - Low Dose Regimen,"Participants received a maximum of 15 milligrams (mg) ecallantide in stages. Intravenous (IV) infusion of 0.6 milligrams per milliliter (mg/mL) ecallantide was administered at 2.92 milliliters per minute (mL/min) for 20 minutes. The infusion rate was then reduced to 0.583 mL/min for 160 minutes, or until the end of cardiopulmonary bypass (CPB), whichever came first. At the termination of the initial infusion, a second infusion of 0.4 mg/mL ecallantide was started at 38 mL/hr for 4 hours."
NCT00448864,Phase 2,8/1/08,NA,Experience gained from this study is sufficient to design and facilitate the follow-on study.,464290,0.16,4,25,NA,NA,Ecallantide - High Dose Regimen,"Participants received a maximum of 91 mg ecallantide in stages. IV infusion of 0.6 mg/mL ecallantide was administered at 2.92 mL/min for 20 minutes. The infusion rate was then reduced to 0.583 mL/min for 160 minutes, or until the end of CPB, whichever came first. At the termination of the initial infusion, an infusion of normal saline was started at 38 mL/hr for 4 hours."
NCT00448864,Phase 2,8/1/08,NA,Experience gained from this study is sufficient to design and facilitate the follow-on study.,464289,0.388888889,7,18,NA,NA,Placebo,"Participants received placebo in stages. IV infusion placebo was administered at 2.92 mL/min for 20 minutes. The infusion rate was then reduced to 0.583 mL/min for 160 minutes, or until the end of CPB, whichever came first. At the termination of the initial infusion, a second infusion of placebo was started at 38 mL/hr for 4 hours."
NCT00449163,Phase 2,3/1/10,A total of 25 subjects were enrolled however; data were analyzed for 22 subjects only. Study was terminated early by the University of Miami Institutional Review Board.,Study terminated by University of Miami Institutional Review Board,464104,0.5,11,22,NA,NA,Single Arm,irinotecan hydrochloride : adjuvant therapy : neoadjuvant therapy : floxuridine : leucovorin calcium : bevacizumab :
NCT00452387,Phase 2,1/1/09,"Early termination, according to the stopping rule included in the protocol, leading to a small number of subjects analyzed",Early stopping rule,463432,0.454545455,10,22,Adverse events were collected beginning on day 1 of study treatment until one month after the end of study treatment.,"Systematic Assessment - subjects were assessed for adverse events on day 1 of each cycle by either the research coordiantor, treating physician, or other appropriate sub-investigator.","Treatment Group: Mitoxantrone, Prednisone, Plus Sorafenib",The treatment plan for all subjects was mitoxantrone 12 mg/m2 IV every 21 days; sorafenib 400 mg po bid daily; and prednisone 5 mg po bid daily.
NCT00453973,Phase 2,9/1/09,Early termination of study due to generation of controlled long-term data in Phase 3 studies. Amended dosing guidelines during the trial to reflect label changes for ESAs; the primary outcome was assessed after the dosing guideline change.,Due to more robust long-term data generated in other active-controlled studies,463015,0.196078431,10,51,NA,NA,Maintenance Switch in Dialysis Participants,"Participants were from a prior Affymax peginesatide treatment study conducted in participants who were on dialysis and had been on Epoetin at study entry, and who were switched to peginesatide (NCT00434330). The median first dose at study start was 0.044 milligram per kilogram (mg/kg) with an interquartile range of 0.028 to 0.076 mg/kg. This group is categorized as Maintenance Switch in Dialysis Participants regardless of dialysis status at the start of or during this study."
NCT00453973,Phase 2,9/1/09,Early termination of study due to generation of controlled long-term data in Phase 3 studies. Amended dosing guidelines during the trial to reflect label changes for ESAs; the primary outcome was assessed after the dosing guideline change.,Due to more robust long-term data generated in other active-controlled studies,463014,0.492063492,31,63,NA,NA,Treatment Initiation in Non-Dialysis Participants,"Participants were from a prior Affymax peginesatide treatment study conducted in participants who were not on dialysis and not on erythropoiesis stimulating agents (ESAs), and who received peginesatide (NCT00228436). The median first dose at study start was 0.024 mg/kg with an interquartile range of 0.017 to 0.035 mg/kg. This group is categorized as Initiation of Treatment in Non-Dialysis Participants regardless of dialysis status at the start of or during this study."
NCT00456846,Phase 2,5/1/13,NA,NA,461811,0.106382979,5,47,"Any Adverse Event (AE) that started after initial study drug administration through the end of the study or 30 days after the last treatment, whichever was later, were followed until the AE had resolved or stabilized. Upt to 61 months.",NA,Abraxane (Prior Taxane Therapy),Participants who had received a taxane as part of their adjuvant therapy received Abraxane (ABI-007) at 100 mg/m^2 given intravenously (IV) over 30 minutes weekly for 3 weeks followed by 1 week rest
NCT00456846,Phase 2,5/1/13,NA,NA,461810,0.184210526,14,76,"Any Adverse Event (AE) that started after initial study drug administration through the end of the study or 30 days after the last treatment, whichever was later, were followed until the AE had resolved or stabilized. Upt to 61 months.",NA,Abraxane (No Prior Taxane Therapy),Participants who had not received a taxane as part of their adjuvant therapy received Abraxane (ABI-007) at 100 mg/m^2 given intravenously (IV) over 30 minutes weekly for 3 weeks followed by 1 week rest
NCT00457951,Phase 2,10/1/09,"PGX-ODSH-2006, Ph II in patients with exacerbation of COPD. There were no safety issues. An interim analysis demonstrated lack of efficacy for the primary and secondary endpoints; therefore, Cantex terminated the study on August 11, 2009.",Interim analysis: safety without efficacy ODSH in patients with acute COPD.,461408,0.028985507,2,69,D1 to D90,"Of the 145 subjects consented in the randomized phase, 138 were randomized. Of the 138 randomized subjects, 134 were included in the safety population; 4 of the 138 randomized subjects did not receive study medication.",ODSH Treatment Group,"Subjects will receive standard of care treatment. ODSH is administered in bolus doses estimated to inhibit inflammatory mediators randomized 1:1 to ODSH 8mg/kg or placebo. The continuous infusion dose will be 0.375 mg/kg/hr over 96 hours.ODSH: Randomized, Blinded, ODSH Arm"
NCT00457951,Phase 2,10/1/09,"PGX-ODSH-2006, Ph II in patients with exacerbation of COPD. There were no safety issues. An interim analysis demonstrated lack of efficacy for the primary and secondary endpoints; therefore, Cantex terminated the study on August 11, 2009.",Interim analysis: safety without efficacy ODSH in patients with acute COPD.,461410,0.076923077,1,13,D1 to D90,"Of the 145 subjects consented in the randomized phase, 138 were randomized. Of the 138 randomized subjects, 134 were included in the safety population; 4 of the 138 randomized subjects did not receive study medication.",Open Label,"Initial six subjects treated with ODSH open-label to confirm safety in subjects with an acute exacerbation of COPD; six additional patients will be enrolled following safety review.Open-Label: ODSH administered open-label"
NCT00457951,Phase 2,10/1/09,"PGX-ODSH-2006, Ph II in patients with exacerbation of COPD. There were no safety issues. An interim analysis demonstrated lack of efficacy for the primary and secondary endpoints; therefore, Cantex terminated the study on August 11, 2009.",Interim analysis: safety without efficacy ODSH in patients with acute COPD.,461409,0.061538462,4,65,D1 to D90,"Of the 145 subjects consented in the randomized phase, 138 were randomized. Of the 138 randomized subjects, 134 were included in the safety population; 4 of the 138 randomized subjects did not receive study medication.",Placebo Comparator: 0.9% Sodium Chloride,"Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride Solution bolus; dose of 0.375mg/kg/hr over 96 hours.Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride: Placebo-Control Arm: Bolus infusion followed by a 96 hour continuous infusion of 0.9%Sodium Chloride"
NCT00459108,Phase 2,4/1/11,"Study was terminated early after the first stage of a two-stage design, allowing for early termination for discouraging results.",Halted early for futility.,461266,0.52,13,25,NA,Other adverse events include all grades and attributions to treatment not included in the Serious adverse event table.,Oral Dasatinib,"Patients receive oral dasatinib at 70 mg twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.dasatinib: Given orally"
NCT00459810,Phase 2,7/1/09,NA,NA,460929,0.142857143,3,21,While on study agents,NA,Transdermal Estradiol and Paclitaxel Poliglumex,All subjects enrolled were treated with transdermal estradiol 0.2 mg/24 hours for 4 weeks followed by the same dose of transdermal estradiol and paclitaxel poliglumex PPX 150 mg/m2 IV every 28 days.
NCT00460551,Phase 2,10/1/08,"The trial was prematurely closed. The original protocol contained Part 1A, followed by Part 1B and Part 2. The trial was terminated when 13 patients were enrolled in Part 1A. Scans for efficacy were planned for Part 1B and Part 2.",Due to considerations regarding the appropriate therapeutic regimen for these patients.,460728,0.538461538,7,13,Up to 3 months,NA,Zalutumumab 8 mg/kg,NA
NCT00470535,Phase 2,9/1/10,This study was terminated earlier due to a phase III study that showed this drug was not better than sorafenib,This study was terminated earlier due to a phase III study that showed this drug inferior to   sorafenib,456562,0.5,9,18,NA,NA,Erlotinib (Tarceva),Erlotinib 150mg orally daily for three weeks
NCT00471718,Phase 1/Phase 2,8/1/09,NA,pharmaceutical company closed study because the treatment was not effective,456342,0.259259259,7,27,NA,NA,Phase I/II: ABT-751,"Phase I: Patients receive oral ABT-751 twice daily on days 1-7 and 15-21. Phase II: Patients receive ABT-751 at 125mg twice daily, 7 days on, 7 days off (x2)for a 28-day cycle"
NCT00472082,Phase 1/Phase 2,4/1/09,NA,This study was terminated at the request of the drug manufacturer.,456291,0.4,2,5,AEs were collected on subjects from time of enrollment through early termination of the study in 02/2009,NA,Efalizumab Conversion,"The study drug Efalizumab will be given as part of a triple drug regimen including mycophenolate mofetil and prednisone. A test dose of Efalizumab 0.7mg/kg will be given at the enrollment visit. Beginning with study visit 2, Efalizumab 1mg/kg will be administered subcutaneously by injection on a weekly basis for 1 year. Mycophenolate mofetil will be given at a dose of 2gm/day which is the same as the standard of care dose. If patient experiences drug toxicity with mycophenolate mofetil they may be reduced and resume a minimum of at least 1gram daily to continue in the study. Patients will be maintained at 10mg of prednisone daily, same as standard of care.efalizumab : Administration of a test dose of efalizumab 0.7mg/kg will be administered at enrollment. Weekly subcutaneous injections of efalizumab 1mg/kg will begin with study visit 2 and continue for 1 year for this pilot study."
NCT00479466,Phase 2,5/1/08,"Sufficient data regarding the dose-response to MK-0893 had been obtained from the first cohort of the study to assess the safety and efficacy, thus the study was discontinued.",Sufficient data regarding the dose-response to MK-0893 had been obtained from the first cohort   of the study to assess the safety and efficacy,453414,0.035714286,2,56,NA,NA,MK0893 80 mg,NA
NCT00479466,Phase 2,5/1/08,"Sufficient data regarding the dose-response to MK-0893 had been obtained from the first cohort of the study to assess the safety and efficacy, thus the study was discontinued.",Sufficient data regarding the dose-response to MK-0893 had been obtained from the first cohort   of the study to assess the safety and efficacy,453416,0.01754386,1,57,NA,NA,MK0893 40 mg,NA
NCT00479466,Phase 2,5/1/08,"Sufficient data regarding the dose-response to MK-0893 had been obtained from the first cohort of the study to assess the safety and efficacy, thus the study was discontinued.",Sufficient data regarding the dose-response to MK-0893 had been obtained from the first cohort   of the study to assess the safety and efficacy,453418,0.087719298,5,57,NA,NA,Placebo,NA
NCT00483119,Phase 2,2/1/11,"Sadly, the trial PI, Dr. Jean-Claude Bystryn, died on August 19, 2010. As a result the study could not be completed and an analysis of the data collected was not performed.",Study was terminated due to the death of the PI.,452394,0.2,1,5,3 years,NA,Group A,"IVIg aloneintravenous immunoglobulin: Gamunex 10% 500/mg/kg/day x four days per cycle total of four cycles"
NCT00483119,Phase 2,2/1/11,"Sadly, the trial PI, Dr. Jean-Claude Bystryn, died on August 19, 2010. As a result the study could not be completed and an analysis of the data collected was not performed.",Study was terminated due to the death of the PI.,452393,0.25,1,4,3 years,NA,Group B,"IVIg with cyclophosphamidecyclophosphamide: cyclophosphamide dose of 2mg/kg/day divided into three-times daily oral administration"
NCT00485472,Phase 2,1/1/08,NA,"Based on the outcome of the planned first interim analysis, it was decided not to continue the   trial. No safety concerns were identified.",451554,0.026315789,2,76,NA,NA,Placebo,Placebo
NCT00485472,Phase 2,1/1/08,NA,"Based on the outcome of the planned first interim analysis, it was decided not to continue the   trial. No safety concerns were identified.",451555,0.055555556,4,72,NA,NA,Lacosamide,Lacosamide (LCM) 400 mg/day
NCT00486265,Phase 1,7/1/09,"On 16 June 2009, the study was terminated for a lack of efficacy. None of the 8 patients had experienced CR or CRi. The secondary efficacy outcome measures were not evaluated due to early termination and small number of participants.",AML assess. of response in Part B patients find treatment failure in all 8 evaluable for   marrow response following a maximum of 2 induction courses of therapy,451369,0.333333333,3,9,NA,NA,AZD4877,"AZD4877 [ Time Frame: administered on days 1,2 and 3]"
NCT00486720,Phase 2,7/1/09,This trial was terminated because the pre-specified futility criterion was met.,NA,451183,0.416666667,5,12,Serious and non-serious adverse experiences occurring from the time of consent up through 30 days after the last dose of study drug were reported.,"One patient was randomized to the Once Daily Dose Schedule, but discontinued before receiving study medication due to a protocol violation and is not included in the safety assessment.",Vorinostat Thrice Daily Dose Schedule,Vorinostat 200 mg three times daily for 14 consecutive days in a 21 day cycle.
NCT00486720,Phase 2,7/1/09,This trial was terminated because the pre-specified futility criterion was met.,NA,451184,0.222222222,2,9,Serious and non-serious adverse experiences occurring from the time of consent up through 30 days after the last dose of study drug were reported.,"One patient was randomized to the Once Daily Dose Schedule, but discontinued before receiving study medication due to a protocol violation and is not included in the safety assessment.",Vorinostat Once Daily Dose Schedule,Vorinostat 400 mg once daily for 14 consecutive days in a 21 day cycle.
NCT00487552,Phase 1,4/1/11,"Enrollment was stopped in Feb 2009, due to the death of a patient after distal stent migration.",Failure to achieve one of the primary endpoints.,450757,0.833333333,10,12,NA,Only 12 of 18 patients are reported in the reported Adverse Events section as Total Number of Participants at Risk. These are the participants that received both the magnets and the stent (primary success).,Magnetic Anastomosis Device (MAD) With Stent,Magnetic Anastomosis Device used with gastro-jejunal or duodenal stent for palliative treatment of gastric outlet obstruction.
NCT00492531,Phase 2,10/1/09,"As a result of early termination due to safety findings, the study was underpowered to assess the effects of sildenafil therapy on the predetermined efficacy endpoints.",Subjects on drug were more likely to have severe pain crises requiring hospitalization.,448593,0.459459459,17,37,"Safety assessments were conducted at baseline, weeks 6, 10 (excluding echocardiography), and 16.","Treatment group differences in AEs and SAEs were evaluated via Cochran-Mantel-Haenszel chi-square tests, controlling for TRV stratum. The study was stopped early due to the higher percentage of subjects experiencing an SAE in the sildenafil arm as compared to the placebo arm.",Sildenafil,"Subjects received oral sildenafil 20 mg three times daily for six weeks, followed by 40 mg three times daily for four weeks, followed by 80 mg three times daily for six weeks (as tolerated)."
NCT00492531,Phase 2,10/1/09,"As a result of early termination due to safety findings, the study was underpowered to assess the effects of sildenafil therapy on the predetermined efficacy endpoints.",Subjects on drug were more likely to have severe pain crises requiring hospitalization.,448592,0.216216216,8,37,"Safety assessments were conducted at baseline, weeks 6, 10 (excluding echocardiography), and 16.","Treatment group differences in AEs and SAEs were evaluated via Cochran-Mantel-Haenszel chi-square tests, controlling for TRV stratum. The study was stopped early due to the higher percentage of subjects experiencing an SAE in the sildenafil arm as compared to the placebo arm.",Placebo,"Subjects received matching oral dose of placebo 20 mg three times daily for six weeks, followed by 40 mg three times daily for four weeks, followed by 80 mg three times daily for six weeks (as tolerated)."
NCT00495625,Phase 2,12/1/10,The Principal Investigator who initiated the study left Moffitt before reaching the target enrollment required to perform the planned analysis.,NA,447549,0.333333333,11,33,3 Years and 4 Months,First Treatment Start Date: 10/13/06 Last Off Study Date: 2/19/10,Sunitinib Malate (SUO11248) Treatment,"Once daily oral doses on days 1-28 of each 42-day cycle. The dose for the first 2 cycles was 37.5 mg daily for 28 days, every 42 days. Dose could be escalated to 50 mg daily for 28 days at the treating investigator's discretion."
NCT00496782,Phase 1,10/1/08,Study terminated prematurely due to slow enrollment. Premature termination of study was not due to any safety concerns. Efficacy data not summarized due to low sample size; only safety was summarized.,See Detailed Description,447194,0.444444444,4,9,NA,NA,CCR5-Tropic HIV-1,"Subjects treated with maraviroc in addition to the antiviral regimen they were receiving at the time of Screening (which was a failing regimen) for 14 days (including Day 14). On Day 15, subjects who had CC chemokine receptor 5 (CCR5) human immunodeficiency virus (HIV) 1 (based on Trofile‰ã¢ assay) continued receiving maraviroc in combination with a new optimized background therapy (OBT) selected by the investigator until End of Study; Maraviroc was dosed orally twice daily (BID) with the total dose adjusted according to the OBT drugs."
NCT00498433,Phase 2,3/1/12,NA,Early termination resulted from interim analysis of the ALTITUDE trial,446878,0.027777778,1,36,NA,"The Safety Population consisted of all patients that received at least one dose of study drug with at least one post-baseline safety assessment.In Part 1 of the study, no events were reported in period 1 when patients received placebo.",Part 2: Placebo run-in Period,"After confirming study eligibility based on inclusion and exclusion criteria, patients will undergo a two week single-blind placebo run-in phase."
NCT00498433,Phase 2,3/1/12,NA,Early termination resulted from interim analysis of the ALTITUDE trial,446880,0.1,1,10,NA,"The Safety Population consisted of all patients that received at least one dose of study drug with at least one post-baseline safety assessment.In Part 1 of the study, no events were reported in period 1 when patients received placebo.",Part 1: Aliskiren,All eligible patients received 4 week treatment of 300 mg aliskiren o.d..
NCT00509249,Phase 2,12/1/10,Study was terminiated after completion of the first stage due to a lack of activity (no hematological responses were observed).,Early termination for discouraging results,443666,0.388888889,7,18,NA,Other Adverse Events table includes events of all grades and attributions to treatment not included in the Serious Adverse Event table.,Arm I,"Patients will receive aflibercept IV at 4 mg/kg over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.ziv-aflibercept: Given IVlaboratory biomarker analysis: Correlative studiespharmacological study: Correlative studies"
NCT00509366,Phase 2,12/1/11,"The microarray-based prediction model of chemotherapy sensitivity, used to allocate patients into the cisplatin treatment arms, was irreproducible and inaccurate. Quality of life measurements were incomplete and could not be analyzed.",Study terminated due to reproducibility issues with genomics prediction model.,443636,0.5,8,16,May 2007 to December 2011,NA,Cisplatin Sensitive (Pre-Amendment),Pre-amendment cisplatin sensitive refers to patients who experienced adverse events and treated with cisplatin-sensitive protocol based therapy per the amendment dated 1/25/2010.
NCT00509366,Phase 2,12/1/11,"The microarray-based prediction model of chemotherapy sensitivity, used to allocate patients into the cisplatin treatment arms, was irreproducible and inaccurate. Quality of life measurements were incomplete and could not be analyzed.",Study terminated due to reproducibility issues with genomics prediction model.,443634,0.705882353,12,17,May 2007 to December 2011,NA,Cisplatin Resistant (Pre-Amendment),Pre-amendment cisplatin resistant refers to patients who experienced adverse events and treated with cisplatin-resistant protocol based therapy per the amendment dated 1/25/2010.
NCT00509366,Phase 2,12/1/11,"The microarray-based prediction model of chemotherapy sensitivity, used to allocate patients into the cisplatin treatment arms, was irreproducible and inaccurate. Quality of life measurements were incomplete and could not be analyzed.",Study terminated due to reproducibility issues with genomics prediction model.,443632,0.066666667,3,45,May 2007 to December 2011,NA,Screen Failure,"Screen failures constitute patients who were registered into the study and underwent protocol-based procedure (e.g. biopsy, genomic screening), but were not enrolled to genomics-directed, protocol-based therapy. From the participant flow, 9 of the 54 screen failures did not have adverse event follow-up, resulting in a final count of 45 screen failures with adverse event follow-up."
NCT00509366,Phase 2,12/1/11,"The microarray-based prediction model of chemotherapy sensitivity, used to allocate patients into the cisplatin treatment arms, was irreproducible and inaccurate. Quality of life measurements were incomplete and could not be analyzed.",Study terminated due to reproducibility issues with genomics prediction model.,443635,0.625,5,8,May 2007 to December 2011,NA,Cisplatin Sensitive (Post-Amendment),Post-amendment cisplatin sensitive refers to patients who experienced adverse events and treated with cisplatin-sensitive protocol based therapy per the amendment dated AFTER 1/25/2010.
NCT00509366,Phase 2,12/1/11,"The microarray-based prediction model of chemotherapy sensitivity, used to allocate patients into the cisplatin treatment arms, was irreproducible and inaccurate. Quality of life measurements were incomplete and could not be analyzed.",Study terminated due to reproducibility issues with genomics prediction model.,443633,0.666666667,4,6,May 2007 to December 2011,NA,Cisplatin Resistant (Post-Amendment),Pre-amendment cisplatin sensitive refers to patients who experienced adverse events and treated with cisplatin-sensitive protocol based therapy per the amendment dated AFTER 1/25/2010.
NCT00510289,Phase 2,7/1/11,"The limitations of our study include the small sample size, the poor toxicity profile and the lack of response.",Early closure of study due to poor response,443206,0.3125,5,16,30 days after the last dose of study drug,"Serious Adverse Events/Other Adverse events are recorded whether or not they are thought to be related to the study drug. SAEs are listed for all patients who took at least one dose of study drug. Due to early study closure and patient withdrawals, Other AEs are listed for 9 patients only.",All Patients,"SAEs are listed for all patients who took at least one dose of study drug. Due to early study closure and patient withdrawals, Other AEs are listed for 9 patients only."
NCT00512148,Phase 2,4/1/11,NA,24 months follow up completed without substantial change to the profile.,442394,0.571428571,4,7,periodically within the first 12 months as well as during long term follow up out to 5 years.,Adverse events are reported for 7 subjects who were enrolled in the study. One patient withdrew prior to bladder biopsy and is included in the safety population but not in the all implanted population used for efficacy analysis.,Safety Population,Patients who underwent screening procedures and met inclusion/exclusion criteria.
NCT00512798,Phase 1/Phase 2,3/1/08,NA,This study was terminated due to lack of efficacy,442355,0.142857143,4,28,NA,NA,Phase II,NA
NCT00512798,Phase 1/Phase 2,3/1/08,NA,This study was terminated due to lack of efficacy,442356,0.315789474,6,19,NA,NA,Phase I,NA
NCT00521989,Phase 2,7/1/09,NA,"CRx-102-006 study results, negative",438734,0.017241379,1,58,NA,NA,Placebo,Placebo
NCT00521989,Phase 2,7/1/09,NA,"CRx-102-006 study results, negative",438730,0.01754386,1,57,NA,NA,CRx-102 (2.7/360 mg),CRx-102 dose 3 (2.7 mg prednisolone + 360 mg dipyridamole)
NCT00521989,Phase 2,7/1/09,NA,"CRx-102-006 study results, negative",438731,0.018518519,1,54,NA,NA,CRx-102 (2.7/180 mg),CRx-102 dose 2 (2.7 mg prednisolone + 180 mg dipyridamole)
NCT00521989,Phase 2,7/1/09,NA,"CRx-102-006 study results, negative",438732,0.035714286,2,56,NA,NA,CRx-102 (2.7/90 mg),CRx-102 dose 1 (2.7 mg prednisolone + 90 mg dipyridamole)
NCT00521989,Phase 2,7/1/09,NA,"CRx-102-006 study results, negative",438733,0.018518519,1,54,NA,NA,Prednisolone,Prednisolone 2.7 mg
NCT00522301,Phase 2,3/1/08,Early termination as it would not meet it's primary endpoint of improved survival. None of the patients completed the study.,NA,438681,0.2,1,5,NA,NA,Oral Sorafenib (BAY43-9006),Sorafenib will be administered as 400 mg orally daily x 28 days (continuous).
NCT00524589,Phase 2,9/1/10,NA,closed due to futility,437715,0.222222222,4,18,NA,NA,Dexamethasone and Calcitriol,"Patients receive oral dexamethasone once on days 1 and 2 and calcitriol IV over 1 hour on day 2. Treatment repeats weekly.calcitriol: IVdexamethasone: Oralprotein expression analysis: Correlative Studylaboratory biomarker analysis: Correlative Study"
NCT00526890,Phase 2,9/1/10,NA,lack of efficacy,436859,0.25,4,16,NA,NA,CPSR,"Concurrent Carboplatin, Paclitaxel and Selenomethionine in Combination with Radiation"
NCT00527878,Phase 2,6/1/11,NA,Failure to enroll adequate patient numbers due to small number of eligible patients,436472,0.333333333,4,12,NA,Adverse events were not analyzed for each participant as 7 participants did not complete the study and so we were not able to evaluate for adverse events for both placebo and study medication.,Ranitidine,"This was a crossover study and patients received 12 months of ranitidine and 12 months of placebo, unless they terminated the study."
NCT00527878,Phase 2,6/1/11,NA,Failure to enroll adequate patient numbers due to small number of eligible patients,436473,0.363636364,4,11,NA,Adverse events were not analyzed for each participant as 7 participants did not complete the study and so we were not able to evaluate for adverse events for both placebo and study medication.,Placebo,"this was a crossover study and patients received both placebo and study drug (ranitidine), both of which for 12 months, unless they terminated the study."
NCT00528775,Phase 2,3/1/14,"Due to the study‰Ûªs early termination and inadequate number of patients, no patients were analyzed.",drug cannot be prepared commercially,435872,0.833333333,5,6,NA,NA,HPPH,"Patients will receive 4 mg/m2 HPPH (given light exposure precautions) and approximately 2 days later be treated endoscopically with 150J/cm of 665 +-5nm light.HPPH: 4 mg/m2 IVendoscopic procedure: Treatment with 150 joules from laser"
NCT00534209,Phase 1/Phase 2,4/1/10,Study closed early due to low enrollment. A minimum of 2 patients were required for Phase 1. Only 1 patient enrolled.,Per request of Principal Investigator this study was closed.,433465,1,1,1,NA,NA,Arm I,"Patients will receive B7 vaccine once every other week for 2 courses over 12 weeks, for a maximum of 6 vaccines.Given intradermally."
NCT00534313,Phase 2,5/1/11,NA,Lack of efficacy with respect to skin-related lesions in the short-term phase,433444,0.023809524,1,42,NA,NA,Placebo (Short-term Period),"Participants received IV infusions of either dextrose 5% solution or 0.9% sodium chloride solution at a constant rate over approximately 30 minutes on Days 1, 15, and 29 and every 28 days thereafter up to and including Day 141."
NCT00534313,Phase 2,5/1/11,NA,Lack of efficacy with respect to skin-related lesions in the short-term phase,433446,0.093023256,4,43,NA,NA,Abatacept 30/10 (Short-term Period),"Participants received IV infusions of abatacept (30 mg/kg, calculated-dose) over approximately 30 minutes on Days 1 and 15, followed by 10 mg/kg (fixed-dose) abatacept infusion on Day 29 and every 28 days thereafter up to and including Day 141. All participants received a calculated dose on Days 1 and 15 followed by fixed dose based on their screening visit weight (participants weighing <60 kg received 500 mg, 60 to 100 kg received 750 mg, and >100 kg received 1000 mg."
NCT00534313,Phase 2,5/1/11,NA,Lack of efficacy with respect to skin-related lesions in the short-term phase,433445,0.136054422,20,147,NA,NA,Abatacept (Long-term Period),Participants received an open-label abatacept weight-tiered dose of 10 mg/kg at Day 169 and every 28 days.
NCT00534313,Phase 2,5/1/11,NA,Lack of efficacy with respect to skin-related lesions in the short-term phase,433448,0.05,2,40,NA,NA,Abatacept 10/10 (Short-term Period),"Participants received IV infusions of abatacept (10 mg/kg) over approximately 30 minutes on Days 1, 15, and 29 and every 28 days thereafter up to and including Day 141. All participants received a dose based on their screening visit weight as per rheumatoid arthritis label (participants weighing <60 kg received 500 mg, 60 to 100 kg received 750 mg, and >100 kg received 1000 mg)."
NCT00534313,Phase 2,5/1/11,NA,Lack of efficacy with respect to skin-related lesions in the short-term phase,433447,0.022222222,1,45,NA,NA,Abatacept 3/3 (Short-term Period),"Participants received IV infusions of abatacept (3 mg/kg, calculated-dose) over approximately 30 minutes on Days 1, 15, and 29 and every 28 days thereafter up to and including Day 141. All participants received calculated dose based on their screening visit weight."
NCT00538291,Phase 2,NA,Study was terminated due to a lack of efficacy (less than 2 of 13 patients responded to treatment in the first stage of a Simon's two stage design).,Study was terminated early due to lack of efficacy.,431763,0.307692308,4,13,Adverse events occurred over a period of of 17 months.,Other adverse events include all grades and attribution to treatment that are not included in Serious adverse events,Arm 1,Cetuximab 400mg/m2 IV on day 1 over 2 hours then 250 mg/m2 over 1 hour weekly + Xeloda(Capecitabine) 1000mg/m2 BID on days 1-14 repeated every 21 days.
NCT00544674,Phase 2,1/1/09,Decision to close study early based on new data showing that PR104A could also be activated under oxic conditions in tumors that express high levels of AKR1C3. SCLC does not express meaningful levels of the enzyme aldo keto reductase 1C3 (AKR1C3).,Terminated early due to discovery of new mechanism of activation.,429275,0.5,2,4,NA,NA,PR104,1100 mg/m^2 PR104 by IV over one hour every three weeks
NCT00544908,Phase 2,NA,Study was terminated early due to toxicity.,Toxicity,429189,0.285714286,2,7,Other Adverse Events include all events that were not severe adverse events regardless of grade or relation to treatment.,Adverse events recorded over a period of 13 months.,Dasatinib,Dasatinib 70 mg po bid (1 cycle=28 days)
NCT00545948,Phase 2,1/1/12,NA,Study terminated due to reproducibility issues with genomics prediction model.,428656,0.5,4,8,NA,No adverse events were observed for patients considered screen failures.,Arm A-Vinorelbine,Resected tumor was used for genomic expression profiling. Patients with a genomic expression pattern suggestive of vinorelbine sensitivity were given cisplatin + vinorelbine.
NCT00545948,Phase 2,1/1/12,NA,Study terminated due to reproducibility issues with genomics prediction model.,428655,0.142857143,2,14,NA,No adverse events were observed for patients considered screen failures.,Arm B-Pemetrexed,Resected tumor was used for genomic expression profiling. Patients with a genomic expression pattern suggestive of pemetrexed sensitivity were given cisplatin + pemetrexed.
NCT00549328,Phase 2,4/1/09,NA,Study enrolment was delayed in starting and too slow to support further development in this   setting,427414,0.071428571,1,14,NA,NA,Pazopanib 800 mg,Pazopanib 800 milligrams (mg) monotherapy given orally once daily
NCT00551759,Phase 2,4/1/16,NA,"The study used a two-stage design. After stage one, the study was terminated due to excess   toxicity.",425907,0.863636364,19,22,Assessed every 6 weeks while on treatment and for 30 days after the end of treatment,NA,"Neoadjuvant Therapy, Surgery, Adjuvant Therapy",35 days of neoadjuvant chemoradiotherapy with oxaliplatin and infusional 5-fluorouracil plus cetuximab followed by post-operative docetaxel and cetuximab.
NCT00555321,Phase 2,6/1/11,NA,NA,424696,0.807692308,21,26,NA,NA,Tacrolimus,NA
NCT00556075,Phase 2,7/1/09,"The study was prematurely terminated for safety reasons (Proellex studies were put on clinical hold due to liver toxicity). Sponsor was unable to pay vendor, and was therefore not provided with complete study data.",Clinical hold for safety,424008,0.043478261,1,23,NA,NA,50 mg,Proellex 50 mg: 2 capsules daily for 4 months
NCT00556075,Phase 2,7/1/09,"The study was prematurely terminated for safety reasons (Proellex studies were put on clinical hold due to liver toxicity). Sponsor was unable to pay vendor, and was therefore not provided with complete study data.",Clinical hold for safety,424010,0.045454545,1,22,NA,NA,Placebo,Placebo: 1 capsule daily for 4 months
NCT00560352,Phase 1,2/1/11,"The study was terminated due to an unexpectedly low recruitment rate, and no participants were enrolled in a planned dose-expansion phase.",NA,421940,0.666666667,2,3,Continuously from Day 1 until last day of study medication + 30 days (maximum reached: 10 months),NA,"Dasatinib, 100 mg QD","Dasatinib, 100 mg, given QD with 1.3 mg/m^2 of bortezomib in 21-day cycles. Dexamethasone, fixed at 20 mg QD, was administered the day of and 1 day after each bortezomib dosing. In a 21-day cycle, bortezomib was administered by IV bolus twice weekly, on Days 1, 4, 8, and 11, followed by a 10-day (Days 12 to 21) rest period. In a 21-day cycle, dasatinib was taken orally every day, QD in the morning. In a 21-day cycle, dexamethasone was taken orally on Days 1, 2, 4, 5, 8, 9, 11, and 12, at the same time as dasatinib. On the days when bortezomib and dasatinib were administered together, the morning dose of dasatinib was to be followed 1-2 hours by the dose of bortezomib."
NCT00560352,Phase 1,2/1/11,"The study was terminated due to an unexpectedly low recruitment rate, and no participants were enrolled in a planned dose-expansion phase.",NA,421939,0.25,1,4,Continuously from Day 1 until last day of study medication + 30 days (maximum reached: 10 months),NA,"Dasatinib, 140 mg QD","Dasatinib, 140 mg, administered QD with 1.3 mg/m^2 of bortezomib in 21-day cycles. Dexamethasone, fixed at 20 mg QD, was administered the day of and 1 day after each bortezomib dosing.In a 21-day cycle, bortezomib was administered by IV bolus twice weekly, on Days 1, 4, 8, and 11, followed by a 10-day (Days 12 to 21) rest period. In a 21-day cycle, dasatinib was taken orally every day, QD in the morning. In a 21-day cycle, dexamethasone was taken orally on Days 1, 2, 4, 5, 8, 9, 11, and 12, at the same time as dasatinib. On the days when bortezomib and dasatinib were administered together, the morning dose of dasatinib was to be followed 1-2 hours by the dose of bortezomib."
NCT00560352,Phase 1,2/1/11,"The study was terminated due to an unexpectedly low recruitment rate, and no participants were enrolled in a planned dose-expansion phase.",NA,421938,0.857142857,6,7,Continuously from Day 1 until last day of study medication + 30 days (maximum reached: 10 months),NA,"Dasatinib, 50 mg BID","Dasatinib, 50 mg administered twice daily (BID), with 1.0 mg/m^2 of bortezomib in 21-day cycles. Dexamethasone, fixed at 20 mg once daily (QD), was administered the day of and 1 day after each bortezomib dosing. In a 21-day cycle, bortezomib was administered by intravenous (IV) bolus twice weekly, on Days 1, 4, 8, and 11, followed by a 10-day (Days 12 to 21) rest period. In a 21-day cycle, dasatinib was taken orally every day, BID. In a 21-day cycle, dexamethasone was taken orally on Days 1, 2, 4, 5, 8, 9, 11, and 12, at the same time as dasatinib. On the days when bortezomib and dasatinib were administered together, the morning dose of dasatinib was to be followed 1-2 hours by the dose of bortezomib."
NCT00567879,Phase 1/Phase 2,5/1/11,NA,The study was terminated early due to insufficient evidence of clinical benefit.,418993,0.333333333,1,3,NA,NA,Oral Arm - Schedule B 20mg,20 mg was given three times weekly for two consecutive weeks as part of a 21-day treatment cycle.
NCT00567879,Phase 1/Phase 2,5/1/11,NA,The study was terminated early due to insufficient evidence of clinical benefit.,418996,0.238095238,5,21,NA,NA,Escalation/Expansion: i.v. Arm -20mg/m^2,20 mg/m^2 i.v. was given on day 1 and day 8 of a 21 day cycle.
NCT00567879,Phase 1/Phase 2,5/1/11,NA,The study was terminated early due to insufficient evidence of clinical benefit.,418994,0.166666667,2,12,NA,NA,Oral Arm - Schedule B 15 mg,15 mg was given three times weekly for two consecutive weeks as part of a 21-day treatment cycle.
NCT00567879,Phase 1/Phase 2,5/1/11,NA,The study was terminated early due to insufficient evidence of clinical benefit.,418997,0.142857143,1,7,NA,NA,Escalation: i.v. Arm - 15mg/m^2,15 mg/m^2 i.v. was given on day 1 and day 8 of a 21 day cycle.
NCT00567879,Phase 1/Phase 2,5/1/11,NA,The study was terminated early due to insufficient evidence of clinical benefit.,418995,0.5,3,6,NA,NA,Oral Arm - Schedule A 20mg,20 mg was given twice weekly for two consecutive weeks as part of a 21-day treatment cycle.
NCT00567879,Phase 1/Phase 2,5/1/11,NA,The study was terminated early due to insufficient evidence of clinical benefit.,418998,0.428571429,3,7,NA,NA,Escalation: i.v. Arm - 10mg/m^2,10 mg/m^2 i.v. was given on day 1 and day 8 of a 21 day cycle.
NCT00570531,Phase 2,6/1/13,The study was unable the accrue the required number of patients within a reasonable time and therefore the primary objective was not analyzed.,The study was unable the accrue the required number of patients within a reasonable time.,418195,0.666666667,4,6,NA,NA,Bevacizumab,"Bevacizumab: Pre-Operative Treatment: Bevacizumab will be given over 60-90 minutes through an I.V. catheter on days 2 and 16. Post-Operative Treatment:Bevacizumab given over 60-90 minutes through an I.V. catheter every 21 days for 12 months, starting 6-8 weeks after surgery.Paclitaxel: Pre-Operative Chemotherapy treatment: Paclitaxel 45 mg/m^2 will be administered as a 1-hour intravenous infusion on days 2, 9, 16, 23, and 30. It will be given before cisplatin administration.Cisplatin: Pre-Operative Chemotherapy Treatment: Cisplatin 30 mg/m^2 over 1 hour on days 2, 9, 16, 23, and 30. It will be given after paclitaxel.5-Fluorouracil: Pre-Operative Chemotherapy Treatment: 5-Fluorouracil at 200 mg/m2/day will be given as a continuous intravenous infusion on days #2-33.Radiation Therapy: Pre-Operative Treatment: Radiotherapy will be given Monday through Friday five days a week on days 1-5, 8-12, 15-19, 22-26, and 29-33. Radiotherapy will be administered using MV x-rays."
NCT00572156,Phase 2,3/1/12,The study was prematurely terminated once the last subject had completed three years of treatment (compared to the six years planned in protocol Amendment) for strategic reasons.,The study was prematurely terminated due to strategic reasons.,417703,0.038461538,1,26,Approximate up to 4 years,"Treatment emergent adverse event (TEAEs) Reported in ‰ä´5% Subjects Receiving rhGH Alone or Receiving Combination Therapy.Safety population consisted of all subjects who were randomized. Note that post baseline follow-up data were received for all subjects who were randomized.",1. rhGH Alone,Nutropin AQå¨ (Somatropin [rDNA origin]): rhGH (Somatropin) 45åµg/kg once daily injection
NCT00573131,Phase 2,11/1/10,Study prematurely terminated due to lack of efficacy in primary endpoint.,OncoGel did not show any impact on overall tumor response,417486,0.416666667,30,72,Adverse events were collected through the 12 week Assessment Period,Serious adverse events were collected through the first 30 days after the Week 12 visit,Group 1,"OncoGel, radiation therapy and systemic chemotherapy (cisplatin plus 5-FU) prior to surgical resection."
NCT00573131,Phase 2,11/1/10,Study prematurely terminated due to lack of efficacy in primary endpoint.,OncoGel did not show any impact on overall tumor response,417485,0.307692308,20,65,Adverse events were collected through the 12 week Assessment Period,Serious adverse events were collected through the first 30 days after the Week 12 visit,Group 2,Radiation therapy and systemic chemotherapy (cisplatin plus 5-FU) prior to surgical resection.
NCT00578903,Phase 2,7/1/12,NA,NA,414984,0.454545455,10,22,NA,NA,Patients,Patients with a diagnosis of severe aplastic anemia who require an allogeneic stem cell transplant but lack an Human Leukocyte Antigen (HLA) identical family member.
NCT00581529,Phase 2,8/1/14,The trial was terminated early because fair/poor cosmesis developed in 7 of 32 women.,The trial was terminated early because fair/poor cosmesis developed in 7 of 32 women.,414044,0.235294118,8,34,NA,NA,Radiotherapy,"Patients on protocol will be treated with accelerated radiotherapy, 3.85 Gy per fraction, bid, for 5 consecutive days for a total dose of 38.5 Gy."
NCT00582400,Phase 2,4/1/10,NA,recruiting or enrolling participants has halted prematurely and will not resume; participants   are no longer being examined or treated,413866,0.222222222,2,9,NA,NA,Arsenic Trioxide (Trisenox),"arsenic trioxide: Trisenox will be diluted with 100 to 250 mL 0.9% Sodium Chloride injection, USP, using proper aseptic technique, immediately after withdrawal from the ampule. The Trisenox ampule is single-use and does not contain any preservatives. Unused portions of each ampule should be discarded properly. Trisenox is not to be mixed with other medications.The loading dose of Trisenox will be administered intravenously over 2 hours. The infusion duration may be extended up to 4 hours if acute vasomotor reactions are observed. The drug will be administered IV through a functional peripheral or central venous line. Trisenox is not a vesicant, and may be a mild irritant if administered into the skin without dilution."
NCT00582738,Phase 2,1/1/10,NA,NA,413758,0.5,11,22,NA,NA,EVR (Everolimus),"Initiation of everolimus with discontinuation of CNI/MPA, with or without steroids."
NCT00583115,Phase 2,12/1/13,NA,Unable to enroll subjects,413670,1,1,1,NA,NA,Gleevec,"Drug taken orally 260mg/M2/day once per dayGleevec: 260 mg/M2/day, given once daily by mouth"
NCT00584740,Phase 2,8/1/10,NA,The study was terminated prematurely after futility criterion was met at planned interim   analysis of 41 patients.,413395,0.179487179,7,39,NA,NA,AIN457 Twice 10mg/kg,AIN457 10 mg/kg was given as an intravenous infusion at day 1 and day 22.
NCT00584740,Phase 2,8/1/10,NA,The study was terminated prematurely after futility criterion was met at planned interim   analysis of 41 patients.,413394,0.15,3,20,NA,NA,Placebo,Matching placebo to AIN457 was given as an infusion at day 1 and day 22.
NCT00588146,Phase 2,9/1/11,The study was terminated early because Schering-Plough discontinued supplying study drug.,Schering-Plough discontinued supplying study drug.,412325,0.3,3,10,"Adverse events were collected over the 1-year study by telephone or direct interview. Adverse events were graded according to Modified NCI Common Toxicity Criteria. If a subject discontinued for an adverse event, they were observed for 12 weeks.",NA,Pegylated Interferon Alpha-2b,Weekly subcutaneous injection of pegylated interferon alpha2b 1 microgram/kg/week
NCT00593645,Phase 2,7/1/09,Enrollment was halted after 3 of the first 7 patients expired on days 15/26/32. Predefined early stopping rules were defined that if three deaths occurred in the first 11 patients then it was unlikely to achieve a low treatment-related mortality.,toxicities were worse than expected,410800,0.714285714,5,7,Adverse event collection started from the beginning of treatment through 1 year post transplant.,NA,Arm 1,"Clofarabine 40mg/m2/day IV over two hours daily x 5 days on Days -6 thru -2Cytarabine 1gm/m2/day IV over two hours daily x 5 days on Days -6 thru -2 after the START of Clofarabine.Thymoglobulin 1.0mg/kg IV over 6 hours X 1 day on Day -4, then 2.5mg/kg/day x 2 days on Days -3 and -2.Stem Cell Transplant - On day 0 a minimum of total CD34+ cell dose of 2 x10E6/kg (actual weight of recipient) will be infused."
NCT00594230,Phase 2,3/1/11,"Results of a planned interim analysis demonstrated that the regimen did not demonstrate sufficient evidence of efficacy necessary to justify further enrollment. Per protocol, the results of this analysis led to early termination of the study.","Per protocol, the results of a planned interim analysis demonstrated insufficient efficacy and   led to early termination of the study.",410382,0.3,3,10,NA,NA,Panobinostat 20 mg,"Panobinostat(20 mg PO) will be administered three times a week on Monday, Wednesday and Friday. Treatment will be given over 21 days followed by a 7 day rest period and repeated every 28 days. Patients will be assessed for toxicity on an ongoing basis and disease assessment will be determined every 2 treatment cycles (8 weeks). Patients will be allowed to continue on treatment for a maximum of eight four week treatment cycles. Treatment will be discontinued if there is evidence of disease progression, unacceptable toxicity and/or at the discretion of the investigator."
NCT00594230,Phase 2,3/1/11,"Results of a planned interim analysis demonstrated that the regimen did not demonstrate sufficient evidence of efficacy necessary to justify further enrollment. Per protocol, the results of this analysis led to early termination of the study.","Per protocol, the results of a planned interim analysis demonstrated insufficient efficacy and   led to early termination of the study.",410381,0.375,6,16,NA,NA,Panobinostat 30 mg,"Panobinostat(30 mg PO) will be administered three times a week on Monday, Wednesday and Friday. Treatment will be given over 21 days followed by a 7 day rest period and repeated every 28 days. Patients will be assessed for toxicity on an ongoing basis and disease assessment will be determined every 2 treatment cycles (8 weeks). Patients will be allowed to continue on treatment for a maximum of eight four week treatment cycles. Treatment will be discontinued if there is evidence of disease progression, unacceptable toxicity and/or at the discretion of the investigator."
NCT00595920,Phase 2,12/1/08,NA,Financial Constraints,409758,0.026315789,1,38,NA,NA,Open Label Extension,"30-45 million autologous myelin reactive T cellsTovaxin: 2 mL subcutaneous injections administered by a healthcare provider at weeks 0, 4, 8, 12, and 24 every year as required."
NCT00599131,Phase 2,10/1/10,The study was discontinued prematurely due to an early stopping rule.,The study was discontinued prematurely due to early stopping rules.,408950,0.5,2,4,NA,NA,Chemotherapy/Radiation/Surgery,"Patients will undergo induction chemotherapy with (TPF): Docetaxel (Taxotere) 75 mg/m2 and cisplatin 100 mg/m2 on day 1, and 5-FU 750 mg/m2 days 1-4.On day 20 patients will receive a single dose of cetuximab (C-225) 400 mg/m2.Depending upon disease response, patients will undergo salvage laryngectomy followed by radiation therapy and chemotherapy."
NCT00617890,Phase 2,8/1/13,The study was stopped prematurely for administrative reasons; not all planned endpoints were analyzed.,"The study was prematurely terminated for strategic reasons, not for a safety concern.",401126,0.242424242,8,33,Adverse events are reported from enrollment up to 5 weeks after the end of treatment (up to 2 years),All treated participants; adverse events in the Group 1: 0.3 mg/kg arm that occurred after switching to the 10 mg/kg dose are displayed under the originally assigned treatment.,Group 1: 10mg/kg,"Participants received robatumumab 10 mg/kg IV as a single dose on Day 1, followed by surgery on Day 10 to 14, and four weeks later, resumption of robatumumab 10 mg/kg on the same calendar day (å± 3 days) once every 2 weeks until disease recurrence or up to 1 year of dosing. This group comprised participants with resectable osteosarcoma that relapsed within 6 months of prior definitive treatment (eg surgical metastasectomy) and having at least one prior chemotherapy regimen containing a platinum agent and doxorubicin."
NCT00617890,Phase 2,8/1/13,The study was stopped prematurely for administrative reasons; not all planned endpoints were analyzed.,"The study was prematurely terminated for strategic reasons, not for a safety concern.",401124,0.495652174,57,115,Adverse events are reported from enrollment up to 5 weeks after the end of treatment (up to 2 years),All treated participants; adverse events in the Group 1: 0.3 mg/kg arm that occurred after switching to the 10 mg/kg dose are displayed under the originally assigned treatment.,Group 3: 10mg/kg,"Participants received robatumumab 10 mg/kg IV biweekly until disease recurrence or up to 1 year of dosing. This group comprised participants with Ewing's sarcoma refractory to prior treatment with at least 3 of the following agents: ifosfamide, etoposide, cyclophosphamide, doxorubicin, or vincristine."
NCT00617890,Phase 2,8/1/13,The study was stopped prematurely for administrative reasons; not all planned endpoints were analyzed.,"The study was prematurely terminated for strategic reasons, not for a safety concern.",401127,0.5,17,34,Adverse events are reported from enrollment up to 5 weeks after the end of treatment (up to 2 years),All treated participants; adverse events in the Group 1: 0.3 mg/kg arm that occurred after switching to the 10 mg/kg dose are displayed under the originally assigned treatment.,Group 1: 0.3mg/kg,"Participants received robatumumab 0.3 mg/kg intravenously (IV) as a single dose on Day 1, followed by surgery on Day 10 to 14, and four weeks later, resumption of robatumumab 0.3 mg/kg on the same calendar day (å± 3 days) once every 2 weeks until disease recurrence or up to 1 year of dosing. This group comprised participants with resectable osteosarcoma that relapsed within 6 months of prior definitive treatment (eg surgical metastasectomy) and having at least one prior chemotherapy regimen containing a platinum agent and doxorubicin."
NCT00617890,Phase 2,8/1/13,The study was stopped prematurely for administrative reasons; not all planned endpoints were analyzed.,"The study was prematurely terminated for strategic reasons, not for a safety concern.",401125,0.352941176,12,34,Adverse events are reported from enrollment up to 5 weeks after the end of treatment (up to 2 years),All treated participants; adverse events in the Group 1: 0.3 mg/kg arm that occurred after switching to the 10 mg/kg dose are displayed under the originally assigned treatment.,Group 2: 10mg/kg,Participants received robatumumab 10 mg/kg IV biweekly until disease recurrence or up to 1 year of dosing. This group comprised participants with relapsed and unresectable osteosarcoma refractory to prior chemotherapy with a platinum- and doxorubicin-containing regimen.
NCT00620659,Phase 2,2/1/09,NA,NA,399926,0.017094017,2,117,Patients reported adverse experiences starting from the Screening Visit up until 14 days after the last dose of study drug.,"Patients reported AEs at each visit, and the occurrence of serious adverse experiences was assessed during a telephone contact fourteen days after the last dose of study drug.",Placebo,Matching placebo tablets were provided for the MK0249 1 and 5 mg tablets and for the modafinil 100 mg tablet.
NCT00623727,Phase 2,10/1/10,The recruitment and double-blind study phase were prematurely terminated after a scheduled interim analysis confirmed overt failure regarding the primary endpoint as judged by the independent Data and Safety Monitoring Board.,NA,398702,0.104477612,7,67,NA,NA,rFVIII-FS/Pegylated Liposomes (BAY79-4980) - Double Blind,"Reporting Group 1 (RG1): Double Blind Study, 35 IU/kg body weight of BAY79-4980 1x/week plus 2 dummy injections/week (dummy = rFVIII-FS excipient reconstituted in WFI)"
NCT00623727,Phase 2,10/1/10,The recruitment and double-blind study phase were prematurely terminated after a scheduled interim analysis confirmed overt failure regarding the primary endpoint as judged by the independent Data and Safety Monitoring Board.,NA,398701,0.013888889,1,72,NA,NA,rFVIII-FS/WFI (BAY14-2222) - Double Blind,"Reporting group 2 (RG2): Double Blind Study, 25 IU/kg body weight of rFVIII-FS 3x/week (employing 1 percent POPC-alone liposome (rFVIII-FS-POPC) as blinding agent used for first weekly injection and rFVIII-FS in WFI for 2nd and 3rd injection)"
NCT00623727,Phase 2,10/1/10,The recruitment and double-blind study phase were prematurely terminated after a scheduled interim analysis confirmed overt failure regarding the primary endpoint as judged by the independent Data and Safety Monitoring Board.,NA,398699,0.05,1,20,NA,NA,rFVIII-FS/Pegylated Liposomes (BAY79-4980) - Extension,"Reporting group 4 (RG4): Open Label Extension, 35 IU/kg body weight of BAY79-4980 1x/week plus 2 dummy injections/week (dummy = rFVIII-FS excipient reconstituted in WFI)"
NCT00624468,Phase 2,1/1/11,The Sponsor voluntarily terminated this trial after observing increased Multiple Sclerosis (MS) disease activity in trial 28063 (ATAMS).,EMD Serono voluntarily decided to terminate this trial after observing increased MS disease   activity in trial 28063 ATAMS [Please refer to ATAMS],398374,0.142857143,2,14,Baseline up to Week 48,"ITT population of the double-blind period included all randomized subjects according to their randomized treatment. SFU period population included all randomized participants of double-blind period who participated in the 60-week SFU (N=13,14 for Placebo and Atacicept arms respectively).",Atacicept: SFU Period,Participants who received atacicept in double-blind period were included in SFU period (60 weeks) following premature termination of the trial.
NCT00624468,Phase 2,1/1/11,The Sponsor voluntarily terminated this trial after observing increased Multiple Sclerosis (MS) disease activity in trial 28063 (ATAMS).,EMD Serono voluntarily decided to terminate this trial after observing increased MS disease   activity in trial 28063 ATAMS [Please refer to ATAMS],398375,0.076923077,1,13,Baseline up to Week 48,"ITT population of the double-blind period included all randomized subjects according to their randomized treatment. SFU period population included all randomized participants of double-blind period who participated in the 60-week SFU (N=13,14 for Placebo and Atacicept arms respectively).",Placebo: SFU Period,Participants who received placebo matched to atacicept in double-blind period were included in SFU period (60 weeks) following premature termination of the trial.
NCT00625729,Phase 1/Phase 2,4/1/10,Study was terminated early due to lack of NK expansion and failure to meet primary outcome.,No patients exhibited natural killer cell expansion (primary endpoint).,397978,0.833333333,5,6,Serious adverse events were collected after start of chemotherapy treatment (Day -1) through date of death (all within 6 months).,"Stopping Rules for excess toxicity:Any non-hematologic grade 4 toxicity except for fevers aloneGrade III/IV GvHD or GvHD requiring more than 7 days of therapyHematologic toxicity: prolonged neutropenia defined as an absolute neutrophil count of less than 500 on day +35. Prolonged anemia or thrombocytopenia will not constitute toxicity.",Patients Treated With Natural Killer Cells,"Patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with 1 dose donor natural killer cells infusion, 4 doses rituximab, 6 doses aldesleukin and 5 doses fludarabine and 1 dose cyclosphosphamide."
NCT00630344,Phase 2,1/1/16,NA,Low overall response rate,396742,0.527777778,19,36,NA,NA,RAD-001 in Combination With Bicalutamide,"RAD001 will be administered orally as once daily dose of 10 mg (5 mg tablets) continuously from study day 1 until progression of disease or unacceptable toxicity. Bicalutamide will be administered orally as once daily dose of 50 mg (50 mg tablets) continuously from study day 1 until progression of disease or unacceptable toxicity.RAD001: Taken orally once dailyBicalutamide: Taken orally once daily"
NCT00632203,Phase 2,1/1/11,The interpretation of the study results should be taken with caution because of the small sample size due to early termination.,NA,396032,0.307692308,8,26,NA,NA,Temozolomide Treatment,"Participants received temozolomide at a dose of 75 mg/m^2 orally (PO) daily for 21 consecutive days, followed by a 7-day rest period per 28-day cycle, until progression or up to a maximum of 6 cycles, whichever occurred first."
NCT00632203,Phase 2,1/1/11,The interpretation of the study results should be taken with caution because of the small sample size due to early termination.,NA,396031,0.148148148,4,27,NA,NA,Observation,Observation
NCT00632541,Phase 2,3/1/09,"The study was terminated early due to a poor safety profile as well as the lack of significant efficacy of this combination over bevacizumab alone in the short followup period where it was evaluated. Therefore, secondary objectives were not analyzed.",Significant Toxicities Experienced,395907,0.222222222,4,18,NA,NA,Single Arm A,"Sorafenib 200mg po daily, Bevacizumab 5mg/kg every other week, 1 Cycle = 4 weeks. Imaging every third cycle"
NCT00634933,Phase 2,10/1/12,"As the results of the primary analysis did not meet the predefined efficacy criteria, the development of TRU-015 was discontinued.",The study was terminated on 21 June 2010 due to results not meeting the primary endpoint. No   safety reasons contributed to the termination of the study.,394805,0.036363636,2,55,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",TRU-015 Induction Dose (Part B),"Placebo infusion, matched to TRU-015 (800 mg), IV, placebo matched to methylprednisolone 100 mg IV 1 hr prior to infusion and placebo capsule matched to prednisone 20 mg orally each day for 2 days prior to and on the morning of infusion at Week 24. TRU-015 (800 mg) infusion IV, methylprednisolone 100 mg IV 1 hr prior to infusion and prednisone 20 mg capsule orally each day for 2 days prior to and on the morning of infusion at Week 36."
NCT00634933,Phase 2,10/1/12,"As the results of the primary analysis did not meet the predefined efficacy criteria, the development of TRU-015 was discontinued.",The study was terminated on 21 June 2010 due to results not meeting the primary endpoint. No   safety reasons contributed to the termination of the study.,394808,0.053333333,4,75,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",TRU-015 Single Dose (Part A),"TRU-015 (800 mg) infusion IV, methylprednisolone 100 mg IV 1 hr prior to infusion and prednisone 20 mg capsule orally each day for 2 days prior to and on the morning of infusion at baseline. Placebo infusion, matched to TRU-015 (800 mg), IV, methylprednisolone 100 mg or matching placebo IV 1 hr prior to infusion and prednisone 20 mg capsule or matching placebo orally each day for 2 days prior to and on the morning of infusion at Week 12. Participants in this group were assigned to TRU-SD in the Part B of the study."
NCT00634933,Phase 2,10/1/12,"As the results of the primary analysis did not meet the predefined efficacy criteria, the development of TRU-015 was discontinued.",The study was terminated on 21 June 2010 due to results not meeting the primary endpoint. No   safety reasons contributed to the termination of the study.,394807,0.095890411,7,73,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",TRU-015 Induction Dose (Part A),"TRU-015 (800 mg) infusion IV, methylprednisolone 100 mg IV 1 hr prior to infusion and prednisone 20 mg capsule orally each day for 2 days prior to and on the morning of infusion at baseline. TRU-015 (800 mg) infusion IV, methylprednisolone 100 mg IV 1 hr prior to infusion and prednisone 20 mg capsule or matching placebo orally each day for 2 days prior to and on the morning of infusion at Week 12. Participants in this group were assigned to TRU-ID in the Part B of the study."
NCT00634933,Phase 2,10/1/12,"As the results of the primary analysis did not meet the predefined efficacy criteria, the development of TRU-015 was discontinued.",The study was terminated on 21 June 2010 due to results not meeting the primary endpoint. No   safety reasons contributed to the termination of the study.,394806,0.035714286,2,56,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",TRU-015 Single Dose (Part B),"TRU-015 (800 mg) infusion IV, methylprednisolone 100 mg IV 1 hr prior to infusion and prednisone 20 mg capsule orally each day for 2 days prior to and on the morning of infusion at Week 24. Placebo infusion, matched to TRU-015 (800 mg) IV along with placebo matched to methylprednisolone 100 mg IV 1 hr prior to infusion and placebo matched to prednisone 20 mg capsule orally each day for 2 days prior to and on the morning of infusion at Week 36."
NCT00634933,Phase 2,10/1/12,"As the results of the primary analysis did not meet the predefined efficacy criteria, the development of TRU-015 was discontinued.",The study was terminated on 21 June 2010 due to results not meeting the primary endpoint. No   safety reasons contributed to the termination of the study.,394809,0.094594595,7,74,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",Placebo (Part A),"Placebo infusion, matched to TRU-015 (800 mg), IV along with methylprednisolone 100 mg IV 1 hr prior to infusion and prednisone 20 mg capsule orally each day for 2 days prior to and on the morning of infusion at baseline. Placebo infusion, matched to TRU-015 (800 mg), IV along with methylprednisolone 100 mg or matching placebo IV 1 hr prior to infusion and prednisone 20 mg capsule or matching placebo orally each day for 2 days prior to and on the morning of the infusion at Week 12. Participants in this group were assigned to either Placebo/TRU-SD or Placebo/TRU-ID in the Part B of the study."
NCT00636441,Phase 2,4/1/13,NA,Study terminated due to reproducibility issues with genomics prediction model,393868,0.166666667,1,6,NA,NA,Non-guided AC,"Non-genomics guided treatment; randomized to ACAC: Doxorubicin 60 mg/må_ and Cyclophosphamide 600 mg/må_ (AC) every 3 weeks for 4 cycles as neoadjuvant therapy"
NCT00636441,Phase 2,4/1/13,NA,Study terminated due to reproducibility issues with genomics prediction model,393870,0.5,3,6,NA,NA,Guided AC Non-sensitive,"Genomics guided treatment <60% probability of response to both AC and TC; randomized to ACAC: Doxorubicin 60 mg/må_ and Cyclophosphamide 600 mg/må_ (AC) every 3 weeks for 4 cycles as neoadjuvant therapy"
NCT00636441,Phase 2,4/1/13,NA,Study terminated due to reproducibility issues with genomics prediction model,393867,0.285714286,2,7,NA,NA,Non-guided TC,"Non-genomics guided treatment; randomized to TCTC: Docetaxel 75 mg/må_ and Cyclophosphamide 600 mg/må_ (TC) every 3 weeks for 4 cycles as neoadjuvant therapy"
NCT00636441,Phase 2,4/1/13,NA,Study terminated due to reproducibility issues with genomics prediction model,393872,0.333333333,2,6,NA,NA,Guided AC Sensitive,"Genomically-guided >60% probability of response to ACAC: Doxorubicin 60 mg/må_ and Cyclophosphamide 600 mg/må_ (AC) every 3 weeks for 4 cycles as neoadjuvant therapy"
NCT00636441,Phase 2,4/1/13,NA,Study terminated due to reproducibility issues with genomics prediction model,393866,0.055555556,1,18,NA,NA,Screen Failures,Screen failures constitute patients who were registered to the study but were not assigned treatment for various reasons.
NCT00636441,Phase 2,4/1/13,NA,Study terminated due to reproducibility issues with genomics prediction model,393869,0.333333333,2,6,NA,NA,Guided TC Non-Sensitive,"Genomics guided treatment <60% probability of response to both AC and TC; randomized to TCTC: Docetaxel 75 mg/må_ and Cyclophosphamide 600 mg/må_ (TC) every 3 weeks for 4 cycles as neoadjuvant therapy"
NCT00638378,Phase 2,1/1/09,NA,"According to the protocol, the sponsor terminated the study after it was determined that less   than 2 of the first 22 patients showed a PSA50 response.",392885,0.409090909,9,22,NA,NA,Ruxolitinib,Participants received ruxolitinib 25 mg orally twice daily in 12-hour intervals for 21-day cycles for as long as the study medication was tolerated and provided clinical benefit.
NCT00638820,Phase 2,5/1/08,Only 3 participants were treated in this study; all died by Day 100. Data for both treatment arms were combined due to low number. (Arm 1 utilized mobilized peripheral blood or marrow (related or unrelated). Arm 2 received cord blood transplants).,Excess toxicity,392824,1,3,3,Adverse events were collected from Day 1 through Day 100 of the study.,NA,Patients With Osteopetrosis Who Received Transplant,All patients enrolled with osteopetrosis and received transplant.
NCT00642902,Phase 2,9/1/09,Sponsor voluntarily decided to prematurely terminate this trial due to an increase in multiple sclerosis (MS) disease activity observed in atacicept arms as compared to placebo during a routine independent data monitoring committee (IDMC) review.,Sponsor voluntarily decided to terminate trial due to increased MS disease activity in   atacicept arms as compared to placebo during a routine IDMC review.,391381,0.047619048,3,63,From the first dose of study drug administration up to 12 weeks after the last dose of the study drug,NA,Atacicept 75 mg,"Atacicept was administered subcutaneously at a dose of 75 mg twice a week for initial 4 weeks as loading dose, followed by 75 mg once a week for subsequent 32 weeks."
NCT00642902,Phase 2,9/1/09,Sponsor voluntarily decided to prematurely terminate this trial due to an increase in multiple sclerosis (MS) disease activity observed in atacicept arms as compared to placebo during a routine independent data monitoring committee (IDMC) review.,Sponsor voluntarily decided to terminate trial due to increased MS disease activity in   atacicept arms as compared to placebo during a routine IDMC review.,391382,0.047619048,3,63,From the first dose of study drug administration up to 12 weeks after the last dose of the study drug,NA,Atacicept 25 mg,"Atacicept was administered subcutaneously at a dose of 25 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 25 mg once a week for subsequent 32 weeks."
NCT00642902,Phase 2,9/1/09,Sponsor voluntarily decided to prematurely terminate this trial due to an increase in multiple sclerosis (MS) disease activity observed in atacicept arms as compared to placebo during a routine independent data monitoring committee (IDMC) review.,Sponsor voluntarily decided to terminate trial due to increased MS disease activity in   atacicept arms as compared to placebo during a routine IDMC review.,391383,0.015873016,1,63,From the first dose of study drug administration up to 12 weeks after the last dose of the study drug,NA,Placebo,"Placebo matched to atacicept was administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 32 weeks."
NCT00642902,Phase 2,9/1/09,Sponsor voluntarily decided to prematurely terminate this trial due to an increase in multiple sclerosis (MS) disease activity observed in atacicept arms as compared to placebo during a routine independent data monitoring committee (IDMC) review.,Sponsor voluntarily decided to terminate trial due to increased MS disease activity in   atacicept arms as compared to placebo during a routine IDMC review.,391380,0.015384615,1,65,From the first dose of study drug administration up to 12 weeks after the last dose of the study drug,NA,Atacicept 150 mg,"Atacicept was administered subcutaneously at a dose of 150 mg twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 32 weeks."
NCT00652899,Phase 2,8/1/09,"Endpoint for association of clinical benefit response with donor/recipient KIR ligand matching status is not evaluable due to 0 complete responders.Correlative laboratory objectives are irrelevant due to ineffectiveness of study regimen.",Withdrawn due to toxicity,389091,0.642857143,9,14,Serious adverse events were monitored through the follow-up period; death was followed for up to 2 years after Day 1 treatment.,Adverse event collection for the purposes of this study focused on targeted adverse events and unexpected adverse events at specific time points in relation to the NK cell infusion and post infusion IL-2 injections.,All Patients Enrolled,This group includes all patients consented to participate in this study.
NCT00655824,Phase 2,3/1/13,Development of the IV route of ofatumumab (OFA) administration in RA will no longer be pursued. This study was prematurely terminated; OFA treatment was discontinued. Participants could complete only <=7 treatment courses and a follow-up evaluation.,"The clinical development of intravenously administered ofatumumab in RA will no longer be   pursued, so this study was prematurely terminated by the Sponsor.",388177,0.025316456,2,79,Adverse events (AEs) were collected in the period beginning from the first treatment cycle until the end of the Treatment Period (up to Study Week 144). Only Serious adverse events (SAEs) were collected up to the Follow-up Period (up to Study Week 204).,"Although the study was designed such that only SAEs were to be collected for the Follow-up Period, non-serious AEs were recorded for some participants.",Ofatumumab 700 mg IV Infusion: Follow-up Period,"After completing or withdrawing from the Treatment Period, participants were followed up every 12 weeks (for a maximum of 2 years in the Follow-up Period) until CD19+ cells returned to Baseline or normal levels."
NCT00655824,Phase 2,3/1/13,Development of the IV route of ofatumumab (OFA) administration in RA will no longer be pursued. This study was prematurely terminated; OFA treatment was discontinued. Participants could complete only <=7 treatment courses and a follow-up evaluation.,"The clinical development of intravenously administered ofatumumab in RA will no longer be   pursued, so this study was prematurely terminated by the Sponsor.",388178,0.119565217,11,92,Adverse events (AEs) were collected in the period beginning from the first treatment cycle until the end of the Treatment Period (up to Study Week 144). Only Serious adverse events (SAEs) were collected up to the Follow-up Period (up to Study Week 204).,"Although the study was designed such that only SAEs were to be collected for the Follow-up Period, non-serious AEs were recorded for some participants.",Ofatumumab 700 mg IV Infusion: Treatment Period,"Ofatumumab was administered in the dose of 700 milligrams (mg) as two intravenous (IV) infusions separated by 2 weeks for the first treament course. The remaining treatment courses were given at individualized time intervals when a clinical response had been achieved following the previous treatment course and a subsequent worsening in disease activity had been observed. For the remaining treatment courses, the interval between the treatment courses was at least 16 weeks from the first infusion in the previous treatment course irrespective of progression in disease activity. After each treatment course, the participants attended their next trial visit 8 weeks after the first infusion of that course, followed by trial visits every 4 weeks up to Week 24, and subsequent visits every 8 weeks until the next treatment course. A maximum of 9 treatment courses were allowed."
NCT00659334,Phase 2,3/1/10,Early trial termination due to study drug Combidex no longer manufactured.,"AMAG not continuing with Combidex, the study drug",386876,0.4,2,5,NA,"Other adverse events were collected/assessed, but none affected over 5% of the patient population.",Neurosurgery Only (Group 3),Adults with brain tumors to receive neurosurgery only (NO Combidex)
NCT00659334,Phase 2,3/1/10,Early trial termination due to study drug Combidex no longer manufactured.,"AMAG not continuing with Combidex, the study drug",386877,0.243902439,10,41,NA,"Other adverse events were collected/assessed, but none affected over 5% of the patient population.",Combidex and Neurosurgery (Group 2),Adults with brain tumors to receive Combidex infusion and neurosurgery
NCT00659334,Phase 2,3/1/10,Early trial termination due to study drug Combidex no longer manufactured.,"AMAG not continuing with Combidex, the study drug",386875,0.5,1,2,NA,"Other adverse events were collected/assessed, but none affected over 5% of the patient population.",Combidex Only (Group 4),Children with brain tumors to receive Combidex only
NCT00659334,Phase 2,3/1/10,Early trial termination due to study drug Combidex no longer manufactured.,"AMAG not continuing with Combidex, the study drug",386878,0.217391304,10,46,NA,"Other adverse events were collected/assessed, but none affected over 5% of the patient population.",Combidex Only (Group 1),Adults with brain tumor to receive Combidex infusion only
NCT00664105,Phase 2,6/1/08,"Outcome measure #4, Number of participants with AEs by grade, will not match the total number of participants in this study. Some participants have multiple events in one or more grade designations or some participants have no events at all.",Treatment became standard.,385214,0.587301587,37,63,NA,NA,Chemo-radio Therapy,"Patients will receive carboplatin and docetaxel will be given weekly for seven weeks during concurrent radiotherapy. After a 3-week rest, patients will receive treatment every 3 weeks for two cycles of consolidation treatment."
NCT00667277,Phase 2,3/1/10,The study was terminated due to lack of response activity in the setting of an unacceptable toxicity profile at the completion of the first stage.,lack of response activity in the setting of an unacceptable toxicity profile,383485,0.538461538,7,13,NA,NA,Bevacizumab (Avastin),"Use of bevacizumab (Avastin) in the treatment of myelofibrosis.bevacizumab (Avastin): 15 mg/kg of bevacizumab by IV infusion once every 3 weeks (1 cycle) for 12 weeks (4 cycles)"
NCT00669903,Phase 2,11/1/08,NA,"Since AZD0328 is unlikely to meet the current Target Product Profile, Astrazeneca decided to   stop further development of AZD0328",382560,0.045454545,1,22,NA,NA,Placebo,Placebo
NCT00677924,Phase 1/Phase 2,4/1/09,The trial was prematurely closed when 9 out of 97 patients were enrolled. The trial design was originally divided in two parts. Patient allocation was terminated before Part 2 was started.,Due to changes in portfolio review,379878,0.666666667,2,3,Adverse events were collected during 10 months,NA,Zalatumumab 8 mg/kg,NA
NCT00677924,Phase 1/Phase 2,4/1/09,The trial was prematurely closed when 9 out of 97 patients were enrolled. The trial design was originally divided in two parts. Patient allocation was terminated before Part 2 was started.,Due to changes in portfolio review,379877,0.5,3,6,Adverse events were collected during 10 months,NA,Zalutumumab 16 mg/kg,NA
NCT00678288,Phase 2,6/1/09,The study was terminated early by the Sponsor due to low accrual. No efficacy analyses were performed.,NA,379767,0.5,5,10,NA,"Acronyms in Adverse Event section: not otherwise specified (NOS), Alanine transaminase (ALT), Aspartate transaminase (AST)","Sorafenib (Nexavar, BAY43-9006)","Sorafenib 400 mg (two 200 mg tablets) twice daily (bid) per os (po), continuously."
NCT00681811,Phase 2,10/1/10,Early termination due to lack of efficacy.,Terminated prior to planned completion date due to lack of efficacy.,378647,0.333333333,2,6,"Up to end of study (Week 139) which was defined as until HGT-1111 was commercially available, the patient's participation was discontinued, or the study was terminated by the Sponsor.","All other adverse events (>5% reporting frequency) reported here are related to drug administration, all were infusion-related reactions.",100 U/kg HGT1111,Participants received 100 U/kg of HGT1111 IV infusion every other week.
NCT00681811,Phase 2,10/1/10,Early termination due to lack of efficacy.,Terminated prior to planned completion date due to lack of efficacy.,378646,0.8,4,5,"Up to end of study (Week 139) which was defined as until HGT-1111 was commercially available, the patient's participation was discontinued, or the study was terminated by the Sponsor.","All other adverse events (>5% reporting frequency) reported here are related to drug administration, all were infusion-related reactions.",200 U/kg HGT1111,Participants received 200 U/kg of HGT1111 IV infusion every other week.
NCT00683085,Phase 1/Phase 2,5/1/09,Early termination leading to small numbers of subjects analyzed,Lack of eligible patient,378305,0.5,1,2,During 2 months after initiation of vaccination,Serious adverse events include grade 4 hematological or grade 3 to 4 non-hematological adverse events,Peptide 1 mg Twice Weekly for 8 Weeks With Gemcitabine,"HLA-A*0201-restricted VEGFR1-specific peptide, VEGFR1-A02-770(TLFWLLLTL) 1 mg, subcutaneous injection, twice every weeks for eight weeks (total 16 doses) combined with incomplete Freund adjuvant (IFA) and gemcitabine 1,000 mg/m^2 of body surface area"
NCT00683449,Phase 2,3/1/09,NA,"Data from Dose Groups 1,2 and other MN-221 studies resulted in the determination of a more   appropriate dosing scheme for MN-221 in subjects with asthma.",378265,0.307692308,4,13,NA,NA,MN-221 Placebo i.v. Infusion,"MN-221 Placebo i.v. infusion. Until the subject‰Ûªs FEV1 reached ‰ä´ 70% predicted, the subject continued to receive the following standard treatment and assessment during the study treatment period: Assessment of subject‰Ûªs signs and symptoms,Completion of a dyspnea index scale,Supplemental oxygen to maintain oxygen saturation, as measured by pulse oximetry of ‰ä´ 90%,Albuterol (2.5 mg) via nebulizer given hourly. NOTE: Albuterol (2.5 mg) via nebulizer may have been given up to every 20 minutes if deemed to be indicated by the Investigator.Ipratropium (0.5 mg) via nebulizer may have been given every hour if deemed to be indicated by the Investigator.Spirometry completed within 10 minutes of nebulizer treatments, followed byReassessment of signs and symptoms. If the subject did not improve to FEV1 ‰ä´70% of predicted during the study treatment period, the subject may have continued to receive further treatment, including hospital admission, at the discretion of the Investigator."
NCT00683449,Phase 2,3/1/09,NA,"Data from Dose Groups 1,2 and other MN-221 studies resulted in the determination of a more   appropriate dosing scheme for MN-221 in subjects with asthma.",378262,0.5,1,2,NA,NA,"1,995 ë_g MN-221 i.v. Over 15 Minutes and 25 Minutes","Two subjects were randomized to receive 450 ë_g dose i.v. Instead, Subject 0010015 received 1,995 ë_g i.v. over 15 minutes infusion; Subject 0010016 received 1,995 ë_g i.v. over 25 minutes infusion."
NCT00683449,Phase 2,3/1/09,NA,"Data from Dose Groups 1,2 and other MN-221 studies resulted in the determination of a more   appropriate dosing scheme for MN-221 in subjects with asthma.",378263,0.166666667,1,6,NA,NA,450 ë_g MN-221 i.v. for 15 Minutes,30 ë_g/minute for 15 minutes (total dose of 450 ë_g) administered i.v.
NCT00689052,Phase 2,NA,Early termination leading to no number of subjects analysed for any outcome measure,NA,375927,0.032258065,1,31,Up to 72 days,NA,Placebo,NA
NCT00695318,Phase 2,NA,NA,NA,374487,0.176470588,3,17,NA,Each patient received a sham injection in one eye and active treatment in the other eye.,Sham Injection,"Sham InjectionSham Injection: Sham injectionOcular AEs"
NCT00695318,Phase 2,NA,NA,NA,374485,0.285714286,2,7,NA,Each patient received a sham injection in one eye and active treatment in the other eye.,0.5 ug/Day,"0.5 åµg/DayFluocinolone Acetonide: 0.5 åµg/DayOcular AEs"
NCT00695318,Phase 2,NA,NA,NA,374486,0.3,3,10,NA,Each patient received a sham injection in one eye and active treatment in the other eye.,0.2 ug/Day,"0.2 åµg/DayFluocinolone Acetonide: 0.2 åµg/DayOcular AEs"
NCT00696787,Phase 2,1/1/09,NA,NA,373848,0.023255814,1,43,NA,NA,Pregabalin,"In the first stage, subjects were randomly assigned to receive Pregabalin 450 mg/day. Study was stopped after stage 1 by sponsor."
NCT00718523,Phase 2,11/1/14,NA,The steering committee of the TRIO014 study has taken the decision to stop the TRIO014 trial.,364531,0.402597403,31,77,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,For participant flow module it is based on Intent To Treat so the patients are counted according to their ‰ÛÏrandomization group‰Û.For ‰ÛÏparticipants at risk‰Û the patients are grouped by the ‰ÛÏactual treatment‰Û 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.,A Control,"Placebo plus paclitaxel/carboplatin chemotherapy administered on Day 1 of each 21-day cycle for 6 cycles - then 6 additional cycles of placebo administered on Day 1 of each 21-day cycle.AMG 479 Placebo: Matching placebo administered Day 1 of each 21 day cycle."
NCT00718523,Phase 2,11/1/14,NA,The steering committee of the TRIO014 study has taken the decision to stop the TRIO014 trial.,364530,0.340909091,30,88,The monitoring period for AEs started from signature of the ICF and continued up to 30 days after last dose.,For participant flow module it is based on Intent To Treat so the patients are counted according to their ‰ÛÏrandomization group‰Û.For ‰ÛÏparticipants at risk‰Û the patients are grouped by the ‰ÛÏactual treatment‰Û 4 patients were allocated with incorrect treatment and received AMG479 instead of Placebo.The total number of patients treated remains the same.,B Experimental,"AMG 479 plus paclitaxel/carboplatin chemotherapy administered on Day 1 of each 21-day cycle for 6 cycles - then 6 additional cycles of AMG 479 single agent administered on Day 1 of each 21-day cycle.AMG 479: Solution for infusion - 18 mg/kg on day 1 of each 21-day cycle"
NCT00718640,Phase 2,1/1/10,Participants‰Ûª recruitment was limited due to pre-defined criteria of renal disease and requirement of repeated evaluation of creatinine clearance. Due to insufficient number of participants the outcome measure data was not analyzed.,Study stopped due to lagging enrolment.,364518,0.4,4,10,Day 1 up to 30 days after last dose of study medication,NA,Bortezomib and Dexamethasone,"Bortezomib 1.3 milligram (mg) per meter^2 (m^2) bolus (a large amount) intravenous (into the vein) injection will be administered once daily on Days 1, 4, 8 and 11 of each 21-day cycle with addition of Dexamethasone 20 mg per day administered orally, once daily on Days 1 and 2, Days 4 and 5, Days 8 and 9 and Days 11 and 12 of each 21-day cycle as per Investigator‰Ûªs discretion for those participants who experience disease progression after treatment completion up to Cycle 2 or have no change from Baseline after completion of at least 4 cycles. The treatment will be given up to 8 cycles (24 weeks)."
NCT00718809,Phase 2,10/1/13,NA,NA,364502,0.166666667,2,12,"Beginning of treatment until the end of the study, up to 5 years",NA,Thymoma,Patients classified as having Thymoma. Patients receive 175 mg oral saracatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
NCT00718809,Phase 2,10/1/13,NA,NA,364501,0.111111111,1,9,"Beginning of treatment until the end of the study, up to 5 years",NA,Thymic Carcinoma,Patients classified as having Thymic carcinoma. Patients receive 175 mg oral saracatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
NCT00720629,Phase 2,12/1/13,"Study closed early during the first stage, did not proceed to the second stage comparison as planned. Investigators exercised right to close the study prematurely for lack of efficacy, although no protocol-defined end points had been met.",NA,363816,1,8,8,5 years,"The time of administration of visilizumab on Day 1 through Day 360. Per protocol, expected transplant/GVHD-related (other than serious) adverse event details were not tabulated in the same manner as serious adverse events.",First Stage: Study Treatment,"Visilizumab, Tacrolimus and Methotrexate. All participants."
NCT00722072,Phase 2,7/1/12,NA,NA,363164,0.333333333,3,9,NA,NA,Sorafenib and Fulvestrant,"Fulvestrant:Will be administered to the subject intramuscularly. Administered to all subjects during cycle 1 of treatment as follows:500 mg IM on Day 1250 mg IM on Day 15Sorafenib: 800 mg/day administered as 400 mg bid (twice daily) each morning and evening approximately 12 hours apart. Treatment will begin on Day 1 of the study and continue daily until tumor progression or until an unacceptable toxicity occurs which would require delay, modification or discontinuation of study therapy."
NCT00723203,Phase 2,9/1/10,There were no responses observed in the first 12 evaluable patients accrued to the first stage of the two-stage Optimum design of Simon. As a result the study was terminated due to a lack of efficacy.,Terminated early due to a lack of efficacy,362859,0.6875,11,16,Adverse events occurred over a time period of 1 year and 9 months.,Other adverse events includes all grades and attributions to treatment that are not included in Serious adverse events.,Treatment (Panobinostat),"Patients receive oral panobinostat once on days 1, 3, and 5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.panobinostat: 40 mg Monday, Wednesday and Friday of every week in a 28 day cyclegene expression analysis: Day 1 and day 28 samplesreverse transcriptase-polymerase chain reaction: Day 1 and day 28 sampleslaboratory biomarker analysis: Day 1 and day 28 samples"
NCT00726739,Phase 2,6/1/11,NA,Pre-planned analysis established it unlikely study would meet primary objective.,361577,0.3,3,10,"Adverse events were followed for 28 days (+/- 14 day) after last dose of study drug, an average of 1 year.",One patient withdrew after randomization and before LMI (large multivalent immunogen) +IL2 (aldesleukin) started and was excluded from the evaluation of toxicity (Arm I group).,Arm II (Control) - Aldesleukin,Patients receive aldesleukin SC on days 1 and 2. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross over and receive treatment on arm I.
NCT00726986,Phase 2,7/1/12,This study was terminated after enrolling 18 patients on the basis of excessive toxicity observed and preliminary efficacy data showing that study was unlikely to meet primary end point.,Extreme toxicity,361518,0.823529412,14,17,Patients were followed for adverse events while on treatment and post-treatment follow up for up to 1 year.,NA,"Sorafenib, Cisplatin, and Etoposide","Sorafenib, Cisplatin, and Etoposide for 4 cycles (months) during maintenance phase. If no disease progression continue with sorafenib for a maximum of 12 months."
NCT00727194,Phase 2,7/1/11,"Small sample size limited ability to detect intercohort differences. Carryover effect from Treatment Period (TP) 1 warrants cautious interpretation of TP 2 data.Study terminated early; 13 patients received eculizumab or placebo in TP2.",NA,361449,0.076923077,1,13,"46 weeks (Screening Period [up to 4 weeks], Treatment Period 1 [16 weeks], Washout Period [5 weeks], Treatment Period 2 [16 weeks], Follow-up Period [5 weeks]) for adverse events (AEs); 42 weeks for treatment emergent AEs (TEAEs).",TEAEs were collected at every visit and follow-up,Eculizumab,"EculizumabEculizumab: eculizumab 600 mg IV weekly for 4 doses followed by eculizumab 900 mg IV every two weeks for 7 dosesEvents that occurred during the Washout Period were attributed to treatment assignment during Treatment Period 1."
NCT00727194,Phase 2,7/1/11,"Small sample size limited ability to detect intercohort differences. Carryover effect from Treatment Period (TP) 1 warrants cautious interpretation of TP 2 data.Study terminated early; 13 patients received eculizumab or placebo in TP2.",NA,361450,0.076923077,1,13,"46 weeks (Screening Period [up to 4 weeks], Treatment Period 1 [16 weeks], Washout Period [5 weeks], Treatment Period 2 [16 weeks], Follow-up Period [5 weeks]) for adverse events (AEs); 42 weeks for treatment emergent AEs (TEAEs).",TEAEs were collected at every visit and follow-up,Placebo,"PlaceboPlacebo: Placebo IV weekly for 4 doses then every two weeks for 7 dosesEvents that occurred during the Washout Period were attributed to treatment assignment during Treatment Period 1."
NCT00734851,Phase 2,11/1/14,NA,Dose Limiting Toxicities,357981,0.205882353,7,34,36 Months,"The adverse events were gathered in Common Terminology Criteria for Adverse Events v.3.0, and have been converted to v.4.0 for entry into ClinicalTrials.gov",Multimodality,4 cycles of 70 mg/m2 Docetaxel + 37.5 mg daily Sunitinib for 14 days followed by a 7 day break for 3 cycles + external beam radiotherapy to 66 Gray over 6-7 weeks
NCT00737360,Phase 2,2/1/12,NA,NA,356787,0.555555556,15,27,Adverse events were summarized for all courses of study medication.,NA,TAS-106,NA
NCT00737633,Phase 2,6/1/09,NA,Limited regulatory value to uncontrolled trials. No safety/efficacy concerns.,356679,0.022727273,1,44,AEs were collected from when written informed consent was provided through 28 days after the last dose of investigational product.,NA,16-week Population,subjects who were randomized to placebo in previous study
NCT00740181,Phase 2,4/1/10,NA,Lack of efficacy,355997,0.888888889,8,9,"Pre-study and prior to each cycle of treatment (on average for 2 cycles, approximately 8-10 weeks)",NA,Chemotherapy,Decitabine 20 mg/m2 IV over 1 hr days 1-5 Cytarabine 20 mg/m2 subcut days 1-5 G-CSF 5mcg/kg subcut days 1-5
NCT00746941,Phase 1/Phase 2,11/1/10,"From ongoing analysis, it became clear, based on conditional power calculations, that the study would not reach its primary endpoint, a decrease of JC viral load in CSF with mefloquine treatment; therefore, the study was terminated early.",Primary endpoint not achieved,354077,0.65,13,20,Day 1 to Month 6,"Because participants were primarily patients with HIV/Acquired Immunodeficiency Syndrome (AIDS), SAEs considered to be AIDS-Defining Events (ADEs) were exempt from SAE reporting and were collected on a specific case report form instead of being captured as SAEs. However, any ADE that resulted in death did not qualify for an SAE exemption.",Local Standard of Care Plus Mefloquine 250 mg,"Participants were randomized to receive local standard of care (which may have included any treatment or procedure that the Investigator would normally use in the treatment of a PML patient at their study site or hospital) and 250 mg mefloquine by mouth on Days 0, 1, and 2 and then weekly through Week 24."
NCT00746941,Phase 1/Phase 2,11/1/10,"From ongoing analysis, it became clear, based on conditional power calculations, that the study would not reach its primary endpoint, a decrease of JC viral load in CSF with mefloquine treatment; therefore, the study was terminated early.",Primary endpoint not achieved,354078,0.6,3,5,Day 1 to Month 6,"Because participants were primarily patients with HIV/Acquired Immunodeficiency Syndrome (AIDS), SAEs considered to be AIDS-Defining Events (ADEs) were exempt from SAE reporting and were collected on a specific case report form instead of being captured as SAEs. However, any ADE that resulted in death did not qualify for an SAE exemption.",Local Standard of Care; Mefloquine at Week 8,"Participants were randomized to receive local standard of care, which may have included any treatment or procedure that the Investigator would normally use in the treatment of a PML patient at their study site or hospital.Participants who chose to add mefloquine at Week 8 to their standard of care treatment are counted in this treatment arm once mefloquine treatment started."
NCT00746941,Phase 1/Phase 2,11/1/10,"From ongoing analysis, it became clear, based on conditional power calculations, that the study would not reach its primary endpoint, a decrease of JC viral load in CSF with mefloquine treatment; therefore, the study was terminated early.",Primary endpoint not achieved,354080,0.294117647,5,17,Day 1 to Month 6,"Because participants were primarily patients with HIV/Acquired Immunodeficiency Syndrome (AIDS), SAEs considered to be AIDS-Defining Events (ADEs) were exempt from SAE reporting and were collected on a specific case report form instead of being captured as SAEs. However, any ADE that resulted in death did not qualify for an SAE exemption.",Local Standard of Care,"Participants were randomized to receive local standard of care, which may have included any treatment or procedure that the Investigator would normally use in the treatment of a PML patient at their study site or hospital.Participants who chose to add mefloquine at Weeks 4 or 8 to their standard of care treatment are counted in this treatment arm until the time of switching to mefloquine treatment."
NCT00746941,Phase 1/Phase 2,11/1/10,"From ongoing analysis, it became clear, based on conditional power calculations, that the study would not reach its primary endpoint, a decrease of JC viral load in CSF with mefloquine treatment; therefore, the study was terminated early.",Primary endpoint not achieved,354079,0.2,1,5,Day 1 to Month 6,"Because participants were primarily patients with HIV/Acquired Immunodeficiency Syndrome (AIDS), SAEs considered to be AIDS-Defining Events (ADEs) were exempt from SAE reporting and were collected on a specific case report form instead of being captured as SAEs. However, any ADE that resulted in death did not qualify for an SAE exemption.",Local Standard of Care; Mefloquine at Week 4,"Participants were randomized to receive local standard of care, which may have included any treatment or procedure that the Investigator would normally use in the treatment of a PML patient at their study site or hospital.Participants who chose to add mefloquine at Week 4 to their standard of care treatment are counted in this treatment arm once mefloquine treatment started."
NCT00748709,Phase 2,NA,"Due to early study termination, only data on the primary efficacy endpoint were summarized, no CIs were produced and efficacy and safety results were presented for the overall population rather than by tumor category.",NA,353538,0.3,6,20,First administration of trial medication until 28 days after last administration of trial medication,NA,Afatinib 50mg,Patients with genetically pre-screened cancers with EGFR and/or HER2 gene amplification or EGFR activating mutations treated with afatinib 50mg once daily.
NCT00751296,Phase 2,4/1/14,"Original study protocol used a starting lenalidomide dose of 10mg OD for 21days of a 28-day cycle, escalating weekly by 5mg to a target of 25mg daily. Toxicities reported with the first two enrolled patients lead to the current protocol amendment.",Seven years of follow-up & final analysis done in Dec 2012.,352821,0.68,17,25,NA,CTCAE Version 3.0 was used for adverse event grading and categorizing,Lenalidiomide,"Lenalidomide target dose of 10 mg PO OD X 3 weeks (days 1-21) followed by 1 week off therapy (days 22-28) on a 28-day cycle.Lenalidomide: Subjects will receive lenalidomide, starting at 2.5 mg daily x 3 weeks (days 1-21) and escalating up to a target dose of 10 mg daily X 3 weeks (days 1-21) followed by 1 week off therapy (days 22-28) on a 28 day cycle. Patients will be treated with lenalidomide until disease progression or 2 cycles past CR. (no maximum of cycles).Dose escalation beyond 10 mg daily to a maximum of 25 mgs daily was permitted for nonresponders."
NCT00752986,Phase 2,9/1/13,NA,NA,352505,0.090909091,1,11,NA,NA,Placebo to Match Vandetanib 100 mg and 300 mg,"placebo to match vandetanib 100 mg orally once-daily plus placebo to match vandetanib 300 mg orally once-daily plus fulvestrant LD (500 mg im. at day 1 and 250 mg at day 14, 28 and thereafter every 28th day +/- 3)."
NCT00752986,Phase 2,9/1/13,NA,NA,352507,0.1875,3,16,NA,NA,Vandetanib at the Dose of 100 mg,"vandetanib at the dose of 100 mg orally once-daily plus placebo to match vandetanib 300 mg orally once-daily plus fulvestrant LD (500 mg im. at day 1 and 250 mg at day 14, 28 and thereafter every 28th day +/- 3)"
NCT00752986,Phase 2,9/1/13,NA,NA,352506,0.166666667,2,12,NA,NA,Vandetanib at the Dose of 300 mg,"vandetanib at the dose of 300 mg orally once-daily plus placebo to match vandetanib 100 mg orally once-daily plus fulvestrant LD (500 mg im. at day 1 and 250 mg at day 14, 28 and thereafter every 28th day +/- 3)"
NCT00754923,Phase 2,4/1/12,"The study was discontinued, after withdrawal from the sponsor due to slow accrual. The discovery of EGFR mutations changed the scope of the trial.",NA,351330,0.090909091,1,11,NA,NA,Treatment: Sorafenib,"Sorafenib will be administered at a dose of 400 mg taken twice daily, continuously on a 28 day cycle.sorafenib: administered orally at 400 mg taken twice daily , continuously on a 28 day cycle as an outpatient."
NCT00758680,Phase 1,3/1/10,NA,NA,349937,0.05,1,20,NA,NA,MK-1006 120 mg Once Daily Outpatient (Panel H),"After a 2-week run-in/wash-off period, participants received single daily doses of 120 mg MK-1006 over a 7-day multiple-dosing period while remaining domiciled in the CRU. Participants were then discharged from the CRU and continued daily dosing of MK-1006 for an additional 21 days as outpatients."
NCT00758680,Phase 1,3/1/10,NA,NA,349935,0.034482759,1,29,NA,NA,Placebo,"After a 2-week run-in/wash-off period, participants received dose-matched placebo to MK-1006 over a multiple-dosing period while remaining domiciled in the CRU."
NCT00764660,Phase 2,7/1/10,NA,"Based on the outcome of a planned interim analysis, the study was stopped early due to   futility.",347012,0.166666667,11,66,Up to 16 weeks,The APT population consisted of all participants who received at least one dose of study drug.,Placebo,Participants received matching placebo tablets by mouth twice daily for 12 weeks.
NCT00764660,Phase 2,7/1/10,NA,"Based on the outcome of a planned interim analysis, the study was stopped early due to   futility.",347013,0.133333333,10,75,Up to 16 weeks,The APT population consisted of all participants who received at least one dose of study drug.,SCH 900435 12 mg,Participants received SCH 900435 12 mg (as three SCH 900435 4 mg tablets) by mouth twice daily for 12 weeks.
NCT00767000,Phase 2,6/1/10,NA,NA,345994,0.056768559,13,229,Adverse events were collected for the entire study including the 54-week study and 104-week extension,NA,MK-0941 40 mg,MK-0941 40 mg three times daily plus insulin once daily with or without metformin
NCT00767000,Phase 2,6/1/10,NA,NA,345997,0.092436975,11,119,Adverse events were collected for the entire study including the 54-week study and 104-week extension,NA,MK-0941 10 mg,MK-0941 10 mg three times daily plus insulin once daily with or without metformin
NCT00767000,Phase 2,6/1/10,NA,NA,345995,0.094017094,11,117,Adverse events were collected for the entire study including the 54-week study and 104-week extension,NA,MK-0941 30 mg,MK-0941 30 mg three times daily plus insulin once daily with or without metformin
NCT00767000,Phase 2,6/1/10,NA,NA,345993,0.034632035,8,231,Adverse events were collected for the entire study including the 54-week study and 104-week extension,NA,Placebo,Placebo three times daily plus insulin once daily with or without metformin
NCT00767000,Phase 2,6/1/10,NA,NA,345996,0.102564103,12,117,Adverse events were collected for the entire study including the 54-week study and 104-week extension,NA,MK-0941 20 mg,MK-0941 20 mg three times daily plus insulin once daily with or without metformin
NCT00770770,Phase 2,NA,NA,NA,344816,0.666666667,4,6,NA,NA,Fluocinolone Acetonide: 0.5 åµg/Day,Fluocinolone Acetonide: 0.5 åµg/day
NCT00770770,Phase 2,NA,NA,NA,344817,0.571428571,8,14,NA,NA,Fluocinolone Acetonide: 0.2 åµg/Day,Fluocinolone Acetonide: 0.2 åµg/day
NCT00771810,Phase 2,12/1/11,"Feasibility considerations (e.g., slow patient enrollment and lower incidence of Grade 3-4 thrombocytopenia than planned) necessitated early termination of the study after 34 patients had been enrolled.",Insufficient incidence of thrombocytopenia in control population,344168,0.230769231,3,13,February 2009 to May 2011,The assessment types were coded using MedDRA.,TXA127 300 ug/kg,Group 3: combination gemcitabine and platinum-based chemotherapy with concurrent 300 ug/kg/day TXA127
NCT00771810,Phase 2,12/1/11,"Feasibility considerations (e.g., slow patient enrollment and lower incidence of Grade 3-4 thrombocytopenia than planned) necessitated early termination of the study after 34 patients had been enrolled.",Insufficient incidence of thrombocytopenia in control population,344169,0.090909091,1,11,February 2009 to May 2011,The assessment types were coded using MedDRA.,TXA127 100 ug/kg,Group 2: combination gemcitabine and platinum-based chemotherapy with concurrent 100 ug/kg/day TXA127
NCT00771810,Phase 2,12/1/11,"Feasibility considerations (e.g., slow patient enrollment and lower incidence of Grade 3-4 thrombocytopenia than planned) necessitated early termination of the study after 34 patients had been enrolled.",Insufficient incidence of thrombocytopenia in control population,344170,0.3,3,10,February 2009 to May 2011,The assessment types were coded using MedDRA.,Placebo,Group 1: combination gemcitabine and platinum-based chemotherapy with concurrent placebo
NCT00773383,Phase 2,2/1/10,NA,NA,342896,0.352941176,12,34,"From start of treatment until 30 days after last dose (up to 64 weeks) or if the AE was related to study drug, up until the AE resolved",NA,R1507,9 mg/kg once a week (qw) IV administered over 60-90 minutes erlotinib ‰ÛÒ 150 mg Once daily administration (qd) Oral administration(PO)
NCT00778817,Phase 2,3/1/14,"After the treatment of 20 subjects, a protocol defined interim analysis was completed for safety and futility. The trial was permanently halted based on futility concerns.",The trial was permanently halted due to futility concerns.,340706,0.45,9,20,6 months,NA,Chemotherapy and Monoclonal Antibody Therapy,Patients receive mitotane as in arm I and anti-IGF-1R recombinant monoclonal antibody IMC-A12 IV over 1 hour once every 2 weeks in the absence of disease progression or unacceptable toxicity.
NCT00779311,Phase 1,3/1/11,"Early termination due to the MTD determined to be Dose Level 1, leading to a small number of subjects analyzed.",Dose limiting toxicity at the lowest planned dose level.,340539,0.625,5,8,Adverse events were collected beginning on day 1 of study treatment until one month after the end of study treatment.,"Systematic Assessment - subjects were assessed for adverse events on day 1 of each cycle (every other week) by either the research coordinator, treating physician, or other appropriate sub-investigator.",Dose Level (DL) 1 for MTD Determination,"All eligible patients will receive the mFOLFOX6 regimen at full dose followed by IV bevacizumab 5mg/kg on Day 1 of each treatment cycle, and sorafenib 200mg every other day."
NCT00780676,Phase 2,5/1/14,Study terminated according to early stopping rules.,Closed early for futility.,340263,0.1,3,30,Adverse event data collected with each cycle of therapy i.e. every 28 days. Overall collection period June 2009 to July 2012.,"Selumetinib pathway predictor groups (both MEK pathway activity predictor positive and MEK pathway predictor negative) had no patients assigned to treatment, only treated participants (30) included in analysis and adverse event reporting. Adverse event reporting was by treatment population rather than predictive groups.",Dasatinib 100 mg,"Participants with one of 3 predictive gene signatures (dasatinib sensitivity signature, SRC pathway activity signature and dasatinib target index) received Dasatinib 100 mg orally daily."
NCT00786682,Phase 2,10/1/12,NA,"Lack of improved efficacy compared to historical controls, competing studies",337939,0.272727273,3,11,3 years,NA,Docetaxel and Hydroxychloroquine,"Drug: Docetaxel 75 mg/m2 intravenously every 21 days on Day 1 of the treatment cycleDrug: hydroxychloroquine 200 mg twice dailyA cycle is defined as an interval of 21 days."
NCT00787852,Phase 1,12/1/11,NA,for efficacy and safety reasons,337046,0.4,2,5,"Baseline then approximately 30 days post the last dose of drug, which could be up to 2.5 years.",NA,Group 1,"DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-40 43-47 Paclitaxel 1 8 15 22 29 36 43 Carboplatin 1 8 15 22 29 36 43 Dasatinib ----------------------------------------------------------------------Maintenance Dasatinib RT: External radiotherapy, 64.8 Gy, for 35 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36, 43 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36, 43 Dasatinib Dose Level With chemoradiation Maintenance x 2 years* Dasatinib is to be taken 1x daily 50 mg daily"
NCT00787852,Phase 1,12/1/11,NA,for efficacy and safety reasons,337045,0.8,4,5,"Baseline then approximately 30 days post the last dose of drug, which could be up to 2.5 years.",NA,Group 2,"DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-40 43-47 Paclitaxel 1 8 15 22 29 36 43 Carboplatin 1 8 15 22 29 36 43 Dasatinib ----------------------------------------------------------------------Maintenance Dasatinib RT: External radiotherapy, 64.8 Gy, for 35 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36, 43 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36, 43 Dasatinib Dose Level With chemoradiation Maintenance x 2 years* Dasatinib is to be taken 1x daily70 mg daily"
NCT00790855,Phase 1/Phase 2,3/1/12,NA,Lack of Response,336170,0.12,3,25,3 years 3 months,NA,Bendamustine,Starting dose 50 mg/m^2 intravenously over 2 hours twice on Days 1-4 of every 4 week study cycle.
NCT00793650,Phase 1/Phase 2,9/1/11,NA,NA,334878,0.1,2,20,NA,NA,Bortezomib After HD melphalanAll,"patients received melphalan (100 mg/m^2/day ÌÑ 2; days‰öÕ3 and ‰öÕ2), for a total dose of 200 mg/m^2. Patients were randomized to receive bortezomib 24 hours after administration of high-dose melphalan in escalating dose cohorts of 1.0, 1.3, and 1.6 mg/m^2"
NCT00793650,Phase 1/Phase 2,9/1/11,NA,NA,334879,0.210526316,4,19,NA,NA,Bortezomib Before HD Melphalan,"All patients received melphalan (100 mg/m^2/day ÌÑ 2; days‰öÕ3 and ‰öÕ2), for a total dose of 200 mg/m^2. Patients were randomized to receive bortezomib 24 hours before administration of high-dose melphalan in escalating dose cohorts of 1.0, 1.3, and 1.6 mg/m^2"
NCT00797667,Phase 2,5/1/09,"Based on a recommendation from the external Data Safety Monitoring Board (DSMB), a decision to terminate the trial was made on 26-Mar-2009.",The study was terminated based on a recommendation of the DSMB following the identification of   two patients with significant elevations in serum transaminases,333014,0.015209125,4,263,up to 14 days after last dose of study drug (up to 12 weeks),"All Patients as Treated, which consisted of all participants who received at least 1 dose of study drug and were included in the treatment arm corresponding to the study treatment actually received. If participants took incorrect or mixed study treatment they were included in treatment arm corresponding to the highest dose they actually received.",MK-0974 140 mg,"Participants receive one telcagepant 140 mg tablet and one 280 mg telcagepant placebo, orally, twice daily for 12 weeks"
NCT00797667,Phase 2,5/1/09,"Based on a recommendation from the external Data Safety Monitoring Board (DSMB), a decision to terminate the trial was made on 26-Mar-2009.",The study was terminated based on a recommendation of the DSMB following the identification of   two patients with significant elevations in serum transaminases,333012,0.0078125,1,128,up to 14 days after last dose of study drug (up to 12 weeks),"All Patients as Treated, which consisted of all participants who received at least 1 dose of study drug and were included in the treatment arm corresponding to the study treatment actually received. If participants took incorrect or mixed study treatment they were included in treatment arm corresponding to the highest dose they actually received.",Placebo,"Participants receive one 140 mg telcagepant placebo and one 280 mg telcagepant placebo, orally, twice daily for 12 weeks"
NCT00797667,Phase 2,5/1/09,"Based on a recommendation from the external Data Safety Monitoring Board (DSMB), a decision to terminate the trial was made on 26-Mar-2009.",The study was terminated based on a recommendation of the DSMB following the identification of   two patients with significant elevations in serum transaminases,333013,0.011320755,3,265,up to 14 days after last dose of study drug (up to 12 weeks),"All Patients as Treated, which consisted of all participants who received at least 1 dose of study drug and were included in the treatment arm corresponding to the study treatment actually received. If participants took incorrect or mixed study treatment they were included in treatment arm corresponding to the highest dose they actually received.",MK-0974 280 mg,"Participants receive one telcagepant 280 mg tablet and one 140 mg telcagepant placebo, orally, twice daily for 12 weeks"
NCT00806585,Phase 2,6/1/10,NA,NA,329836,0.03649635,5,137,76 weeks,All Randomized Participants. Adverse events were reported for Phase A only (24 weeks). Phase B (52 weeks) was not completed.,Placebo,"One placebo tablet daily, orally, for 24 weeks (Phase A). Participant will continue to receive placebo, once daily for 52 weeks (Phase B)"
NCT00806585,Phase 2,6/1/10,NA,NA,329838,0.042553191,6,141,76 weeks,All Randomized Participants. Adverse events were reported for Phase A only (24 weeks). Phase B (52 weeks) was not completed.,MK-0736 8.0 mg,"One MK-0736 8.0 mg tablet, orally, once daily for 24 weeks (Phase A). Participant will continue to receive MK-0736 8.0 mg, once daily for 52 weeks (Phase B)."
NCT00806585,Phase 2,6/1/10,NA,NA,329839,0.052238806,7,134,76 weeks,All Randomized Participants. Adverse events were reported for Phase A only (24 weeks). Phase B (52 weeks) was not completed.,MK-0736 2.0 mg,"One MK-0736 2.0 mg tablet, orally, once daily for 24 weeks (Phase A). Participant will then be switched to MK-0736 8.0 mg, once daily for 52 weeks (Phase B)."
NCT00806585,Phase 2,6/1/10,NA,NA,329840,0.065693431,9,137,76 weeks,All Randomized Participants. Adverse events were reported for Phase A only (24 weeks). Phase B (52 weeks) was not completed.,MK-0736 0.5 mg,"One MK-0736 0.5 mg tablet, orally, once daily for 24 weeks (Phase A). Participant will then be switched to MK-0736 8.0 mg, once daily for an additional 52 weeks (Phase B)."
NCT00808899,Phase 2,7/1/09,"NB2008 was closed because of the publication of a new standard of care for treating high-risk neuroblastoma.At the time of closure, NB2008 had enrolled only 4 patients, which was an insufficient number of patients to answer the primary objective.",Voluntarily closed and terminated by the PI due to lack of feasibility,328890,0.25,1,4,10 months,NA,Temsirolimus With Irinotecan,Participants enrolled in the Temsiolimus and Irinotecan group were high-risk neuroblastoma patients.
NCT00816348,Phase 2,2/1/14,NA,NA,325353,0.066666667,1,15,NA,NA,Omegaven,"All subjects will receive OmegavenOmegaven: Omegavenå¨ will be initiated at a dose of 0.5 gram/kg/day and is infused over 24 hours for 1-2 days, and then advanced to 1 gram/kg/day. Omegavenå¨ will be infused intravenously through either a central or peripheral catheter alone or in conjunction with parenteral nutrition. Omegavenå¨ will continue until weaned from PN. Monotherapy with Omegavenå¨ can continue as an additional source of calories after the dextrose/protein portion of PN is discontinued. Omegaven may be restarted within seven days of discontinuing therapy. After seven days, and meeting inclusion criteria, Omegaven can resume at the initial dose of 0.5 grams/kg/day, advancing to 1 gm/kg/day."
NCT00817531,Phase 2,2/1/11,The study was terminated after internal analysis due to treatment futility. It does not meet the required number of responses to continue the study.,terminated due to futility after interim analysis,325225,0.045454545,1,22,3-4 weeks,"Following the patient's written consent to participate in the study, then to the end of 3-4 week treatment",Dasatinib,Patients took Dasatinib 100mg daily
NCT00818961,Phase 2,3/1/12,NA,terminated early due to meeting end point with fewer patients than anticipated,324656,0.277777778,10,36,NA,NA,Hematopoietic Stem Cell Transplantation,All patients received a hematopoietic Stem Cell Transplantation as part of this clinical trial.
NCT00823979,Phase 2,10/1/12,"The trial was terminated on 12 April, 2012 due to lack of efficacy at the Week 24 analysis. The decision to terminate the trial was not based on any safety concerns.",See termination reason in detailed description.,322863,0.029411765,1,34,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",Etravirine 200 mg,"Etravirine 100 mg 2 tablets equivalent to etravirine 200 mg, orally twice daily up to 96 weeks in combination with 1 optimized NRTI as per individual prescribing information, darunavir 600 mg tablet orally twice daily and ritonavir 100 mg tablet or capsule orally twice daily."
NCT00823979,Phase 2,10/1/12,"The trial was terminated on 12 April, 2012 due to lack of efficacy at the Week 24 analysis. The decision to terminate the trial was not based on any safety concerns.",See termination reason in detailed description.,322864,0.125,4,32,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",Lersivirine 1000 mg,"Lersivirine (UK-453,061) 250 mg 4 tablets equivalent to lersivirine 1000 mg, orally once daily up to 96 weeks in combination with 1 optimized NRTI as per individual prescribing information, darunavir 600 mg tablet orally twice daily and ritonavir 100 mg tablet or capsule orally twice daily."
NCT00823979,Phase 2,10/1/12,"The trial was terminated on 12 April, 2012 due to lack of efficacy at the Week 24 analysis. The decision to terminate the trial was not based on any safety concerns.",See termination reason in detailed description.,322865,0.032258065,1,31,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",Lersivirine 750 mg,"Lersivirine (UK-453,061) 250 milligram (mg) 3 tablets equivalent to lersivirine 750 mg and 1 placebo tablet matched to lersivirine 250 mg tablet, orally once daily up to 96 weeks in combination with 1 optimized nucleoside reverse transcriptase inhibitors (NRTI) as per individual prescribing information, darunavir 600 mg tablet orally twice daily and ritonavir 100 mg tablet or capsule orally twice daily."
NCT00824161,Phase 2,12/1/10,NA,NA,322673,0.346153846,9,26,Patients were monitored for any adverse events from the time of signed Informed Consent Form through 30 days post study medication.,NA,TAS-109,TAS-109 2.0 mg/m^2/day
NCT00825227,Phase 2,2/1/10,This trial was discontinued early after only 10 of 160 planned subjects had been recruited. No efficacy data was analyzed.,NA,322026,0.25,1,4,Study drug was administered during cycle 2 of taxane therapy which lasted 21 or 28 days. This was followed by a 24-week open-label extension period during which they received armodafinil for a total of 28 weeks during which adverse events were collected.,NA,Matching Placebo,"placebotaxane chemotherapy treatment alone or in combination with other agents"
NCT00825227,Phase 2,2/1/10,This trial was discontinued early after only 10 of 160 planned subjects had been recruited. No efficacy data was analyzed.,NA,322027,0.5,3,6,Study drug was administered during cycle 2 of taxane therapy which lasted 21 or 28 days. This was followed by a 24-week open-label extension period during which they received armodafinil for a total of 28 weeks during which adverse events were collected.,NA,150 mg/Day Armodafinil,"150 mg/day armodafiniltaxane chemotherapy treatment alone or in combination with other agents"
NCT00837824,Phase 2,8/1/03,"The trial was terminated early due to inadequate study design, leading to small numbers of subjects analyzed.",The trial was terminated early due to inadequate study design.,317346,0.363636364,4,11,NA,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (number of affected participants) of both adverse event tables.",Fabrazyme 1mg/kg Every 2 Weeks,Fabrazyme 1.0 mg/kg every 2 weeks
NCT00837824,Phase 2,8/1/03,"The trial was terminated early due to inadequate study design, leading to small numbers of subjects analyzed.",The trial was terminated early due to inadequate study design.,317345,0.111111111,1,9,NA,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (number of affected participants) of both adverse event tables.",Fabrazyme 3mg/kg Every 2 Weeks,Fabrazyme 3.0 mg/kg every 2 weeks
NCT00837824,Phase 2,8/1/03,"The trial was terminated early due to inadequate study design, leading to small numbers of subjects analyzed.",The trial was terminated early due to inadequate study design.,317344,0.25,5,20,NA,"In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (number of affected participants) of both adverse event tables.",Total,NA
NCT00843050,Phase 2,8/1/12,The Sponsor has terminated the study based on interim results. All subjects were off study at the time of termination. There are no major safety or tolerability concerns from this study. The study results published here are preliminary results.,The study was terminated based on interim results and all subjects were off study at that   time. No major safety or tolerability concerns,315872,0.153846154,2,13,NA,NA,P276-00,P276-00: All patients will receive P276-00 185 mg/m2/day as intravenous infusion over 30 minutes in 200 ml of 5% dextrose from day 1 to day 5 in each 21 days cycle for minimum 6 and maximum 12 cycles or until there is progression of disease or unacceptable toxicity
NCT00848107,Phase 2,9/1/11,Interpretation of the change in digital ulcer status was limited by the lack of a control group and the discontinuation of the study prior to subjects completing all scheduled visits.,"The TDE-DU-202 extension study was discontinued after the randomized, placebo-controlled   TDE-DU-201 study did not meet its primary efficacy objective.",313652,0.147826087,17,115,48 months,NA,Oral Treprostinil Diethanolamine,Oral Treprostinil Diethanolamine initiated at 0.25 mg and titrated up to a maximum dose of 16 mg BID or the individual's maximum tolerated dose (MTD).
NCT00850993,Phase 2,5/1/12,"It should be noted that the study was discontinued before enrollment of the full 4.5 mg/kg cohort,and therefore, the stannsoporfin 4.5 mg/kg treatment group included 8 patients and the placebo group included 15 patients.",To redefine study population,312592,0.125,1,8,30 days,NA,Stannsoporfin 4.5 mg/kg,"3 sequential cohorts of approximately 24 subjects will be recruited. Subjects in the first cohort who are randomized to receive active drug treatment will receive a single dose of 1.5 mg/kg by IM injection. Subjects in the second and third cohorts will receive 3.0 and 4.5 mg/kg, respectively."
NCT00850993,Phase 2,5/1/12,"It should be noted that the study was discontinued before enrollment of the full 4.5 mg/kg cohort,and therefore, the stannsoporfin 4.5 mg/kg treatment group included 8 patients and the placebo group included 15 patients.",To redefine study population,312595,0.133333333,2,15,30 days,NA,Placebo,Saline : Normal saline (0.9%) solution
NCT00850993,Phase 2,5/1/12,"It should be noted that the study was discontinued before enrollment of the full 4.5 mg/kg cohort,and therefore, the stannsoporfin 4.5 mg/kg treatment group included 8 patients and the placebo group included 15 patients.",To redefine study population,312593,0.055555556,1,18,30 days,NA,Stannsoporfin 3.0 mg/kg,"3 sequential cohorts of approximately 24 subjects will be recruited. Subjects in the first cohort who are randomized to receive active drug treatment will receive a single dose of 1.5 mg/kg by IM injection. Subjects in the second and third cohorts will receive 3.0 and 4.5 mg/kg, respectively."
NCT00852397,Phase 2,12/1/10,NA,See termination reason in detailed description.,312291,0.156862745,8,51,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",Placebo,Placebo was administered twice a day in addition to the standard therapy (aspirin with or without clopidogrel or ticlopidine) for 24 weeks.
NCT00852397,Phase 2,12/1/10,NA,See termination reason in detailed description.,312290,0.224489796,11,49,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",Apixaban 2.5 mg BID,Apixaban 2.5 mg was administered twice a day in addition to the standard therapy (aspirin with or without clopidogrel or ticlopidine) for 24 weeks.
NCT00852397,Phase 2,12/1/10,NA,See termination reason in detailed description.,312289,0.142857143,7,49,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",Apixaban 5.0 mg BID,Apixaban 5.0 mg was administered twice a day in addition to the standard therapy (aspirin with or without clopidogrel or ticlopidine) for 24 weeks.
NCT00853762,Phase 2,2/1/11,Sponsor voluntarily decided to terminate this trial after observing increased MS disease activity in trial 28063 ATAMS.,EMD Serono voluntarily decided to terminate this trial after observing increased MS disease   activity in trial 28063 ATAMS [Please refer to ATAMS],311231,0.058823529,1,17,From the first dose of study drug administration up to Week 24,AEs were collected for Double-blind safety analysis set which included all the subjects who received at least 1 dose of trial medication in the ATAMS extension study.,Atacicept 75 mg (With Loading),"Subjects who received atacicept 75 mg SC as loading dose twice weekly for first 4 weeks, followed by atacicept 75 mg SC for 32 weeks, in 28063 study were continued with atacicept 75 mg SC once weekly up to 5 years or up to early termination of treatment or early termination of the study."
NCT00854581,Phase 1/Phase 2,NA,NA,Investigator Decision,310891,0.230769231,3,13,NA,NA,Induction Therapy,"Zidovudine + Interferon alfa-2bInterferon alfa-2b: Days 3 - 14: Interferon Alpha-2b 5 10 million units IV twice daily.Zidovudine: Days 1-2: (0-48 hours) Zidovudine (AZT) 1.5 grams intravenously (IV) twice daily. Days 3-14: Zidovudine (AZT) 1.5 grams IV twice daily and Interferon Alpha-2b 5 10 million units IV twice daily. Subsequent doses dependent on patient response.NF-kB Inhibition: Blood Sample - Baseline/Pre-Treatment, Induction,"
NCT00854581,Phase 1/Phase 2,NA,NA,Investigator Decision,310890,0.428571429,3,7,NA,NA,Maintenance Therapy,"Zidovudine + Interferon alfa-2b + PEG Interferon alfa-2bPEG-interferon alfa-2b: PEG-IFN-alfa2b 1.5 ug/kg SQ weekly.Interferon alfa-2b: Days 3 - 14: Interferon Alpha-2b 5 10 million units IV twice daily.Valproic Acid: Patients will be started on one capsule (250 mg) with water twice daily.Zidovudine: Days 1-2: (0-48 hours) Zidovudine (AZT) 1.5 grams intravenously (IV) twice daily. Days 3-14: Zidovudine (AZT) 1.5 grams IV twice daily and Interferon Alpha-2b 5 10 million units IV twice daily. Subsequent doses dependent on patient response.Molecular Evaluation/Analysis of Malignant Clones of ATLL: Blood Sample - Baseline/Pre-Treatment, months 3 and 6, End of Month 12, Disease Progession"
NCT00855062,Phase 1/Phase 2,12/1/09,"The estimated sample size was 100; however, due to early termination of the study, the total number of randomized participants was 73.",The Neurologic AIDS Research Consortium Data Safety and Monitoring Board committee recommended   to terminate the study early due to futility on 11/6/2009.,310817,0.027027027,1,37,48 weeks,"The lab assessments were conducted at weeks 0, 12, 24, and 48.",Placebo,Placebo minocycline capsules every 12 hours
NCT00855062,Phase 1/Phase 2,12/1/09,"The estimated sample size was 100; however, due to early termination of the study, the total number of randomized participants was 73.",The Neurologic AIDS Research Consortium Data Safety and Monitoring Board committee recommended   to terminate the study early due to futility on 11/6/2009.,310818,0.055555556,2,36,48 weeks,"The lab assessments were conducted at weeks 0, 12, 24, and 48.",Minocycline,Minocycline 100 mg orally every 12 hours
NCT00862134,Phase 2,5/1/10,NA,Interim analysis indicated low probability of clinically significant result,307913,0.470588235,8,17,NA,NA,Docetaxel,"75 mg/m^2 docetaxel, IV, every 21 days"
NCT00862836,Phase 1/Phase 2,9/1/10,NA,Lack of efficacy,307485,0.214285714,3,14,NA,NA,Vandetanib 100 mg,Once daily oral Vandetanib 100 mg added to standard therapy (pegylated liposomal doxorubicin 50 mg/m2 iv every 4 weeks)
NCT00864513,Phase 2,7/1/09,"study was closed at interim analysis so only 12 subjects were evaluable for response, 15 subjects received treatment and were evaluable for adverse events",At interim analysis the study did not meet the response criteria to continue,307102,0.133333333,2,15,NA,NA,Chemotherapy,pemetrexed
NCT00868790,Phase 2,7/1/10,"A pre-specified interim analysis of the efficacy and safety data for the initial cohort of participants in this study (Cohort 1) determined that sufficient data had been accrued to assess the study hypotheses, thus the study was discontinued.","Upon interim analysis, sufficient data was accrued to assess study hypotheses.",305969,0.018867925,2,106,From first dose of study treatment (Week 0 Visit) to Week 18 Post-study Visit (up to 18 weeks).,"All randomized participants who took ‰ä´1 dose of study treatment (N=118). Because this was a cross-over study, participants were counted in more than one treatment group. AEs were reported by the treatment that participants were receiving at the time of the event. Not all participants received all treatments.",MK-3577 AM,Participants received 10 mg MK-3577 orally QD in the AM for 4 weeks.
NCT00868790,Phase 2,7/1/10,"A pre-specified interim analysis of the efficacy and safety data for the initial cohort of participants in this study (Cohort 1) determined that sufficient data had been accrued to assess the study hypotheses, thus the study was discontinued.","Upon interim analysis, sufficient data was accrued to assess study hypotheses.",305970,0.009259259,1,108,From first dose of study treatment (Week 0 Visit) to Week 18 Post-study Visit (up to 18 weeks).,"All randomized participants who took ‰ä´1 dose of study treatment (N=118). Because this was a cross-over study, participants were counted in more than one treatment group. AEs were reported by the treatment that participants were receiving at the time of the event. Not all participants received all treatments.",Placebo,"Participants received a placebo tablet matching the respective MK-3577 dose (10 mg, 6 mg, 25 mg) and metformin, depending upon randomization, for 4 weeks."
NCT00868790,Phase 2,7/1/10,"A pre-specified interim analysis of the efficacy and safety data for the initial cohort of participants in this study (Cohort 1) determined that sufficient data had been accrued to assess the study hypotheses, thus the study was discontinued.","Upon interim analysis, sufficient data was accrued to assess study hypotheses.",305968,0.019047619,2,105,From first dose of study treatment (Week 0 Visit) to Week 18 Post-study Visit (up to 18 weeks).,"All randomized participants who took ‰ä´1 dose of study treatment (N=118). Because this was a cross-over study, participants were counted in more than one treatment group. AEs were reported by the treatment that participants were receiving at the time of the event. Not all participants received all treatments.",MK-3577 PM,Participants received 6 mg MK-3577 orally QD in the PM for 4 weeks.
NCT00871689,Phase 2,10/1/11,"Quantitative, phenotypic and functional assessment of the in vivo expanded UCB-derived NK cells on Day 72 were not performed. Patients were not well enough to provide research samples.",Due to graft failure.,305206,1,2,2,Patients were followed from Day 1 up to death ( within 6 months).,NA,Patients Receiving Double Umbilical Cord Blood Transplant,"Patients that receive myeloablative preparative regimen (allopurinol 300 mg by mouth Day -8 through +14; fludarabine 25 mg/m^2 intravenously on days -7 through -5; cyclophosphamide 60 mg/kg intravenously on days -7 and -6; total body irradiation 165 cGy*2 on days -4 through -2), 2 units T cell depleted umbilical cord blood transplant on day 0, followed by IL-2 every other day beginning day +3 and day +60 for a total of 6 doses."
NCT00878501,Phase 2,7/1/09,NA,The study was terminated after the planned interim analysis.,303357,0.010752688,1,93,NA,One participant in the Experimental 90 mg Arm did not receive study drug since incorrectly enrolled and is therefore not included.,Placebo Control,Placebo bid for 4 weeks
NCT00878501,Phase 2,7/1/09,NA,The study was terminated after the planned interim analysis.,303358,0.022727273,1,44,NA,One participant in the Experimental 90 mg Arm did not receive study drug since incorrectly enrolled and is therefore not included.,Experimental 30 mg,AZD1386 30 mg twice a day (bid) for 4 weeks
NCT00881504,Phase 2,12/1/11,NA,It was not possible to get insurance companies to cover bevacizumab.,302199,0.125,1,8,8 weeks,NA,FOLFOX6 and Bevacizumab,"Treatment with modified FOLFOX6 and BevacizumabModified FOLFOX6 and Bevacizumab: Oxaliplatin 85 mg/m2 IV on Day 1 5-FU: 400 mg/m2 IV bolus on Day 1, followed by 2400 mg/M2 over 46 hours Leucovorin: 400 mg IV Day 1 Bevacizumab: 10 mg/kg IV on Day 1 Repeat cycles every 2 weeks until death, disease progression, unacceptable toxicity, patient refusal, or treatment delay > 4 weeks"
NCT00881712,Phase 2,10/1/14,NA,projected enrollment rate not feasible,302092,0.153846154,2,13,Cumulative adverse events assessed across all available post-treatment follow-up for each patient.,NA,PET Positive Nodal Disease Measuring 15 mm or Greater,"Proton radiation with concomitant chemotherapyPET positive nodal disease measuring 15 mm or greater: Proton radiation at 2 cobalt gray equivalent per fraction to a total of 74 cobalt gray equivalent with concomitant weekly chemotherapy."
NCT00887640,Phase 2,8/1/12,NA,NA,300045,0.363636364,4,11,2 years,"The adverse events were gathered in Common Terminology Criteria for Adverse Events v.3.0, and have been converted to v.4.0 for entry into ClinicalTrials.gov",Temsirolimus 25 mg,"Temsirolimus 25mg was administered by IV infusion each week (days 1, 8, 15, and 22 of each 28 day cycle). The infusion was to be administered over a period not less than 30 minutes and was to be completed within 60 minutes. Subjects were premedicated with 25 to 50 mg IV or PO diphenhydramine (or an alternative antihistamine in case of allergies) 30 minutes prior to the infusion."
NCT00895895,Phase 2,5/1/11,Study terminated early due to futility. Period 2 events include those that started in Period 2 or started in Period 1 and continued in to Period 2.,See termination reason in detailed description.,297960,0.077669903,8,103,NA,"The same event may appear as both an adverse event (AE) and a serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",SAM-531 3.0 mg Period 1,"SAM-531 3.0 mg capsule administered QD (morning dose) through 24 weeks. Matching encapsulated Donepezil placebo tablet administered QD (evening dose) through 24 weeks. From Week 7 until Week 52 (end of study), the evening dose could have been increased to 2 tablets and adjusted back to 1 tablet at the investigator‰Ûªs discretion."
NCT00895895,Phase 2,5/1/11,Study terminated early due to futility. Period 2 events include those that started in Period 2 or started in Period 1 and continued in to Period 2.,See termination reason in detailed description.,297956,0.019607843,2,102,NA,"The same event may appear as both an adverse event (AE) and a serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",SAM-531 1.5 mg Period 2,"SAM-531 1.5 mg capsule administered QD (morning dose) Week 25 up to 52 weeks. Matching encapsulated Donepezil placebo tablet administered QD (evening dose) for up to 52 weeks. From Week 7 until Week 52 (end of study), the evening dose could have been increased to 2 tablets and adjusted back to 1 tablet at the investigator‰Ûªs discretion."
NCT00895895,Phase 2,5/1/11,Study terminated early due to futility. Period 2 events include those that started in Period 2 or started in Period 1 and continued in to Period 2.,See termination reason in detailed description.,297961,0.068627451,7,102,NA,"The same event may appear as both an adverse event (AE) and a serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",SAM-531 1.5 mg Period 1,"SAM-531 1.5 mg capsule administered QD (morning dose) through 24 weeks. Matching encapsulated Donepezil placebo tablet administered QD (evening dose) through 24 weeks. From Week 7 until Week 52 (end of study), the evening dose could have been increased to 2 tablets and adjusted back to 1 tablet at the investigator‰Ûªs discretion."
NCT00895895,Phase 2,5/1/11,Study terminated early due to futility. Period 2 events include those that started in Period 2 or started in Period 1 and continued in to Period 2.,See termination reason in detailed description.,297962,0.066037736,7,106,NA,"The same event may appear as both an adverse event (AE) and a serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",Placebo/5.0 mg Period 1,Matching SAM-531 placebo capsule administered QD (morning dose) and one encapsulated Donepezil placebo tablet administered QD (evening dose) for up to 24 weeks (Period 1). From Week 7 the evening dose could have been increased to 2 tablets and adjusted back to 1 tablet at the investigator‰Ûªs discretion.
NCT00895895,Phase 2,5/1/11,Study terminated early due to futility. Period 2 events include those that started in Period 2 or started in Period 1 and continued in to Period 2.,See termination reason in detailed description.,297955,0.067961165,7,103,NA,"The same event may appear as both an adverse event (AE) and a serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",SAM-531 3.0 mg Period 2,"SAM-531 3.0 mg capsule administered QD (morning dose) Week 25 up to 52 weeks. Matching encapsulated Donepezil placebo tablet administered QD (evening dose) for up to 52 weeks. From Week 7 until Week 52 (end of study), the evening dose could have been increased to 2 tablets and adjusted back to 1 tablet at the investigator‰Ûªs discretion."
NCT00895895,Phase 2,5/1/11,Study terminated early due to futility. Period 2 events include those that started in Period 2 or started in Period 1 and continued in to Period 2.,See termination reason in detailed description.,297958,0.038461538,4,104,NA,"The same event may appear as both an adverse event (AE) and a serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",Donepezil Period 1,"Matching SAM-531 placebo capsule administered QD (morning dose) and 1 encapsulated Donepezil 5 mg tablet administered orally QD (evening dose) through 24 weeks. From Week 7 until Week 52 (end of study), the evening dose could have been increased to 2 tablets and adjusted back to 1 tablet at the investigator‰Ûªs discretion and according to tolerance."
NCT00895895,Phase 2,5/1/11,Study terminated early due to futility. Period 2 events include those that started in Period 2 or started in Period 1 and continued in to Period 2.,See termination reason in detailed description.,297954,0.029126214,3,103,NA,"The same event may appear as both an adverse event (AE) and a serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",SAM-531 5.0 mg Period 2,"SAM-531 5.0 mg capsule administered QD (morning dose) Week 25 up to 52 weeks. Matching encapsulated Donepezil placebo tablet administered QD (evening dose) for up to 52 weeks. From Week 7 until Week 52 (end of study), the evening dose could have been increased to 2 tablets and adjusted back to 1 tablet at the investigator‰Ûªs discretion."
NCT00895895,Phase 2,5/1/11,Study terminated early due to futility. Period 2 events include those that started in Period 2 or started in Period 1 and continued in to Period 2.,See termination reason in detailed description.,297957,0.075471698,8,106,NA,"The same event may appear as both an adverse event (AE) and a serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",SAM-531 5.0 mg Crossover Period 2,"Participants who received Placebo in Period 1, beginning in Week 25 and up to Week 52 (Period 2) received SAM-531 5.0 mg capsule administered QD (morning dose) and matching encapsulated Donepezil placebo tablet administered QD (evening dose). The evening dose could have been increased to 2 tablets and adjusted back to 1 tablet at the investigator‰Ûªs discretion."
NCT00895895,Phase 2,5/1/11,Study terminated early due to futility. Period 2 events include those that started in Period 2 or started in Period 1 and continued in to Period 2.,See termination reason in detailed description.,297959,0.038834951,4,103,NA,"The same event may appear as both an adverse event (AE) and a serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",SAM-531 5.0 mg Period 1,"SAM-531 5.0 mg capsule administered QD (morning dose) through 24 weeks. Matching encapsulated Donepezil placebo tablet administered QD (evening dose) through 24 weeks. From Week 7 until Week 52 (end of study), the evening dose could have been increased to 2 tablets and adjusted back to 1 tablet at the investigator‰Ûªs discretion."
NCT00895895,Phase 2,5/1/11,Study terminated early due to futility. Period 2 events include those that started in Period 2 or started in Period 1 and continued in to Period 2.,See termination reason in detailed description.,297953,0.067307692,7,104,NA,"The same event may appear as both an adverse event (AE) and a serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",Donepezil Period 2,"Matching SAM-531 placebo capsule administered QD (morning dose) for up to 52 weeks. One encapsulated Donepezil 5 mg tablet administered orally QD (evening dose) from Week 25 up to 52 weeks. From Week 7 until Week 52 (end of study), the evening dose could have been increased to 2 tablets and adjusted back to 1 tablet at the investigator‰Ûªs discretion and according to tolerance."
NCT00899678,Phase 2,7/1/12,NA,higher than projected discontinuation rate during Maintenance Phase,297198,0.141414141,14,99,Adverse Events (AEs) were collected over 68 weeks (from Week -6 to Week 62).,Adverse Events (AEs) refer to the Safety Set (SS) population. All subjects in the Safety Population (n=99) participated in the Induction Period. There were 27 subjects who did not continue into the Maintenance Period.,Overall Study,Overall Study comprises Induction Period and Maintenance Period (Week -6 to Week 62).
NCT00899678,Phase 2,7/1/12,NA,higher than projected discontinuation rate during Maintenance Phase,297199,0.114285714,4,35,Adverse Events (AEs) were collected over 68 weeks (from Week -6 to Week 62).,Adverse Events (AEs) refer to the Safety Set (SS) population. All subjects in the Safety Population (n=99) participated in the Induction Period. There were 27 subjects who did not continue into the Maintenance Period.,Maintenance High-Dose,"Maintenance High-Dose group*: 400 mg Certolizumab Pegol once every 4 weeks for subjects ‰ä´ 40 kg or 200 mg Certolizumab Pegol once every 4 weeks for subjects 20 to < 40 kg*prior to this dosing regimen, subjects underwent an induction of Certolizumab Pegol administered subcutaneously every 2 weeks (total 3 injections) at of either 400 mg for subjects ‰ä´ 40 kg or 200 mg for subjects 20 to < 40 kg"
NCT00899678,Phase 2,7/1/12,NA,higher than projected discontinuation rate during Maintenance Phase,297201,0.060606061,6,99,Adverse Events (AEs) were collected over 68 weeks (from Week -6 to Week 62).,Adverse Events (AEs) refer to the Safety Set (SS) population. All subjects in the Safety Population (n=99) participated in the Induction Period. There were 27 subjects who did not continue into the Maintenance Period.,Induction Period,"Induction Only is the period between the Week 0 dose and prior to first maintenance dose (Week 8). Induction Only includes all subjects who received a dose during the Induction Period but did not receive any treatment during the Maintenance Period. During the Induction Period (Weeks 0 to 6), subjects were administered Certolizumab Pegol (CZP) subcutaneously every 2 weeks (Q2W) (for a total of 3 administrations of drug) at a dose of either:400 mg for subjects ‰ä´ 40 kg200 mg for subjects 20 to < 40 kg"
NCT00899678,Phase 2,7/1/12,NA,higher than projected discontinuation rate during Maintenance Phase,297200,0.108108108,4,37,Adverse Events (AEs) were collected over 68 weeks (from Week -6 to Week 62).,Adverse Events (AEs) refer to the Safety Set (SS) population. All subjects in the Safety Population (n=99) participated in the Induction Period. There were 27 subjects who did not continue into the Maintenance Period.,Maintenance Low-Dose,"Maintenance Low-Dose group*: 200 mg Certolizumab Pegol once every 4 weeks for subjects ‰ä´ 40 kg or 100 mg Certolizumab Pegol once every 4 weeks for subjects 20 to < 40 kg*prior to this dosing regimen, subjects underwent an induction of Certolizumab Pegol administered subcutaneously every 2 weeks (total 3 injections) at of either 400 mg for subjects ‰ä´ 40 kg or 200 mg for subjects 20 to < 40 kg"
NCT00910000,Phase 1/Phase 2,10/1/15,The study was terminated early for toxicities and the emergence of better tolerated and more promising biologic agents added to platinum-based chemotherapy and/or use as maintenance.,Terminated due to unacceptable toxicity,294021,0.6,9,15,Adverse events were assessed every cycle on treatment. Phase Ib participants received up to 8 cycles of treatment. The median number of cycles started was 2 (range 1-8).,"Maximum grade toxicity by type was first calculated. Serious AEs were defined as events with treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv3. Other AEs were defined as events with treatment-attribution of possible, probable or definite and grades 1 or 2 per CTCAEv3.",All Phase Ib Participants,"All Phase Ib participants received Vorinostat according to the established dose escalation schedule during a 3-week cycle in combination with IV carboplatin AUC 4 (day 2) and IV gemcitabine 1000 mg/m2 (days 2 and 9). Participants received up to 8 cycles of therapy without the occurrence of disease progression, unacceptable adverse events, patient withdrawal, or discontinuation per MD decision."
NCT00910299,Phase 2,4/1/11,"The study was terminated early, and no formal statistical time-to-event analysis was performed.",Due to the low rate of primary endpoint events experienced in the study to date,293899,0.19047619,40,210,NA,NA,Prasugrel,One time 60 milligram (mg) oral loading dose and 10 mg once daily oral maintenance dose up to 6 months
NCT00910299,Phase 2,4/1/11,"The study was terminated early, and no formal statistical time-to-event analysis was performed.",Due to the low rate of primary endpoint events experienced in the study to date,293898,0.180952381,38,210,NA,NA,Clopidogrel,75 mg oral daily maintenance dose up to 6 months.
NCT00915278,Phase 1,1/1/13,This study was terminated prematurely because PK data did not enable sufficient confidence in producing desired clinical benefit. Potential re-occurrence of cytokine mediated infusion reaction at higher doses did not support further development.,The study was terminated on 26 February 2013. Risk-benefit assessment is no longer positive   and does not support further development,292446,0.625,5,8,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",PF-04605412 7.5 mg,"PF-04605412 7.5 mg was administered intravenously as 2 hour infusion on Day 1 of each cycle. The first cycle lasted 4 weeks and the following cycles lasted 2 weeks each. Treatment was continued until intolerable toxicity, disease progression or participant withdrawal."
NCT00915278,Phase 1,1/1/13,This study was terminated prematurely because PK data did not enable sufficient confidence in producing desired clinical benefit. Potential re-occurrence of cytokine mediated infusion reaction at higher doses did not support further development.,The study was terminated on 26 February 2013. Risk-benefit assessment is no longer positive   and does not support further development,292443,0.2,1,5,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",PF-04605412 34 mg,"PF-04605412 34 mg was administered intravenously as 2 hour infusion on Day 1 of each cycle. The first cycle lasted 4 weeks and the following cycles lasted 2 weeks each. Treatment was continued until intolerable toxicity, disease progression or participant withdrawal."
NCT00915278,Phase 1,1/1/13,This study was terminated prematurely because PK data did not enable sufficient confidence in producing desired clinical benefit. Potential re-occurrence of cytokine mediated infusion reaction at higher doses did not support further development.,The study was terminated on 26 February 2013. Risk-benefit assessment is no longer positive   and does not support further development,292445,0.4,2,5,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",PF-04605412 11.25 mg,"PF-04605412 11.25 mg was administered intravenously as 2 hour infusion on Day 1 of each cycle. The first cycle lasted 4 weeks and the following cycles lasted 2 weeks each. Treatment was continued until intolerable toxicity, disease progression or participant withdrawal."
NCT00915278,Phase 1,1/1/13,This study was terminated prematurely because PK data did not enable sufficient confidence in producing desired clinical benefit. Potential re-occurrence of cytokine mediated infusion reaction at higher doses did not support further development.,The study was terminated on 26 February 2013. Risk-benefit assessment is no longer positive   and does not support further development,292444,0.333333333,1,3,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",PF-04605412 16.9 mg,"PF-04605412 16.9 mg was administered intravenously as 2 hour infusion on Day 1 of each cycle. The first cycle lasted 4 weeks and the following cycles lasted 2 weeks each. Treatment was continued until intolerable toxicity, disease progression or participant withdrawal."
NCT00915278,Phase 1,1/1/13,This study was terminated prematurely because PK data did not enable sufficient confidence in producing desired clinical benefit. Potential re-occurrence of cytokine mediated infusion reaction at higher doses did not support further development.,The study was terminated on 26 February 2013. Risk-benefit assessment is no longer positive   and does not support further development,292441,0.555555556,5,9,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",PF-04605412 136 mg,"PF-04605412 136 mg was administered intravenously as 2 hour infusion on Day 1 of each cycle. The first cycle lasted 4 weeks and the following cycles lasted 2 weeks each. Treatment was continued until intolerable toxicity, disease progression or participant withdrawal."
NCT00923117,Phase 2,6/1/12,The study was terminated based on results of an interim analysis for futility.,The study was terminated based on results of an interim analysis for futility.,290111,0.363636364,16,44,NA,NA,Bevacizumab Resistant Patients,Patients who had tumor progression while treated with bevacizumab.
NCT00923117,Phase 2,6/1/12,The study was terminated based on results of an interim analysis for futility.,The study was terminated based on results of an interim analysis for futility.,290110,0.302325581,13,43,NA,NA,Bevacizumab Naive Patients,Patients with progressive tumor who have not been treated with bevacizumab.
NCT00924287,Phase 1/Phase 2,12/1/10,This study was terminated after the first patient on study died as a result of the treatment.,This study was terminated after the first patient treated on study died as a result of the   treatment.,289758,1,1,1,12 days,NA,Metastatic Cancer,Cancer that has invaded other parts of the body
NCT00924781,Phase 2,5/1/10,"Cohort 3 (MK2578 1mcg/200U) was not initiated because the study was prematurelyterminated by the sponsor. All randomized participants received at least one dose of study medication. Data presented are for Cohort 1 and Cohort 2, where applicable.",NA,289607,0.105263158,2,19,NA,NA,MK2578 QM,MK2578 IV administered once every 4 weeks.
NCT00924781,Phase 2,5/1/10,"Cohort 3 (MK2578 1mcg/200U) was not initiated because the study was prematurelyterminated by the sponsor. All randomized participants received at least one dose of study medication. Data presented are for Cohort 1 and Cohort 2, where applicable.",NA,289608,0.05,1,20,NA,NA,MK2578 QW,MK2578 IV administered once weekly.
NCT00927953,Phase 2,5/1/11,Early termination due to the inability to enroll (only 13 of 120 subjects enrolled); leading to small numbers of subjects analyzed and therefore many pre-specified analyses were not performed.,Early termination due to the inability to enroll (13 of 120 subjects enrolled),288344,0.5,3,6,NA,NA,MGAWN1,30 mg/kg single intravenous infusion of MGAWN1
NCT00927953,Phase 2,5/1/11,Early termination due to the inability to enroll (only 13 of 120 subjects enrolled); leading to small numbers of subjects analyzed and therefore many pre-specified analyses were not performed.,Early termination due to the inability to enroll (13 of 120 subjects enrolled),288343,0.142857143,1,7,NA,NA,Placebo - Normal Saline,single intravenous infusion of saline placebo
NCT00932126,Phase 1,12/1/11,The study was closed due to pharmacokinetic (PK) issues observed from initial PK data. Individual plasma concentration versus time were listed but final PK analysis and pharmacodynamic analyses were not conducted.,See termination reason in detailed description.,286732,0.2,2,10,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","PF-03758309, 60 mg BID",PF-03758309 60 mg administered orally twice daily
NCT00932126,Phase 1,12/1/11,The study was closed due to pharmacokinetic (PK) issues observed from initial PK data. Individual plasma concentration versus time were listed but final PK analysis and pharmacodynamic analyses were not conducted.,See termination reason in detailed description.,286733,0.2,1,5,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","PF-03758309, 50 mg BID",PF-03758309 50 mg administered orally twice daily
NCT00932126,Phase 1,12/1/11,The study was closed due to pharmacokinetic (PK) issues observed from initial PK data. Individual plasma concentration versus time were listed but final PK analysis and pharmacodynamic analyses were not conducted.,See termination reason in detailed description.,286735,0.2,1,5,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","PF-03758309, 20 mg BID",PF-03758309 20 mg administered orally twice daily
NCT00937768,Phase 2,7/1/12,NA,NA,285002,0.125,1,8,NA,NA,No Androgen Deprivation Therapy,Patients undergo observation every 3 months for 9 months.
NCT00939094,Phase 2,11/1/10,Early termination of study for safety reasons leading to fewer subjects analyzed than originally planned.,NA,284539,0.023809524,1,42,NA,NA,A - AZD2066,"AZD2066, 12 mg capsule"
NCT00953706,Phase 2,5/1/13,"In Part B, the treatment duration was 96 weeks; however, due to early study termination all analysis were performed up to Week 64, as planned.",Following review of results obtained from a pre-specified 6-month analysis of Part B data the   study was terminated on the basis of futility.,278449,0.133928571,15,112,Adverse events (serious and non-serious) were collected from signing of informed consent through 2 years after last dose (in Part B) of study drug (median treatment duration: 112 days for Part A and 381 days for Part B),NA,Ivacaftor ‰ÛÒ Part A,Ivacaftor 150 milligram (mg) tablet orally q12h for 16 weeks during Part A (double-blind treatment period).
NCT00953706,Phase 2,5/1/13,"In Part B, the treatment duration was 96 weeks; however, due to early study termination all analysis were performed up to Week 64, as planned.",Following review of results obtained from a pre-specified 6-month analysis of Part B data the   study was terminated on the basis of futility.,278448,0.4,2,5,Adverse events (serious and non-serious) were collected from signing of informed consent through 2 years after last dose (in Part B) of study drug (median treatment duration: 112 days for Part A and 381 days for Part B),NA,Placebo/Ivacaftor ‰ÛÒ Part B,"Participants who received placebo during Part A, received ivacaftor 150 mg tablet orally q12h for 96 weeks during Part B (open-label extension period)."
NCT00953706,Phase 2,5/1/13,"In Part B, the treatment duration was 96 weeks; however, due to early study termination all analysis were performed up to Week 64, as planned.",Following review of results obtained from a pre-specified 6-month analysis of Part B data the   study was terminated on the basis of futility.,278450,0.214285714,6,28,Adverse events (serious and non-serious) were collected from signing of informed consent through 2 years after last dose (in Part B) of study drug (median treatment duration: 112 days for Part A and 381 days for Part B),NA,Placebo ‰ÛÒ Part A,Placebo matched to ivacaftor tablet orally q12h for 16 weeks during Part A (double-blind treatment period).
NCT00953706,Phase 2,5/1/13,"In Part B, the treatment duration was 96 weeks; however, due to early study termination all analysis were performed up to Week 64, as planned.",Following review of results obtained from a pre-specified 6-month analysis of Part B data the   study was terminated on the basis of futility.,278447,0.424242424,14,33,Adverse events (serious and non-serious) were collected from signing of informed consent through 2 years after last dose (in Part B) of study drug (median treatment duration: 112 days for Part A and 381 days for Part B),NA,Ivacaftor/Ivacaftor ‰ÛÒ Part B,"Participants who received ivacaftor during Part A, received ivacaftor 150 mg tablet orally q12h for 96 weeks during Part B (open-label extension period)."
NCT00747812,Phase 2,5/1/12,Insufficient data collected from limited number of implanted subjects.,Sponsor closed enrollment early based on interim data from the PRISM US Pivotal Study.,353791,0.5,2,4,NA,NA,Sham Stimulation (Control Group),Sham stimulation from IPG activation to 12 weeks post-IPG activation. Stimulation on from 12 weeks post-activation on.
NCT00747812,Phase 2,5/1/12,Insufficient data collected from limited number of implanted subjects.,Sponsor closed enrollment early based on interim data from the PRISM US Pivotal Study.,353792,0.8,4,5,NA,NA,Active Stimulation (Treatment Group),Active stimulation from IPG activation to 12 weeks post-IPG activation. Stimulation off from 12 weeks post-activation to 16 weeks post-activation. Stimulation on from 16 weeks post-activation to end of study.
NCT00960934,Phase 2,12/1/10,NA,NA,276181,0.047619048,3,63,"From October 2, 2009 to December 21, 2010, with an in-house data-cut date of February 10, 2011","All Participants as Treated (APaT) Population. Three participants were randomized but not treated, and thus are not included in the adverse event table calculations (one participant was randomized to 5 mg MK-5442; one participant was randomized to 15 mg MK-5442 and one participant was randomized to Placebo.",Placebo,"Following a 2-week open-label placebo run-in, participants received a daily oral dose of placebo dose-matched to MK-5442 for a duration of at least 6 months."
NCT00960934,Phase 2,12/1/10,NA,NA,276182,0.063492063,4,63,"From October 2, 2009 to December 21, 2010, with an in-house data-cut date of February 10, 2011","All Participants as Treated (APaT) Population. Three participants were randomized but not treated, and thus are not included in the adverse event table calculations (one participant was randomized to 5 mg MK-5442; one participant was randomized to 15 mg MK-5442 and one participant was randomized to Placebo.",MK-5442 15 mg,"Following a 2-week open-label placebo run-in, participants received a daily oral dose of 15 mg of MK-5442 for a duration of at least 6 months."
NCT00960934,Phase 2,12/1/10,NA,NA,276186,0.046875,3,64,"From October 2, 2009 to December 21, 2010, with an in-house data-cut date of February 10, 2011","All Participants as Treated (APaT) Population. Three participants were randomized but not treated, and thus are not included in the adverse event table calculations (one participant was randomized to 5 mg MK-5442; one participant was randomized to 15 mg MK-5442 and one participant was randomized to Placebo.",MK-5442 2.5 mg,"Following a 2-week open-label placebo run-in, participants received a daily oral dose of 2.5 mg of MK-5442 for a duration of at least 6 months."
NCT00960934,Phase 2,12/1/10,NA,NA,276184,0.0625,4,64,"From October 2, 2009 to December 21, 2010, with an in-house data-cut date of February 10, 2011","All Participants as Treated (APaT) Population. Three participants were randomized but not treated, and thus are not included in the adverse event table calculations (one participant was randomized to 5 mg MK-5442; one participant was randomized to 15 mg MK-5442 and one participant was randomized to Placebo.",MK-5442 7.5 mg,"Following a 2-week open-label placebo run-in, participants received a daily oral dose of 7.5 mg of MK-5442 for a duration of at least 6 months."
NCT00960934,Phase 2,12/1/10,NA,NA,276183,0.078125,5,64,"From October 2, 2009 to December 21, 2010, with an in-house data-cut date of February 10, 2011","All Participants as Treated (APaT) Population. Three participants were randomized but not treated, and thus are not included in the adverse event table calculations (one participant was randomized to 5 mg MK-5442; one participant was randomized to 15 mg MK-5442 and one participant was randomized to Placebo.",MK-5442 10 mg,"Following a 2-week open-label placebo run-in, participants received a daily oral dose of 10 mg of MK-5442 for a duration of at least 6 months."
NCT00961649,Phase 2,2/1/10,NA,NA,275787,0.024390244,1,41,Adverse events were collected for the duration of the study. The safety population includes all subjects who were exposed to the study medications.,An adverse event was defined as any untoward medical occurrence in a subject who was administered a study treatment regardless of whether or not the event had a causal relationship with the treatment. All AEs were obtained as solicited comments from the study subjects and as observations by the Investigator as outlined in the study protocol.,Brinz/Brim,Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension and Vehicle: 1 drop each instilled in both eyes 3 times a day for 6 weeks
NCT00963872,Phase 1/Phase 2,8/1/13,NA,Lack of efficacy after interim analysis,274816,1,5,5,100 days after umbilical cord blood transplant,NA,Complement Fragment A - Larger Cell Dose,Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.
NCT00963872,Phase 1/Phase 2,8/1/13,NA,Lack of efficacy after interim analysis,274817,0.875,21,24,100 days after umbilical cord blood transplant,NA,Complement Fragment 3A - Small Cell Dose,Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.
NCT00967226,Phase 2,12/1/14,"Not every enrolled participant had an adverse event and some had more than one. The prednioslone participants who had adverse events warranting early withdrawal had severe failure to thrive (<5th percentile), a serious adverse event.","Serious adverse events with prednisolone, primarily temporary growth retardation, <5th   percentile.",273693,0.090909091,1,11,Adverse events collected in first 9 months participants treated with medication.,NA,Propranolol,"Assessing efficacy and tolerability of propranolol in management of symptomatic hemangiomaspropranolol: propranolol 0.5 mg/kg p.o. QID 6 months or less"
NCT00967226,Phase 2,12/1/14,"Not every enrolled participant had an adverse event and some had more than one. The prednioslone participants who had adverse events warranting early withdrawal had severe failure to thrive (<5th percentile), a serious adverse event.","Serious adverse events with prednisolone, primarily temporary growth retardation, <5th   percentile.",273692,0.625,5,8,Adverse events collected in first 9 months participants treated with medication.,NA,Prednisolone,"Assessing efficacy and tolerability of prednisolone in management of symptomatic hemangiomas and comparing to propranolol.Prednisolone: 1.0 mg/kg p.o. BID x 6 months or less"
NCT00975806,Phase 1/Phase 2,10/1/11,NA,MTD determined sub-optimal as efficacious treatment for renal cell carcinoma.,271336,0.571428571,4,7,Phase 1 Only. From the date of the first study drug dose to within 28 days after the study drug treatment was discontinued.,Median treatment duration with Lenalidomide and Sunitinib was shortest in Cohort A at 41 days (range = 17 to 189 days) and longest in Cohort G = 97 days (range: 60 to 125 days) of lenalidomide treatment and 97.5 days (range = 54 to 125 days) of Sunitinib,Cohort F,Lenalidomide 10 mg QD on Days 1-21 of each 21-day cycle and sunitinib 37.5 mg QD on Days 1-14 of each 21-day cycle
NCT00975806,Phase 1/Phase 2,10/1/11,NA,MTD determined sub-optimal as efficacious treatment for renal cell carcinoma.,271337,0.6,3,5,Phase 1 Only. From the date of the first study drug dose to within 28 days after the study drug treatment was discontinued.,Median treatment duration with Lenalidomide and Sunitinib was shortest in Cohort A at 41 days (range = 17 to 189 days) and longest in Cohort G = 97 days (range: 60 to 125 days) of lenalidomide treatment and 97.5 days (range = 54 to 125 days) of Sunitinib,Cohort A,Lenalidomide 10 mg QD and sunitinib 37.5 mg QD on Days 1-21 of each 21-day cycle
NCT00975806,Phase 1/Phase 2,10/1/11,NA,MTD determined sub-optimal as efficacious treatment for renal cell carcinoma.,271335,0.5,2,4,Phase 1 Only. From the date of the first study drug dose to within 28 days after the study drug treatment was discontinued.,Median treatment duration with Lenalidomide and Sunitinib was shortest in Cohort A at 41 days (range = 17 to 189 days) and longest in Cohort G = 97 days (range: 60 to 125 days) of lenalidomide treatment and 97.5 days (range = 54 to 125 days) of Sunitinib,Cohort G,Lenalidomide 15 mg QD on Days 1-21 of each 21-day cycle and sunitinib 37.5 mg QD on Days 1-14 of each 21-day cycle
NCT00976677,Phase 2,11/1/13,NA,NA,270941,0.2,1,5,Assessed every 21 days while on treatment and for 30 days after the end of treatment.,NA,Arm A,"Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes (with or without bevacizumab IV over 30-90 minutes) on day 1. Patients also receive an oral placebo once daily on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After completion of 6 courses, patients with stable or responding disease may continue to receive placebo (with or without bevacizumab) as above in the absence of disease progression or unacceptable toxicity."
NCT00976677,Phase 2,11/1/13,NA,NA,270940,0.6,3,5,Assessed every 21 days while on treatment and for 30 days after the end of treatment.,NA,Arm B,"Patients receive paclitaxel and carboplatin (with or without bevacizumab) as in arm A. Patients also receive oral erlotinib hydrochloride once daily on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After completion of 6 courses, patients with stable or responding disease may continue to receive erlotinib hydrochloride (with or without bevacizumab) as above in the absence of disease progression or unacceptable toxicity."
NCT00977379,Phase 2,2/1/11,Study was prematurely terminated due to an insufficient number of participants enrolled and therefore results are only based on a small sample of breast cancer participants with newly diagnosed brain metastasis and should be considered with caution.,Due to an insufficient number of participants enrolled.,270584,0.5,6,12,Throughout study (up to approximately 1 year 5.5 months overall),Safety population included all participants from ‰ÛÏWBRT Followed by Standard of Care‰Û arm who received at least one fraction of WBRT and all participants from ‰ÛÏWBRT+Capecitabine Followed by Capecitabine Maintenance‰Û arm who received at least one dose of capecitabine or one fraction of WBRT.,WBRT Followed by Standard of Care,"Participants received 3000 cGy WBRT in 10 single daily fractions over 12 to 14 days (300 cGy / fraction) followed by standard of care therapy at the discretion of the treating oncologist starting no earlier than 2 weeks after completion of WBRT. The participants were followed during the treatment until the halting of standard of care for any reason (CNS or extra-cranial tumor progression, unacceptable toxicity, change of therapeutic strategy, withdrawal of participant consent, or death)."
NCT00978432,Phase 2,3/1/16,NA,The toxicity seemed to outweigh the benefit.,270279,0.1,1,10,From the time of consent until 4 weeks after the last dose of study drug; approximately 1 year.,NA,Arm 1a (RAD001 Followed by LBH589),"Part 1a: Sequential single agent therapy with RAD001 and LBH589. Each agent will be given for four-six 28-day cycles.Subjects with less than a CR after 4 cycles of study drug should proceed to the next study drug(s) after the prescribed washout period.Subjects with a CR may receive up to 6 cycles of study drug and will not receive the next study drug(s) until there is evidence of progressive disease.There will be a 1-6 week ‰Û÷washout‰Ûª period between stopping and starting each agent in Part 1, unless rapid progression suggests holding therapy would not be in the patient‰Ûªs best interest.RAD001: 10 mg/day for Part 1 of the trialLBH589: 40 mg on Monday, Wednesday and Friday weekly for Part 1 of the trial"
NCT00978432,Phase 2,3/1/16,NA,The toxicity seemed to outweigh the benefit.,270277,0.333333333,6,18,From the time of consent until 4 weeks after the last dose of study drug; approximately 1 year.,NA,Doublet (Combination RAD001 and LBH589),"Subjects will receive the doublet of RAD001 and LBH589 given in two to thirteen, 28-day cycles. Subjects will be evaluated for the disease status after completion of cycle two and then after every 4 cycles. Subjects with progressive disease will stop after 2 cycles. Subjects with stable disease or better may receive up to 13 cycles. LBH589 will start at 15mg po three days a week at least 2 days apart such as on days M/W/F or T/Th/Sat and RAD001 will start at 7.5mg po daily.Doublet (RAD001 and LBH589): RAD001 7.5 mg by mouth daily and LBH589 15 mg by mouth on Monday/Wednesday/Friday during Part 2."
NCT00978432,Phase 2,3/1/16,NA,The toxicity seemed to outweigh the benefit.,270278,0.2,1,5,From the time of consent until 4 weeks after the last dose of study drug; approximately 1 year.,NA,Arm 1b (LBH589 Followed by RAD001),"Part 1b: Sequential single agent therapy with LBH589 and RAD001 . Each agent will be given for four-six 28-day cycles.Subjects with less than a CR after 4 cycles of study drug should proceed to the next study drug(s) after the prescribed washout period.Subjects with a CR may receive up to 6 cycles of study drug and will not receive the next study drug(s) until there is evidence of progressive disease.There will be a 1-6 week ‰Û÷washout‰Ûª period between stopping and starting each agent in Part 1, unless rapid progression suggests holding therapy would not be in the patient‰Ûªs best interest.RAD001: 10 mg/day for Part 1 of the trialLBH589: 40 mg on Monday, Wednesday and Friday weekly for Part 1 of the trial"
NCT00988169,Phase 2,5/1/10,NA,NA,266624,0.2,1,5,NA,NA,Oral Erlotinib and Pulsed Doses of Oral AT-101,Treatment-naÌøve advanced (Wet Stage IIIB and IV)NSCLC patients with EGFR activating mutations.
NCT00993421,Phase 2,6/1/10,NA,Clinical trial terminated due to results from recent nonclinical studies,264910,0.02,1,50,NA,NA,LY377604 (75 mg)/Sibutramine (30 mg),"LY377604 (75 mg): Given orally, daily for 24 weeks.sibutramine (30 mg): Given orally, daily for 24 weeks.Placebo metoprolol: Given orally, daily for 24 weeks, followed by 2 week taper."
NCT00993421,Phase 2,6/1/10,NA,Clinical trial terminated due to results from recent nonclinical studies,264913,0.041666667,2,48,NA,NA,Sibutramine (30mg)/Metoprolol (200mg),"sibutramine (30 mg): Given orally, daily for 24 weeks.metoprolol (200 mg): Given orally, daily 100 mg for 1 week followed by 200 mg for 23 weeks (Patients unable to tolerate 200 mg will be dose reduced to 100 mg), followed by 2 week taper (1 week at 100 mg/day followed by 1 week at 50 mg/day).Placebo LY377604: given orally, daily for 24 weeks."
NCT00993421,Phase 2,6/1/10,NA,Clinical trial terminated due to results from recent nonclinical studies,264909,0.043478261,2,46,NA,NA,LY377604 (75 mg)/Sibutramine (15 mg),"LY377604 (75 mg): Given orally, daily for 24 weeks.sibutramine (15 mg): Given orally, daily for 24 weeks.Placebo metoprolol: Given orally, daily for 24 weeks, followed by 2 week taper."
NCT00993421,Phase 2,6/1/10,NA,Clinical trial terminated due to results from recent nonclinical studies,264912,0.040816327,2,49,NA,NA,LY377604 (15 mg)/Sibutramine (30 mg),"LY377604 (15 mg): Given orally, daily for 24 weeks.sibutramine (30 mg): Given orally, daily for 24 weeks.Placebo metoprolol: Given orally, daily for 24 weeks, followed by 2 week taper."
NCT00994214,Phase 2,2/1/11,The study was terminated prematurely due to lack of efficacy.,Preliminary data from this study does not support expected inhibition of GH and IGF-1,264487,0.052631579,1,19,Up to Visit 10 (An average of 6.5 Months),"Included Serious Adverse Events (SAEs) and Adverse Events (AEs) during treatment phase for Safety PopulationTEAE are reported by Maximum Dose Received in Each Part of the Study.4 subjects from part B, Arm A were considered under other arms of part B based on the maximum dose received.",Part A: Arm A: BIM 23A760 1 mg,NA
NCT00994214,Phase 2,2/1/11,The study was terminated prematurely due to lack of efficacy.,Preliminary data from this study does not support expected inhibition of GH and IGF-1,264479,0.166666667,2,12,Up to Visit 10 (An average of 6.5 Months),"Included Serious Adverse Events (SAEs) and Adverse Events (AEs) during treatment phase for Safety PopulationTEAE are reported by Maximum Dose Received in Each Part of the Study.4 subjects from part B, Arm A were considered under other arms of part B based on the maximum dose received.",Overall - Part B,NA
NCT00994214,Phase 2,2/1/11,The study was terminated prematurely due to lack of efficacy.,Preliminary data from this study does not support expected inhibition of GH and IGF-1,264483,0.039473684,3,76,Up to Visit 10 (An average of 6.5 Months),"Included Serious Adverse Events (SAEs) and Adverse Events (AEs) during treatment phase for Safety PopulationTEAE are reported by Maximum Dose Received in Each Part of the Study.4 subjects from part B, Arm A were considered under other arms of part B based on the maximum dose received.",Overall - Part A,NA
NCT00994214,Phase 2,2/1/11,The study was terminated prematurely due to lack of efficacy.,Preliminary data from this study does not support expected inhibition of GH and IGF-1,264480,0.4,2,5,Up to Visit 10 (An average of 6.5 Months),"Included Serious Adverse Events (SAEs) and Adverse Events (AEs) during treatment phase for Safety PopulationTEAE are reported by Maximum Dose Received in Each Part of the Study.4 subjects from part B, Arm A were considered under other arms of part B based on the maximum dose received.",Part B: Arm D: BIM 23A760 6 mg,NA
NCT00994214,Phase 2,2/1/11,The study was terminated prematurely due to lack of efficacy.,Preliminary data from this study does not support expected inhibition of GH and IGF-1,264486,0.105263158,2,19,Up to Visit 10 (An average of 6.5 Months),"Included Serious Adverse Events (SAEs) and Adverse Events (AEs) during treatment phase for Safety PopulationTEAE are reported by Maximum Dose Received in Each Part of the Study.4 subjects from part B, Arm A were considered under other arms of part B based on the maximum dose received.",Part A: Arm B: BIM 23A760 2 mg,NA
NCT00995449,Phase 2,2/1/12,The study was terminated upon completion of safety run-in due to program refocus.,Program refocus,264194,0.142857143,1,7,Primary safety data was collected at week 14 and a follow-up(end of study) safety assessment at week 30.,NA,KB003 600 mg,"600 mg, KB003 a monoclonal antibody"
NCT00997243,Phase 2,5/1/11,The study was terminated early by the sponsor due to the removal of lintuzumab from the market.,Drug no longer being supplied by sponsor,262593,1,7,7,Reported Adverse Events (AEs) include events present at screening and after discontinuation from study (day 30).,NA,5-azacytidine and Lintuzumab,"Cycle 1- 5-azacytidine (Vidaza, AZA) 75mg/m2 IV/SC daily on days 1-7.Subsequent Cycles (cycles to be repeated every 28 days) AZA 75mg/m2 IV/SC daily on days 1-7."
NCT00997672,Phase 2,8/1/11,"Limitation of the study is small sample size of nine randomized patients. This may have determined uneven distribution of AEs due to random variation. Taking into account these limitations, we do not encourage future studies with lithium in MSA.",Data Monitoring Committee decision on 22nd August 2011 for safety issues,262415,1,4,4,NA,NA,Lithium CARBONATE 150 or 300 mg,"Lithium Carbonate : Lithium Carbonate will be dosed based on lithiemy, which will be in the range 0.9-1.2 mEq/L. Maximum allowed dose will be 1500mg/day."
NCT00997672,Phase 2,8/1/11,"Limitation of the study is small sample size of nine randomized patients. This may have determined uneven distribution of AEs due to random variation. Taking into account these limitations, we do not encourage future studies with lithium in MSA.",Data Monitoring Committee decision on 22nd August 2011 for safety issues,262414,0.2,1,5,NA,NA,Placebo,"Lithium Carbonate : Lithium Carbonate will be dosed based on lithiemy, which will be in the range 0.9-1.2 mEq/L. Maximum allowed dose will be 1500mg/day."
NCT01004510,Phase 2,4/1/11,NA,failure to accrue projected number of patients,260082,0.333333333,1,3,"Although the protocol was approved to begin enrollment 9/25/09, Adverse event data was collected from first patient enrollment 1/4/10-through study termination on 4/26/11. Aproximately 1 year, 4 months.",NA,Zoledronic Acid,Monthly zoledronic acid in addition to chemotherapy
NCT01004822,Phase 1,5/1/14,"The study was terminated early by the sponsor due to lack of significant pharmacological effects (safety/Pharmacodynamics/efficacy) through 25 mg/kg cohort. Hence, no participant could reach out to Stage 2.",See termination reason in detailed description.,259978,0.4,2,5,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as non-serious in another subject, or one subject may have experienced both a serious and non-serious event during the study.",CVX-241 (PF-05057459) 25 mg/kg,"CVX-241 (PF-05057459) 25 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons."
NCT01004822,Phase 1,5/1/14,"The study was terminated early by the sponsor due to lack of significant pharmacological effects (safety/Pharmacodynamics/efficacy) through 25 mg/kg cohort. Hence, no participant could reach out to Stage 2.",See termination reason in detailed description.,259982,0.5,2,4,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as non-serious in another subject, or one subject may have experienced both a serious and non-serious event during the study.",CVX-241 (PF-05057459) 6 mg/kg,"CVX-241 (PF-05057459) 6 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons."
NCT01004822,Phase 1,5/1/14,"The study was terminated early by the sponsor due to lack of significant pharmacological effects (safety/Pharmacodynamics/efficacy) through 25 mg/kg cohort. Hence, no participant could reach out to Stage 2.",See termination reason in detailed description.,259980,0.25,1,4,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as non-serious in another subject, or one subject may have experienced both a serious and non-serious event during the study.",CVX-241 (PF-05057459) 15 mg/kg,"CVX-241 (PF-05057459) 15 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons."
NCT01004822,Phase 1,5/1/14,"The study was terminated early by the sponsor due to lack of significant pharmacological effects (safety/Pharmacodynamics/efficacy) through 25 mg/kg cohort. Hence, no participant could reach out to Stage 2.",See termination reason in detailed description.,259979,0.25,1,4,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as non-serious in another subject, or one subject may have experienced both a serious and non-serious event during the study.",CVX-241 (PF-05057459) 18 mg/kg,"CVX-241 (PF-05057459) 18 mg/kg intravenous (IV) infusions once-weekly in 4 week cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons."
NCT01005914,Phase 2,5/1/14,Early termination of the study due to adverse events.,Increased rate of bacterial infections,259485,0.818181818,9,11,"All unexpected adverse events (AEs) related, probably related or possibly related to the study drug which are equal or greater than Grade 3 and serious adverse events (SAEs) were collected from first patient enrollment on 10/21/09 through 2010.","Adverse events collected:Unexpected AEs (when type or severity isn't listed in Expected AE List)Deaths within 30 days of drug admin.Grade ‰ä´ 3 (related to the following):Allergic reactionsCNS thrombosis/embolismCoagulopathyElevated AST, ALTHyperbilirubinemiaHyperglycemiaHypertriglyceridemiaPancreatitis",Group 1,"cyclophosphamide D1- 3: 300 m g/m2 IV 6 doses plus mesna 600 mg/ m2 /day cont. IV D1-3, cytarabine D2 & 3: 3g/m2 IV, dexD1-4; 11-14: 40 mg daily, doxorubicin hydrochloride D4: 50 mg/m2 IVDrug:imatinib mesylate 600 mg/dayDrug:methotrexate Day 1: 1g/ m2 (200 mg/ m2load IV over 2 hours plus 800 mg/ m2 over 22 hours as an infusionDrug: methylprednisolone Day 1-3: 50mg IV BIDDrug: pegaspargase Day 3/Day4: 2,500 IU/ m2 IVDrug: vincristine sulfate Day 4 & 11: 2 mg IVcyclophosphamide: Day 1- 3: 300 m g/m2 IV over 2-3 hours every 12 hours for 6 doses plus mesna 600 mg/ m2 /day continuous infusion Days 1-3cytarabine: Day 2 & 3: 3g/m2 IV over 2 hours q12 X 4dexamethasone: Day 1-4; 11-14: 40 mg dailydoxorubicin hydrochloride: Day 4: 50 mg/m2 IV over 2 hoursimatinib mesylate: 600 mg/daymethotrexate: D"
NCT01006616,Phase 2,11/1/11,NA,NA,259324,0.171052632,26,152,Up to one week after last dose of study drug (up to 105 weeks),The ASaT population consisted of all participants who received at least one dose of study drug.,Navarixin 10 mg,"Participants receive navarixin 10 mg, as one navarixin 10 mg capsule and two placebo capsules, administered orally QD for up to 2 years"
NCT01006616,Phase 2,11/1/11,NA,NA,259323,0.147435897,23,156,Up to one week after last dose of study drug (up to 105 weeks),The ASaT population consisted of all participants who received at least one dose of study drug.,Navarixin 30 mg,"Participants receive navarixin 30 mg, as one navarixin 30 mg capsule and two placebo capsules, administered orally QD for up to 2 years"
NCT01006616,Phase 2,11/1/11,NA,NA,259322,0.131578947,20,152,Up to one week after last dose of study drug (up to 105 weeks),The ASaT population consisted of all participants who received at least one dose of study drug.,Navarixin 50 mg,"Participants receive navarixin 50 mg, as two navarixin 10 mg capsules and one navarixin 30 mg capsule, administered orally QD for up to 2 years"
NCT01006616,Phase 2,11/1/11,NA,NA,259321,0.136363636,21,154,Up to one week after last dose of study drug (up to 105 weeks),The ASaT population consisted of all participants who received at least one dose of study drug.,Placebo,"Participants receive placebo to navarixin, as three placebo capsules, administered orally QD for up to 2 years"
NCT01009203,Phase 2,12/1/12,NA,High patient withdrawal rate,258620,0.333333333,4,12,3 years,NA,Erlotinib and Temsirolimus,Erlotinib at 150 mg by mouth daily + Temsirolimus at 15 mg intravenously weekly. Each cycle is comprised of 28 days.
NCT01009346,Phase 1/Phase 2,3/1/11,Early termination leading to small numbers of subjects analyzed,Toxicity,258594,0.888888889,8,9,3 years,NA,Group 1,NA
NCT01010568,Phase 2,8/1/14,NA,Unable to accrue patients due to change in standard CLL therapy,258160,0.3,3,10,1 year,NA,Ofatumumab and Bendamustine,"Ofatumumab and BendamustineOfatumumab and Bendamustine: Ofatumumab 300-mg IV on Day 1 of week -1 and then 1000 mg on Day 1 of each cycle for 6 cycles Bendamustine 70 mg/m2 IV on days 1 and 2 of each cycle for 6 cycles"
NCT01017653,Phase 2,10/1/11,NA,study did not reach benchmark efficacy rule at 16 subjects,255848,0.0625,1,16,16 months,"The adverse events were gathered in Common Terminology Criteria for Adverse Events v.3.0, and have been converted to v.4.0 for entry into ClinicalTrials.gov",Panitumumab and Irinotecan,"Panitumumab in Combination with Irinotecan : Panitumumab, 6mg/kg, as an intravenous infusion every other week in combination with Irinotecan (dose dependent upon whether the patient is taking an enzyme-inducing anti-epileptic drug [EIAED]). On an enzyme-inducing anti-epileptic drug (EIAED), irinotecan will be dosed at 340 mg/m2 every other week. Not on an EIAED, irinotecan will be dosed at 125 mg/m2. Treatment will continue until tumor progression or unacceptable toxicity."
NCT01018953,Phase 2,1/1/11,"Due to premature termination of the study, no data was collected/analyzed and no patient participated in Part B.",Preliminary data from study NCT00994214 do not support expected inhibition of GH and IGF-1,255131,0.125,1,8,Up to week 26,"Dose received prior to AE onset.Two serious adverse events (SAEs) 'Confusional State' and 'Nausea' were not included as they occurred during screening phase, before starting study drug.",BIM 23A760,"This dose adaptive study was planned to treat up to 20 patients in each starting dose cohort, with a maximum of three starting dose cohorts. The doses planned to be assessed were 1, 2, 4, 6 and 8 mg; however, the maximum starting dose was 4 mg. The starting dose of the first cohort was 1 mg and the first cohort would include at least five patients. After the first 15 patients were treated for 4 weeks, the results were to be reviewed by a Data Review Committee. An extension phase (Part B) was planned for those subjects completing the initial study and fulfilling specific eligibility criteria (symptoms control, willingness to participate, safety and tolerability).BIM 23A760 was a solution at a concentration of 5 mg/mL ready for subcutaneous injection. BIM 23A760 doses of 1, 2, 4, 6 and 8 mg were to be given to the patient according to a dose escalation and titration process. Patients would have received 24 weekly injections of BIM 23A760 during the treatment period."
NCT01024244,Phase 2,7/1/10,"Since Study GMAH was terminated after enrolling only 78 participants with just 10 participants completing 12 weeks of treatment with LY2599506, only disposition, demographics, and safety data are reported.",Terminated due to nonclinical safety findings,253649,0.133333333,2,15,NA,NA,200 mg LY2599506 Once Daily,"Participants received 200 mg of LY2599506 po once daily (QD)(Two 100-mg LY2599506 capsules prior to morning meal, 2 matching placebo capsules prior to evening meal for 12 weeks)."
NCT01024244,Phase 2,7/1/10,"Since Study GMAH was terminated after enrolling only 78 participants with just 10 participants completing 12 weeks of treatment with LY2599506, only disposition, demographics, and safety data are reported.",Terminated due to nonclinical safety findings,253650,0.071428571,1,14,NA,NA,400 mg LY2599506,"Participants received two 100-mg capsules of LY2599506 po BID, prior to morning and evening meals for 12 weeks."
NCT01025232,Phase 1/Phase 2,1/1/13,NA,The last remaining subject withdrew consent because the collaborator Genentech stopped   supplying study drug.,253404,0.152173913,7,46,NA,NA,4 Week Re-treatment,"Subjects can receive re-treatment every 4 weeks if there is persistent or recurrent intraretinal, subretinal, or sub-RPE fluid on any OCT modality, or any evidence of hemorrhage on clinical evaluation. Subjects will go no longer than 12 weeks without treatment.Ranibizumab: Intravitreal Injection of 2.0mg formulation"
NCT01025232,Phase 1/Phase 2,1/1/13,NA,The last remaining subject withdrew consent because the collaborator Genentech stopped   supplying study drug.,253403,0.238095238,10,42,NA,NA,6 Week Re-treatment,"Subjects can receive re-treatment every 6 weeks if there is persistent or recurrent intraretinal, subretinal, or sub-RPE fluid on any OCT modality, or any evidence of hemorrhage on clinical evaluation. Every 6 weeks regimen will test potential longer duration of action of 2.0 mg ranibizumab. Subjects will go no longer than 12 weeks without treatment.Ranibizumab: Intravitreal Injection of 2.0mg formulation"
NCT01029795,Phase 2,6/1/10,"Since Study GMAJ was terminated after enrolling only 38 participants with just 1 participant completing 12 weeks of treatment, only disposition, demographics, and safety data are reported.",Terminated due to nonclinical safety findings,251633,0.0625,1,16,NA,NA,LY2599506,"Participants received up to 4 capsules by mouth (po), twice daily (BID), in combinations of 50 milligram (mg) or 100 mg capsules of LY2599506 or matching placebo capsules. (Each dose contained at least 1 capsule of active drug.) LY2599506 was administered, based on predefined glycemic targets, in escalating doses from 100 mg/day up to 800 mg/day."
NCT01029925,Phase 2,11/1/11,The greatest limitation in our study was early termination due to perceived lack of drug efficacy leading to small number of subjects analyzed.,"DSMB determined, due to higher than expected risk/safety concerns, study should be closed.",251549,0.571428571,4,7,NA,NA,Dichloroacetate (DCA),"Dichloroacetate, 6.25mg/kg orally, twice daily, administered with food around the same time every day and at approximately 8-12 hours apart."
NCT01035658,Phase 1/Phase 2,3/1/14,"Per protocol, study did not proceed to phase II based on analyses from phase I. Therefore, Phase II outcomes (all outcomes other than determination of the MTD) were not evaluated and will not be posted.","Based on analyses in Phase I, the study did not advance to Phase II.",249754,0.666666667,2,3,NA,NA,Dose Level 1 Sequential,"Systemic therapy with pazopanib and liposomal doxorubicin (Doxil). In this schedule, liposomal doxorubicin (30mg) was given on day 1, and pazopanib (400mg) was given days 3 - 26 of each 28 day cycle. Cycles will continue until disease progression, unacceptable toxicity or withdrawal.Pazopanib: All patients will begin treatment with a 7-day run in period of single-agent pazopanib. Patients will receive pazopanib orally days 1-28 of a 28 day cycle.Doxil: Liposomal doxorubicin (Doxil) will be administered IV on day 1 of a 28-day treatment cycle"
NCT01035658,Phase 1/Phase 2,3/1/14,"Per protocol, study did not proceed to phase II based on analyses from phase I. Therefore, Phase II outcomes (all outcomes other than determination of the MTD) were not evaluated and will not be posted.","Based on analyses in Phase I, the study did not advance to Phase II.",249755,0.125,1,8,NA,NA,Dose Level -1,"Systemic therapy with pazopanib and liposomal doxorubicin (Doxil). Single-agent pazopanib will be given for a 7 day run-in period, followed by a combination of pazopanib (400mg) and liposomal doxorubicin (30mg) administered in 28-day treatment cycles. Cycles will continue until disease progression, unacceptable toxicity or withdrawal.Pazopanib: All patients will begin treatment with a 7-day run in period of single-agent pazopanib. Patients will receive pazopanib orally days 1-28 of a 28 day cycle.Doxil: Liposomal doxorubicin (Doxil) will be administered IV on day 1 of a 28-day treatment cycle"
NCT01035658,Phase 1/Phase 2,3/1/14,"Per protocol, study did not proceed to phase II based on analyses from phase I. Therefore, Phase II outcomes (all outcomes other than determination of the MTD) were not evaluated and will not be posted.","Based on analyses in Phase I, the study did not advance to Phase II.",249756,0.6,3,5,NA,NA,Dose Level 1,"Systemic therapy with pazopanib and liposomal doxorubicin (Doxil). Single-agent pazopanib will be given for a 7 day run-in period, followed by a combination of pazopanib (400mg) and liposomal doxorubicin (40mg) administered in 28-day treatment cycles. Cycles will continue until disease progression, unacceptable toxicity or withdrawal.Pazopanib: All patients will begin treatment with a 7-day run in period of single-agent pazopanib. Patients will receive pazopanib orally days 1-28 of a 28 day cycle.Doxil: Liposomal doxorubicin (Doxil) will be administered IV on day 1 of a 28-day treatment cycle"
NCT01035658,Phase 1/Phase 2,3/1/14,"Per protocol, study did not proceed to phase II based on analyses from phase I. Therefore, Phase II outcomes (all outcomes other than determination of the MTD) were not evaluated and will not be posted.","Based on analyses in Phase I, the study did not advance to Phase II.",249753,0.166666667,1,6,NA,NA,Dose Level 2 Sequential,"Systemic therapy with pazopanib and liposomal doxorubicin (Doxil). In this schedule, liposomal doxorubicin (40mg) was given on day 1, and pazopanib (400mg) was given days 3 - 26 of each 28 day cycle. Cycles will continue until disease progression, unacceptable toxicity or withdrawal.Pazopanib: All patients will begin treatment with a 7-day run in period of single-agent pazopanib. Patients will receive pazopanib orally days 1-28 of a 28 day cycle.Doxil: Liposomal doxorubicin (Doxil) will be administered IV on day 1 of a 28-day treatment cycle"
NCT01038752,Phase 2,5/1/13,"The study was terminated prematurely due to the loss of follow-up of 6 of 14 participants before progression and slow accrual. Due to the resulting small numbers, no analysis was attempted.",NA,248997,0.375,3,8,NA,NA,Suramin,"This group will receive the combination of non-cytotoxic suramin with docetaxel and carboplatin.Suramin + Docetaxel + Carboplatin: Suramin dosage will be determined by nomogram and administered over 30 minutes. Suramin is followed by docetaxel (56 mg/m2, administered over 1 hour), followed by carboplatin (dosage calculated by Calvert equation to have a target AUC of 6, administered over 1 hour)."
NCT01053663,Phase 1,1/1/13,Low number of participants enrolled in the study at the time that the study was terminated limits conclusions that can be derived from the study data.,The study was terminated prematurely after three influenza seasons.,245052,0.555555556,5,9,Up to Day 30,NA,Oseltamivir: All Participants,"Participants received oseltamivir twice daily (every 12 hours) IV over 5 or 6 days for a total of 10 doses. The oseltamivir doses were based on participant‰Ûªs age. Participants aged 91 to <365 days received 3 mg/kg; participants aged 31 to 90 days received 2.5 mg/kg; and participants aged 0 to 30 days received 2 mg/kg. For participants who did not receive all 10 doses IV, treatment could be completed with oral oseltamivir suspension (twice daily). If medically necessary, participants were allowed to receive an additional 10 doses of IV or oral oseltamivir after the initial 10 doses."
NCT01053663,Phase 1,1/1/13,Low number of participants enrolled in the study at the time that the study was terminated limits conclusions that can be derived from the study data.,The study was terminated prematurely after three influenza seasons.,245055,0.714285714,5,7,Up to Day 30,NA,Oseltamivir: Age 91 to < 365 Days,"Participants aged 91 to <365 days received oseltamivir 3 mg/kg twice daily (every 12 hours) IV over 5 or 6 days for a total of 10 doses. For participants who did not receive all 10 doses IV, treatment could be completed with oral oseltamivir suspension (twice daily). If medically necessary, participants were allowed to receive an additional 10 doses of IV or oral oseltamivir after the initial 10 doses."
NCT01057017,Phase 2,12/1/11,NA,possible lack of efficacy,243852,0.2,1,5,from time of signing consent to 30 days post last dose of drug (occurred up to approximately 10 months),NA,Intervention,"Bevacizumab: 7.5mg/kg, IV over 30-90 minutes every 3 weeks until disease progression.Panitumumab Dose Level 1: 6mg/kg over 60-120 minutes every 3 weeks until disease progression Dose Level 2: 9mg/kg over 60-120 minutes every 3 weeks until disease progression"
NCT01057277,Phase 1,6/1/11,NA,Pharmaceutical co- re aligned their specialties- no longer will fund H&N ca,243777,0.666666667,2,3,NA,NA,RAD001(Afinitor),"Radiation 47 days Cisplatin day 1,8,15,22,29,36,43 RAD001 Day 1 according to assigned group to day 47RAD001(Afinitor): Rad001 in combination withCisplatin and Concurrent RT"
NCT01069861,Phase 2,11/1/11,"The study was prematurely discontinued, therefore not all data was analyzed.",See termination reason in detailed description.,240220,0.25,1,4,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",Sildenafil,"Sildenafil citrate administered intravenously at a loading dose of 0.1 mg/kg over 30 minutes infusion followed by a maintenance dose of 0.03 mg/kg/hr intravenous infusion up to 14 days, based on the need of individual participant."
NCT01074099,Phase 1/Phase 2,4/1/13,The study was terminated early. Only 5 subjects were enrolled and they were followed for a year for safety data only. One efficacy data was collected.,"Pilot results in change to protocol, new study needed.",238422,0.333333333,1,3,From time of treatment through 1 year / study termination,NA,BMAC Enhanced CABG,"Injection of concentrated bone marrow nucleated cells (BMAC) as an adjunct to CABG surgeryBMAC: Injection of BMAC into ischemic myocardium during CABG"
NCT01075815,Phase 2,10/1/10,NA,NA,237752,0.028571429,1,35,"AEs are collected on an ongoing basis from day of written informed consent. All new AEs must be recorded until the post-treatment safety, on day 35-42 post-hCG administration. AEs are classified as pre-treatment, treatment-emergent and post-treatment.",Pre-Treatment:Medical conditions present at the initial study visit that did not worsen in severity or frequency during the study;Treatment-Emergent: If the onset date of the AE was on or after the first dose date of the study medication; Post-Treatment: If the onset date of the AE was post-hCG Days 35- 42 for participants who completed the study.,rFSH,Recombinant follicle stimulating hormone (rFSH) injection 300 IU subcutaneously daily from S1 to S4 and then dose adjusted depending on the ovarian response till r-hCG administration day.
NCT01078974,Phase 1,3/1/16,Pomalidomide and rituximab could have a synergistic effect on serum IgM levels and produce an IgM flare. The highest dose of pomalidomide in this trial was 1mg. The study was permanently closed to accrual given the safety concerns with the IgM flare.,Safety concerns (IgM Flare),235973,0.428571429,3,7,Adverse events were collected over a 3 year period.,NA,"Pomalidomide, Dexamethasone, Rituximab","Drug: pomalidomide Taken orally once a dayDrug: dexamethasone Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15Drug: rituximab Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15pomalidomide: Taken orally once a daydexamethasone: Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15rituximab: Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15"
NCT01090973,Phase 2,3/1/11,"The study was abandoned after only one patient due to low accrual and the sponsor losing interest in the single-agent.The one patient had disease progression requiring more aggressive treatment and did not complete the study.",Pharmaceutical company request.,232285,1,1,1,46 days,NA,Oral Drug Treatment,"LBH589 was to be given orally (by mouth), 40 mg once-a-day, 3 times weekly every week on days 1, 3 & 5, then 8, 10 &12, then 15, 17 & 19, then 22, 24 & 26."
NCT01095094,Phase 2,11/1/11,NA,Study did not meet its primary objective,231387,0.263157895,5,19,Adverse Event data was collected on all patients while on study over a 3 year 5 month period.,NA,Arm I,"Patients receive oral ritonavir and lopinavir twice daily in the absence of disease progression or unacceptable toxicity.ritonavir : Given orallylopinavir : Given orally"
NCT00642746,Phase 2,12/1/11,Study terminated before target enrollment was reached due to excessive toxicities and limited enrollment.,Terminated due to poor enrollment and grade 3 toxicities noted during an interim analysis.,391447,0.222222222,2,9,"Adverse Events have been collected since the study opened to enrollment to study closure, totaling 5.5 years.",NA,FOLFIRI With Erlotinib,NA
NCT01096810,Phase 2,3/1/14,NA,The research is permanently closed to enrollment.,231010,0.05,1,20,NA,NA,TBL 12,"TBL 12, sea cucumber, will be administered orally at a dose of 2 units (20 mL each) twice a day until disease progression"
NCT01098240,Phase 2,9/1/11,NA,See termination reason in detailed description.,230647,0.01010101,3,297,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",Open-Label ADT,"Participants treated with 1 of 5 allowed antidepressant agents in accordance with current product labeling, targeting the following doses by the end of week 2: escitalopram (Lexapro) (10-20 mg/d), citalopram (Celexa) (20-40 mg/d), fluoxetine (Prozac, Sarafem) (20-60 mg/d), paroxetine CR (Paxil CR) (37.5-62.5 mg/d), sertraline (Zoloft) (100-200 mg/d), for up to 8 weeks in open-label phase."
NCT01102218,Phase 2,1/1/12,Release of new FDA guidelines re target Hgb values impacted EPO dosing.,Lack of statistical difference between both arms of the trial.,229623,0.5,12,24,6 months,NA,Erythropoietin Plus Pentoxifylline,Standard of care prescribed erythropoietin dose plus 400mg oral pentoxifylline once a day.
NCT01102218,Phase 2,1/1/12,Release of new FDA guidelines re target Hgb values impacted EPO dosing.,Lack of statistical difference between both arms of the trial.,229622,0.5,12,24,6 months,NA,Erythropoietin Alone,Standard of care prescribed erythropoietin dose.
NCT01117948,Phase 2,4/1/11,NA,Lack of Efficacy,225041,0.099099099,11,111,NA,NA,Lornoxicam,Lornoxicam (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.
NCT01117948,Phase 2,4/1/11,NA,Lack of Efficacy,225040,0.018518519,2,108,NA,NA,Placebo,Placebo (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.
NCT01119118,Phase 2,11/1/11,NA,NA,224517,0.666666667,4,6,14 months,NA,ZD4054,ZD4054 + multimodal PET/MRI imaging
NCT01120275,Phase 2,8/1/15,NA,Administratively complete.,223827,0.125,4,32,"Toxicity assessment was evaluated at least every 3 weeks at the beginning of each cycle, up to 3 years.","Per protocol, Grade 4 myelosuppression does not require expedited reporting via the NCI‰Ûªs Adverse Event Expedited Reporting System (AdEERS). The protocol does not specify that all AEs Gr 3 and higher require expedited reporting.",RO4929097,"Patients receive gamma-secretase/Notch signaling pathway inhibitor RO4929097 PO on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
NCT01121757,Phase 2,1/1/16,NA,"The study closed temporarily in February 2012 pending analysis of samples collected. In   October, 2012, Celgene requested closure of the study.",223151,0.666666667,2,3,We collect adverse event information from the time they start drug until 30 days after the last dose.,NA,1b-Lenalidomide Followed by Azacitidine,"Subjects will take lenalidomide for 4-6 cycles (first drug) followed by a 1-6 week washout period. Subjects with a complete remission (CR) may receive up to 6 cycles of first drug and will not receive the next until disease progression.Subjects with less than a CR after 4 cycles of lenalidomide (first drug) will proceed to receive azacitidine (second drug) for 4-6 cycles.Subjects with a CR after azacitidine may receive up to 6 cycles of azacitidine and will not start on the combination drug until disease progression.The combination therapy (azacitidine and lenalidomide) will be given in 28-day cycles for up to 13 cycles in subjects who have stable disease or better."
NCT01121757,Phase 2,1/1/16,NA,"The study closed temporarily in February 2012 pending analysis of samples collected. In   October, 2012, Celgene requested closure of the study.",223152,0.333333333,2,6,We collect adverse event information from the time they start drug until 30 days after the last dose.,NA,1a-Azacitidine Followed by Lenalidomide,"Subjects will take azacitidine for 4-6 cycles (first drug) followed by a 1-6 week washout period. Subjects with a complete remission (CR) may receive up to 6 cycles of first drug and will not receive the next until disease progression.Subjects with less than a CR after 4 cycles of azacitidine (first drug) will proceed to receive lenalidomide (second drug) for 4-6 cycles.Subjects with a CR after lenalidomide may receive up to 6 cycles of lenalidomide and will not start on the combination drug until disease progression.The combination therapy (azacitidine and lenalidomide) will be given in 28-day cycles for up to 13 cycles in subjects who have stable disease or better."
NCT01132664,Phase 1/Phase 2,8/1/14,NA,Due to the rare patient population and challenges to enroll patients.,219484,0.34,17,50,NA,NA,Phase II Dose Expansion 100 mg/Day,Patients in the phase II expansion + patients from phase Ib dose escalation who received 100 mg/day of buparlisib - investigational drug
NCT01132664,Phase 1/Phase 2,8/1/14,NA,Due to the rare patient population and challenges to enroll patients.,219486,0.4,2,5,NA,NA,Phase Ib Dose Escalation 50 mg/Day,Patients in the phase Ib dose escalation cohort who received 50 mg of buparlisib - investigational drug.
NCT01132664,Phase 1/Phase 2,8/1/14,NA,Due to the rare patient population and challenges to enroll patients.,219482,0.666666667,4,6,NA,NA,BM Cohort 100 mg/Day,Patients in the BM cohort who received 100 mg of buparlisib - investigational drug
NCT01132664,Phase 1/Phase 2,8/1/14,NA,Due to the rare patient population and challenges to enroll patients.,219483,0.666666667,2,3,NA,NA,BM Cohort 80 mg/Day,Patients in the BM cohort who received 80 mg of buparlisib - investigational drug
NCT01132664,Phase 1/Phase 2,8/1/14,NA,Due to the rare patient population and challenges to enroll patients.,219485,0.166666667,2,12,NA,NA,Phase Ib Dose Escalation 100 mg/Day,Patients in the phase Ib dose escalation cohort who received 100 mg of buparlisib - investigational drug
NCT01137071,Phase 2,6/1/15,NA,Total number of pts expected to be enrolled would not be met.,217729,0.103448276,3,29,"They were collected from first application of treatment to 30 days after last. Ongoing AEs were followed up until resolution, start of a new treatment, at the investigator discretion or if they became chronic.","After the 30-day period, the investigator reported the adverse events that in his/her opinion were related to investigational product. In this study, AEs terms were coded using the Medical Dictionary for Regulatory Activities (MedDRA) at the Preferred Term (PT) and System Organ Class (SOC) levels.",hu3S193,"hu3S193: 30mg/m2, intravenous, every other week (total of 12 infusions) for a total of 23 weeks"
NCT01142128,Phase 1,3/1/12,NA,Viokase was taken off market during study and remained off over a year.,216600,0.333333333,1,3,Adverse events were collected from 03/02/2009 until 08/15/2010,NA,"Placebo to Nexium, Alone","Placebo to Nexium is given instead of Nexium for one month. This will be compared to the Nexium alone, Viokase 16 plus Nexium and Viokase 16 plus placebo to Nexium"
NCT01144403,Phase 2,8/1/14,"The study was prematurely terminated with 8 participants enrolled, all of them are included into the statistical analyses.",NA,215974,0.375,3,8,Up to approximately 50 months,NA,Rituximab,"Rituximab, 375 milligram per meter square (mg/m^2) was given intravenously on Day 1 and then every 28 days (+/-7 days) for 6 cycles, followed by 2 consolidated infusions in responders as rituximab induction therapy. Rituximab infusions were administered concomitantly with prescribed chemotherapy i.e., fludarabine, cyclophosphamide and mitoxantrone (maximum 6 cycles).Cyclophosphamide: as prescribed, 6 cyclesFludarabine: as prescribed, 6 cyclesMitoxantrone: as prescribed, 6 cyclesRituximab [Mabthera/Rituxan]: 375 mg/m^2 intravenously, Day 1 of each 28-day cycle, up to 8 cycles"
NCT01145755,Phase 2,11/1/10,NA,NA,215674,0.025,1,40,NA,NA,AZD2066,"AZD2066 12 mg, 18 mg"
NCT01147458,Phase 2,2/1/11,The study was terminated early due to increases in hepatic enzymes for which a relationship to study drug could not be excluded and that could alter the potential benefit-risk for participants continuing in the study.,See termination reason in detailed description.,215249,0.012345679,1,81,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",Placebo,Placebo administered either in Period 1 or Period 2
NCT01149434,Phase 1/Phase 2,8/1/12,NA,Lack of drug efficacy,214532,0.25,1,4,NA,NA,Pharmacokinetic Arm,"Patients going on Pharmacokinetic arm will receive JI-101 & Everolimus (4 patients only)JI-101: JI-101 inhibits angiogenesis, and subsequently tumor growth, by inhibiting three receptor tyrosine kinases: VEGF Receptor Type 2 (VEGFR 2), platelet derived growth factor receptor beta (PDGFR ë_ and Ephrin B4 (EphB4). JI-101 selectively inhibits kinases critical for all three stages of tumor angiogenesis.Everolimus: Everolimus is a signal transduction inhibitor that selectively inhibits mTOR (mammalian target of rapamycin), a key and highly conserved serine-threonine kinase, that is present in all cells and is a central regulator of protein synthesis and ultimately cell growth, cell proliferation, angiogenesis, and cell survival. mTOR is the only currently known target of everolimus (1)."
NCT01149434,Phase 1/Phase 2,8/1/12,NA,Lack of drug efficacy,214531,0.266666667,4,15,NA,NA,Pharmacodynamic Arm,"Patients going on the Pharmacodynamic study will receive JI-101 only.JI-101: JI-101 inhibits angiogenesis, and subsequently tumor growth, by inhibiting three receptor tyrosine kinases: VEGF Receptor Type 2 (VEGFR 2), platelet derived growth factor receptor beta (PDGFR ë_ and Ephrin B4 (EphB4). JI-101 selectively inhibits kinases critical for all three stages of tumor angiogenesis."
NCT01151215,Phase 2,1/1/13,"The final analysis for this study is the analysis that was sent to the study's IDMC, based on a data cut-off of 31 August 2012. At the data cut-off point the data was cleaned, but 9 adverse events were not coded. These events are not included here.",Futility,214005,0.118644068,14,118,NA,NA,AZD8931 20mg,NA
NCT01151215,Phase 2,1/1/13,"The final analysis for this study is the analysis that was sent to the study's IDMC, based on a data cut-off of 31 August 2012. At the data cut-off point the data was cleaned, but 9 adverse events were not coded. These events are not included here.",Futility,214003,0.090909091,11,121,NA,NA,Placebo,NA
NCT01151215,Phase 2,1/1/13,"The final analysis for this study is the analysis that was sent to the study's IDMC, based on a data cut-off of 31 August 2012. At the data cut-off point the data was cleaned, but 9 adverse events were not coded. These events are not included here.",Futility,214004,0.141666667,17,120,NA,NA,AZD8931 40mg,NA
NCT01166126,Phase 2,6/1/12,The study was terminated due to overall low accrual and a high rate of screening failures. Accrual goal was 38 participants and only 4 participants were actually treated.,NA,209404,0.5,2,4,1 year,NA,Treatment (Temsirolimus and Selumetinib),"Treatment Phase: This period begins with the first intravenous (through the vein) infusion of TEMSIROLIMUS and the first AZD6244 administration by mouth (visit 2, Week 1) and will continue until Week 8 (Visit 4).Investigators planned for as many as 38 patients to receive the same dosage of TEMSIROLIMUS injected in the veins once a week for 8 weeks, and the AZD6244 would be given as capsules by mouth twice a day for 8 weeks. That is one cycle. The TEMSIROLIMUS and AZD6244 would be given to participants as an outpatient, unless admission to the hospital was needed for treatment of related side effects or underlying disease. The subsequent cycles of TEMSIROLIMUS and AZD6244 would be given every 8 weeks. The TEMSIROLIMUS would be injected in a vein over 30 minutes.The continuation phase would begin with visits at weeks 12 in patients who received at least two cycles of treatments."
NCT01167192,Phase 2,9/1/16,NA,NA,209200,0.375,3,8,NA,NA,Neoadjuvant Cisplatin or Carboplatin AUC 6 & Radiation,"Cisplatin 75 mg/m^2 IV every 21 days for 4 cycles or Carboplatin AUC 6 IV every 21 days for 4 cycles.Radiation beginning cycle 2 day 1 daily for 5-6 weeks 45-50 Gy.Recommended mastectomyRecommended adjuvant chemotherapy-Doxorubicin 60 mg/m^2 and cyclophosphamide 600 mg/m^2 for 14 days for 4 cycles followed by paclitaxel 175 mg/m^2 for 14 days for 4 cycles)"
NCT01179399,Phase 1,1/1/13,NA,NA,205276,0.40625,13,32,NA,NA,TAK-960,Given orally (PO) for 21 days of a 28-day treatment cycle.
NCT01179737,Phase 2,1/1/13,NA,Study was terminated due to serious adverse event (SAE),205167,0.583333333,7,12,"Adverse events were collected over the duration of treatment 140 days for cohort 1, 168 days for cohort 2 and up to 1092 days in the extension study","23 participants were enrolled into the study; 8 participants completed cohort 1 and 6 of these participants moved into cohort 1 expansion of which 5 participants completed Cohort 1 expansion. Of the 5 participants, 3 went into an Extension. None of the participants completed treatment as trial was terminated",Cohort 1: Nilotinib,"Participants were assigned to receive nilotinib 50 mg during 14 days, followed by 150 mg during 14 days, followed by 300 mg during 140 days."
NCT01179737,Phase 2,1/1/13,NA,Study was terminated due to serious adverse event (SAE),205165,0.5,2,4,"Adverse events were collected over the duration of treatment 140 days for cohort 1, 168 days for cohort 2 and up to 1092 days in the extension study","23 participants were enrolled into the study; 8 participants completed cohort 1 and 6 of these participants moved into cohort 1 expansion of which 5 participants completed Cohort 1 expansion. Of the 5 participants, 3 went into an Extension. None of the participants completed treatment as trial was terminated",Cohort 2: Nilotinib,Participants were assigned to receive nilotinib 300 mg during 168 days
NCT01179737,Phase 2,1/1/13,NA,Study was terminated due to serious adverse event (SAE),205166,0.333333333,1,3,"Adverse events were collected over the duration of treatment 140 days for cohort 1, 168 days for cohort 2 and up to 1092 days in the extension study","23 participants were enrolled into the study; 8 participants completed cohort 1 and 6 of these participants moved into cohort 1 expansion of which 5 participants completed Cohort 1 expansion. Of the 5 participants, 3 went into an Extension. None of the participants completed treatment as trial was terminated",Cohort 1: Placebo,Participants were assigned to receive placebo to nilotinib to match 50 mg and 150 mg capsules during 168 days.
NCT01179737,Phase 2,1/1/13,NA,Study was terminated due to serious adverse event (SAE),205164,0.25,1,4,"Adverse events were collected over the duration of treatment 140 days for cohort 1, 168 days for cohort 2 and up to 1092 days in the extension study","23 participants were enrolled into the study; 8 participants completed cohort 1 and 6 of these participants moved into cohort 1 expansion of which 5 participants completed Cohort 1 expansion. Of the 5 participants, 3 went into an Extension. None of the participants completed treatment as trial was terminated",Cohort 2: Placebo,Participants were assigned to receive placebo to match 50mg and / or 150mg capsules during 168 days
NCT01182610,Phase 2,3/1/12,"This study was closed due to notification and preliminary results from a trial including panitumumab as part of combination chemotherapy for gastroesophageal cancer. The study was closed by mutual consent from the PI, Sponsor, and Funder.",Safety concern in a similar trial enrolling the same patient population,204216,1,1,1,"Adverse events collected beginning on day 1 of study treatment through the End of Treatment visit (30 days post-operative, 6 weeks from last treatment administration if treatment failure, or 30 days from last dose of study treatment if early withdrawal).","Systematic Assessment- subjects were assessed for adverse events on day 1 of each cycle by either the research coordinator, treating physician, or other appropriate sub-investigator.","Treatment Group: Panitumumab, Paclitaxel, Carboplatin and 5FU","Panitumumab 9mg/kg on Days 1, 22, and 43; Paclitaxel 200mg/m2 on Days 1 and 22; Carboplatin AUC=6 on Days 1 and 22; 5FU 225mg/m2/day on Days 1-15 and 22-36"
NCT01183468,Phase 1,7/1/13,"This (Part 1) was the drug dosing portion of the study; however, due to lack of a mechanistic signal and competing industry studies, the study was terminated and the trial portion (Part II, NCT01183455) was withdrawn.",Due to lack of mechanistic signal and competing industry studies,203963,0.25,2,8,"Adverse events were collected for 2.5 years, from the start of the study in January 2011 until the last participant completed the study in July 2013.","Adverse events were collected from the time a participant signed informed consent until the time an event resolved or until 30 days after the participant completed study treatment, whichever came first.",Subjects Aged 16 ‰ÛÒ 35 Years,"Subjects aged 16-35 years at enrollment with new-onset type 1 diabetes mellitus (T1DM) received Aralast NP 45 mg/kg by IV infusion once a week for 6 weeks. Following the Week 6 infusion, participants underwent a minimum 3-week washout period. After the washout period, each participant proceeded to a high dose of Aralast NP 90 mg/kg by IV infusion for the next 6 weeks, for a total of 12 infusions."
NCT01183468,Phase 1,7/1/13,"This (Part 1) was the drug dosing portion of the study; however, due to lack of a mechanistic signal and competing industry studies, the study was terminated and the trial portion (Part II, NCT01183455) was withdrawn.",Due to lack of mechanistic signal and competing industry studies,203962,0.111111111,1,9,"Adverse events were collected for 2.5 years, from the start of the study in January 2011 until the last participant completed the study in July 2013.","Adverse events were collected from the time a participant signed informed consent until the time an event resolved or until 30 days after the participant completed study treatment, whichever came first.",Subjects Aged 8 ‰ÛÒ 15 Years,"Subjects aged 8-15 years at enrollment with new-onset type 1 diabetes mellitus (T1DM) received Aralast NP 45 mg/kg by IV infusion once a week for 6 weeks. Following the Week 6 infusion, participants underwent a minimum 3-week washout period. After the washout period, each participant proceeded to a high dose of Aralast NP 90 mg/kg by IV infusion for the next 6 weeks, for a total of 12 infusions."
NCT01189240,Phase 1/Phase 2,2/1/15,"This is Phase 1/Phase 2 Study. It closed prematurely by Roche, study still in Phase 1. Roche halted pt enrollment in ALL clinical trials w/ RO4929097 & cease production of drug & development. Phase 2 of this study was never activated.",Company decided to stop development of drug - 7/31/12,202085,0.076923077,1,13,"First dose of drug, than weekly during cycle 1 and then once every 28 days until disease progression, approximately 1 year",NA,Phase I Dose Finding,"Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: blood samples for pharmacological study; archived tumor tissue slides for laboratory biomarker analysis.gamma-secretase/Notch signalling pathway inhibitor RO4929097: Given orallybevacizumab: Given IVlaboratory biomarker analysis: Correlative studiespharmacological study: Correlative studies"
NCT01193868,Phase 2,4/1/14,The study closed June 2012 with the NCI discontinuation production of the study drug RO4929097.,Study drug production halted.,199801,0.666666667,4,6,Adverse events reporting includes events that occur within 30 days of the last dose of the investigational agent/treatment. Overall study period: 9/15/2010 to 6/20/2013.,NA,RO4929097,"Oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days"
NCT01208233,Phase 2,12/1/13,The study was terminated prematurely due to demonstrated futility at interim analysis. The final results are consistent with interim results.,See termination reason in detailed description.,195245,0.272727273,3,11,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.","The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",Cohort 2: PF-03049423 3 mg,Participants received PF-03049423 3 mg once daily for 90 days.
NCT01208233,Phase 2,12/1/13,The study was terminated prematurely due to demonstrated futility at interim analysis. The final results are consistent with interim results.,See termination reason in detailed description.,195247,0.181818182,2,11,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.","The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",Cohort 1: PF-03049423 1 mg,Participants received PF-03049423 1 mg once daily for 90 days.
NCT01208233,Phase 2,12/1/13,The study was terminated prematurely due to demonstrated futility at interim analysis. The final results are consistent with interim results.,See termination reason in detailed description.,195243,0.214285714,15,70,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.","The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",Cohort 3: PF-03049423 6 mg,Participants received PF-03049423 6 mg once daily for 90 days.
NCT01208233,Phase 2,12/1/13,The study was terminated prematurely due to demonstrated futility at interim analysis. The final results are consistent with interim results.,See termination reason in detailed description.,195242,0.268656716,18,67,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.","The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",Cohort 3: Placebo,Participants received placebo matched to PF-0304942 6 mg once daily for 90 days.
NCT01208233,Phase 2,12/1/13,The study was terminated prematurely due to demonstrated futility at interim analysis. The final results are consistent with interim results.,See termination reason in detailed description.,195246,0.111111111,1,9,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.","The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",Cohort 1: Placebo,Participants received placebo matched to PF-03049423 1 mg once daily for 90 days.
NCT01208233,Phase 2,12/1/13,The study was terminated prematurely due to demonstrated futility at interim analysis. The final results are consistent with interim results.,See termination reason in detailed description.,195244,0.1,1,10,"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.","The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",Cohort 2: Placebo,Participants received placebo matched to PF-0304942 3 mg once daily for 90 days.
NCT01212094,Phase 1/Phase 2,12/1/15,"The trial was closed prematurely for futility, because pre-determined interim analysis demonstrated that selected dosing led to <50% depletion of B cells from the brain/spinal cord. Therefore, only 5 patients per group finished trial.",The efficacy on CSF biomarkers failed to reach criteria for continuation of the trial,194313,0.444444444,4,9,36 months,"First 12 months (Month -12 to Month 0), all patients were untreated; next 24 months (Month 0 to Month 24) patients were randomized to placebo or active treatment",Placebo,Placebo group
NCT01212094,Phase 1/Phase 2,12/1/15,"The trial was closed prematurely for futility, because pre-determined interim analysis demonstrated that selected dosing led to <50% depletion of B cells from the brain/spinal cord. Therefore, only 5 patients per group finished trial.",The efficacy on CSF biomarkers failed to reach criteria for continuation of the trial,194312,0.222222222,4,18,36 months,"First 12 months (Month -12 to Month 0), all patients were untreated; next 24 months (Month 0 to Month 24) patients were randomized to placebo or active treatment",Rituximab,Group who got active drug
NCT01214174,Phase 2,5/1/12,Early termination leading to small numbers of subjects analyzed,Study C11-01 started,193427,0.0625,1,16,NA,NA,Dose 2,IBI-10090 776ug
NCT01214174,Phase 2,5/1/12,Early termination leading to small numbers of subjects analyzed,Study C11-01 started,193426,0.230769231,3,13,NA,NA,Dose 3,IBI-10090 1046ug
NCT01226420,Phase 2,8/1/12,NA,Discontinuation of drug supply from Astellas.,189642,0.333333333,2,6,NA,NA,Alefacept,"Alefacept administration (13 doses): Days 1 and 4 (subcutaneous), Weeks 1-12 (intravenous)"
NCT01227018,Phase 2,5/1/13,NA,interim analysis found the study drug to be ineffective,189452,0.642857143,9,14,NA,NA,STA-9090,"175 mg/m2 STA-9090 IV over 1 hour once a week for 3 weeks, followed by a 1 week dose-free interval. The 4-week treatment cycle continues to disease progression."
NCT01227434,Phase 2,12/1/13,NA,NA,189279,0.833333333,5,6,3 years,"Adverse events were collected from date of first drug, until 30 days following completion of study treatment",Surgical Group,"PD 0332991 125 mg daily for 7 days prior to an indicated, intended surgical resection for progression, and then resume drug at the same dose after recovery from surgery on a repeating schedule of 21 consecutive days of drug followed by a 7 day break off therapy (cycle length is 28 days). Treatment repeated every 28 days, and in the absence of disease progression patients may receive treatment for 12 cycles. At that time patients given the option to continue on study past 12 cycles, up to a maximum of 24 cycles."
NCT01227434,Phase 2,12/1/13,NA,NA,189278,0.25,4,16,3 years,"Adverse events were collected from date of first drug, until 30 days following completion of study treatment",Non-surgical Group,"Patients not requiring surgery treated with PD 0332991 125 mg daily for 21 consecutive days followed by a 7 day break off therapy (cycle length is 28 days). Treatment repeated every 28 days, and in the absence of disease progression patients may receive treatment for 12 cycles. At that time patients given the option to continue on study past 12 cycles, up to a maximum of 24 cycles."
NCT01236573,Phase 1/Phase 2,3/1/15,"Due to the unexpected toxicities, likely attributable to the tumor infiltrating lymphocytes (TIL) transduced with IL-12, and low percentage of durable responses, we decided to close this study.","Unexpected toxicities, likely due to TIL/IL-12 & low % of durable responses.",186008,0.333333333,1,3,NA,NA,Group 8 - Bulk TIL Expressing IL-12 3x10^8 (Phase 1),"Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hr.IL-12 transduced TIL: On day 0 (one to four days after the last dose of fludarabine), cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes."
NCT01236573,Phase 1/Phase 2,3/1/15,"Due to the unexpected toxicities, likely attributable to the tumor infiltrating lymphocytes (TIL) transduced with IL-12, and low percentage of durable responses, we decided to close this study.","Unexpected toxicities, likely due to TIL/IL-12 & low % of durable responses.",186006,0.25,1,4,NA,NA,Group 10 - Bulk TIL Expressing IL12 3x10^9 (Phase 1),"Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hr.IL-12 transduced TIL: On day 0 (one to four days after the last dose of fludarabine), cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes."
NCT01236573,Phase 1/Phase 2,3/1/15,"Due to the unexpected toxicities, likely attributable to the tumor infiltrating lymphocytes (TIL) transduced with IL-12, and low percentage of durable responses, we decided to close this study.","Unexpected toxicities, likely due to TIL/IL-12 & low % of durable responses.",186005,0.333333333,2,6,NA,NA,Group 11 - Bulk TIL Expressing MTD 1x10^9 (Phase 2),"Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hr.IL-12 transduced TIL: On day 0 (one to four days after the last dose of fludarabine), cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes."
NCT01236573,Phase 1/Phase 2,3/1/15,"Due to the unexpected toxicities, likely attributable to the tumor infiltrating lymphocytes (TIL) transduced with IL-12, and low percentage of durable responses, we decided to close this study.","Unexpected toxicities, likely due to TIL/IL-12 & low % of durable responses.",186009,0.333333333,1,3,NA,NA,Group 7- Bulk TIL Expressing IL-12 1x10^8 (Phase 1),"Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hr.IL-12 transduced TIL: On day 0 (one to four days after the last dose of fludarabine), cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes."
NCT01236573,Phase 1/Phase 2,3/1/15,"Due to the unexpected toxicities, likely attributable to the tumor infiltrating lymphocytes (TIL) transduced with IL-12, and low percentage of durable responses, we decided to close this study.","Unexpected toxicities, likely due to TIL/IL-12 & low % of durable responses.",186007,0.25,1,4,NA,NA,Group 9 - Bulk TIL Expressing IL-12 1x10^9 (Phase 1),"Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.Fludarabine: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.Cyclophosphamide: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hr.IL-12 transduced TIL: On day 0 (one to four days after the last dose of fludarabine), cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes."
NCT01238991,Phase 2,12/1/13,"Since the study was early terminated and the data could not be obtained as planned, only part of the immunogenicity and safety results were summarized.",NA,185612,0.188679245,10,53,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",Total,All participants
NCT01238991,Phase 2,12/1/13,"Since the study was early terminated and the data could not be obtained as planned, only part of the immunogenicity and safety results were summarized.",NA,185614,0.153846154,2,13,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",30ë_g ACC-001 Treat,"A group of participants who received IM injection of active vaccine ACC-001 (30 ë_g) with or without adjuvant QS-21 (50 ë_g) in the preceding studies and ACC-001 (30 ë_g) + adjuvant QS-21 (50 ë_g) in this study (Day 1, month 6, 12, and 18)"
NCT01238991,Phase 2,12/1/13,"Since the study was early terminated and the data could not be obtained as planned, only part of the immunogenicity and safety results were summarized.",NA,185615,0.142857143,1,7,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",10ë_g Control,"A group of participants who received IM injection of adjuvant QS-21 (50 ë_g) or PBS in the preceding studies and active vaccine ACC-001(10 ë_g) + adjuvant QS-21 (50 ë_g) in this study (Day 1, month 6, 12, and 18)"
NCT01238991,Phase 2,12/1/13,"Since the study was early terminated and the data could not be obtained as planned, only part of the immunogenicity and safety results were summarized.",NA,185616,0.411764706,7,17,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",10ug ACC-001 Treat,"A group of participants who received IM injection of active vaccine ACC-001 (10 ë_g) with or without adjuvant QS-21 (50 ë_g) in the preceding studies and ACC-001 (10 ë_g) + adjuvant QS-21 (50 ë_g) in this study (Day 1, month 6, 12, and 18)"
NCT01239355,Phase 2,2/1/13,"Study was terminated early after the first stage of a two-stage design, allowing for early termination for discouraging results",Early termination for discouraging results,185454,0.4,6,15,Adverse events recorded over a period of 1 year and 5 months.,Other Adverse Events include all events that were not severe adverse events regardless of grade or relation to treatment.,Treatment (Akt Inhibitor MK2206),"Patients receive 200mg oral Akt inhibitor MK2206 on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.Akt Inhibitor MK2206: Given POLaboratory Biomarker Analysis: Correlative studies"
NCT01242111,Phase 1/Phase 2,7/1/14,NA,NA,184491,0.95,19,20,"Study Period, up to 240 weeks",NA,BMN 110,"BMN 110: Patients will receive an intravenous infusion of BMN110 at 2.0mg/kg/week, over a period of approximately 4 hours per infusion, for up to 240 weeks."
NCT01251354,Phase 2,7/1/11,Study terminated due to poor enrollment,The futility analysis of study NCT00910091 in patients with endometrial cancer shows that the   primary endpoint will not be reached.,182118,0.333333333,2,6,Up to 28 days after last dose,Treatment emergent Adverse Events (TEAEs) that were reported by more than one patient.,BN83495,"BN83495: 1 tablet of 40 mg, oral, daily until progression or death or unacceptable toxicity develops"
NCT01254656,Phase 2,4/1/13,The study was terminated on 29 Jan 13 due to termination of lersivirine development program. All participants were enrolled from study A5271015 except one from A5271022. Above summarized outcome measures included participants enrolled from A5271015.,See termination reason in detailed description.,181021,0.127659574,6,47,Up to Week 208,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. Treatment emergent AEs included new treatment emergent AEs in A5271037 as well as AEs that were ongoing at the time of enrolment in A5271037 and had a worsened severity grading from that reported in A5271015. All causality events were reported.",Lersivirine (LRV) 500 mg,Participants received LRV 500 mg orally once daily (QD). In addition participants received treatment with tenofovir disoproxil fumarate (TDF) 300 mg/emtricitabine (FTC) 200 mg orally QD
NCT01254656,Phase 2,4/1/13,The study was terminated on 29 Jan 13 due to termination of lersivirine development program. All participants were enrolled from study A5271015 except one from A5271022. Above summarized outcome measures included participants enrolled from A5271015.,See termination reason in detailed description.,181020,0.11627907,5,43,Up to Week 208,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. Treatment emergent AEs included new treatment emergent AEs in A5271037 as well as AEs that were ongoing at the time of enrolment in A5271037 and had a worsened severity grading from that reported in A5271015. All causality events were reported.",LRV 750 mg,Participants received LRV 750 mg orally QD. In addition participants received treatment with tenofovir disoproxil fumarate (TDF) 300 mg/emtricitabine (FTC) 200 mg orally QD
NCT01267266,Phase 2,11/1/13,NA,"Per protocol, study was terminated due to low rate of randomized patients.",176178,0.032258065,1,31,Up to 6 months (lead-in phase); up to 2 months (randomized phase).,NA,"Saracatinib, Lead-in Phase",Patients receive 175 mg oral saracatinib once daily on days 1-28.
NCT01267266,Phase 2,11/1/13,NA,"Per protocol, study was terminated due to low rate of randomized patients.",176176,0.2,1,5,Up to 6 months (lead-in phase); up to 2 months (randomized phase).,NA,"Placebo, Randomized Phase",Patients receive placebo once daily on days 1-28.
NCT01273181,Phase 1/Phase 2,12/1/12,NA,NA,174597,0.333333333,1,3,NA,NA,Phase I:Anti-MAGE A3/12 TCR PBL 3x10e10,"Cyclophosphamide : 60 mg/kg/day x 2 days intravenous (IV)Aldesleukin : 720,000 IU/kg every 8 hours for a maximum of 15 dosesPG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes :Fludarabine : 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days."
NCT01273181,Phase 1/Phase 2,12/1/12,NA,NA,174598,0.666666667,2,3,NA,NA,Phase I: Anti-MAGE A3/12 TCR PBL 5x10e9,"Cyclophosphamide : 60 mg/kg/day x 2 days intravenous (IV)Aldesleukin : 720,000 IU/kg every 8 hours for a maximum of 15 dosesPG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes :Fludarabine : 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days."
NCT01278615,Phase 2,5/1/14,NA,Closed Prematurely.,173270,0.4375,7,16,NA,NA,Treatment (Selumetinib),"Patients receive selumetinib PO BID on days 1-28. Treatment repeats every 28 days for 8 courses in the absence of disease progression or unacceptable toxicityLaboratory Biomarker Analysis: Correlative studiesSelumetinib: Given PO"
NCT01285310,Phase 2,9/1/12,The study was terminated before the 2‰ÛÒyear time point was reached due to lack of clinical efficacy.,Study is terminated due to lack of efficacy,171667,0.092105263,7,76,All AEs were recorded by the Investigator from the time the participant signed the informed consent to 28 days after the last dose of investigational product.,NA,Study Termination: Apremilast 30 mg,"Participants who received 30 mg apremilast, regardless of when the apremilast exposure started (at Week 0, 16, or 24), up until Study Termination."
NCT01285310,Phase 2,9/1/12,The study was terminated before the 2‰ÛÒyear time point was reached due to lack of clinical efficacy.,Study is terminated due to lack of efficacy,171668,0.104575163,16,153,All AEs were recorded by the Investigator from the time the participant signed the informed consent to 28 days after the last dose of investigational product.,NA,Study Termination: Apremilast 20 mg,"Participants who received 20 mg apremilast, regardless of when the apremilast exposure started (at Week 0, 16, or 24), up until Study Termination."
NCT01285310,Phase 2,9/1/12,The study was terminated before the 2‰ÛÒyear time point was reached due to lack of clinical efficacy.,Study is terminated due to lack of efficacy,171671,0.012658228,1,79,All AEs were recorded by the Investigator from the time the participant signed the informed consent to 28 days after the last dose of investigational product.,NA,Week 24: Placebo,"Participants randomized to placebo tablets twice daily during the placebo-controlled phase. Includes data through Week 16 for participants who escaped early, and through Week 24 for all other participants."
NCT01285310,Phase 2,9/1/12,The study was terminated before the 2‰ÛÒyear time point was reached due to lack of clinical efficacy.,Study is terminated due to lack of efficacy,171669,0.052631579,4,76,All AEs were recorded by the Investigator from the time the participant signed the informed consent to 28 days after the last dose of investigational product.,NA,Week 24: Apremilast 30 mg,Participants randomized to receive 30 mg apremilast tablets twice daily during the 24-week placebo-controlled phase.
NCT01285310,Phase 2,9/1/12,The study was terminated before the 2‰ÛÒyear time point was reached due to lack of clinical efficacy.,Study is terminated due to lack of efficacy,171670,0.073170732,6,82,All AEs were recorded by the Investigator from the time the participant signed the informed consent to 28 days after the last dose of investigational product.,NA,Week 24: Apremilast 20 mg,Participants randomized to receive 20 mg apremilast tablets twice daily during the 24-week placebo-controlled phase.
NCT01285635,Phase 2,9/1/15,NA,drug is no longer manufactured,171035,0.636363636,7,11,NA,NA,Pulse AT-101 Then Metronomic AT-101,AT-101 (40 mg b.i.d. on days 1-3) then AT-101 (20mg daily days 1-14) and Docetaxel (75 mg/m2 on Cycle Day 1) for up to 10 cycles.
NCT01285635,Phase 2,9/1/15,NA,drug is no longer manufactured,171036,0.461538462,6,13,NA,NA,Docetaxel Then Metronomic AT-101,Docetaxel (75 mg/m2 on Cycle Day 1) for 2 weeks then AT-101 (20mg daily days 1-14) and Docetaxel (75 mg/m2 on Cycle Day 1) for up to 10 cycles.
NCT01285635,Phase 2,9/1/15,NA,drug is no longer manufactured,171034,0.545454545,6,11,NA,NA,Metronomic AT-101 Arm,AT-101 (20mg daily days 1-14) and Docetaxel (75 mg/m2 on Cycle Day 1) for up to 10 cycles.
NCT01288079,Phase 2,8/1/12,The study was terminated early and thus only a fraction of the planned number of patients were randomized and many did not complete the study. As a consequence the possibility of interpreting efficacy over an 8 week period is considerably reduced.,NA,170329,0.028571429,1,35,NA,NA,Placebo,NA
NCT01288079,Phase 2,8/1/12,The study was terminated early and thus only a fraction of the planned number of patients were randomized and many did not complete the study. As a consequence the possibility of interpreting efficacy over an 8 week period is considerably reduced.,NA,170332,0.027027027,1,37,NA,NA,1 mg BID TC-5214,NA
NCT01307618,Phase 2,2/1/15,NA,"Due to lack of clinical efficacy and lack of drug supply, trial was closed early and   correlative studies were not pursued further.",164931,0.4,2,5,NA,NA,"Arm II (Vaccine Therapy, IL-12)","Patients receive vaccination as in arm I with an admixture of IL-12 ID or SC on days 1, 22, and 50.NA17.A2 Peptide Vaccine: Given SC or IDRecombinant MAGE-3.1 Antigen: Given SC or IDRecombinant Interleukin-12: Given SC or IDLaboratory Biomarker Analysis: Correlative studies"
NCT01313663,Phase 2,7/1/12,NA,NA,163160,0.2,2,10,Participants were analyzed from the time the first dose of study treatment was administered until 28 days following discontinuation of study treatment regardless of initiation of a new cancer therapy or transfer to hospice (up to Study Week 55).,"Serious adverse events (SAEs) and non-serious AEs were collected in the Safety Population, comprisedof all participants who were randomized and took at least one dose of study medication. This population was based on the actual treatment received, if it differed from that to which the participant was randomized.",Pazopanib 800 mg,"Participants received pazopanib 800 milligrams (mg) orally once a day at approximately the same time each day, either 1 hour before a meal or 2 hours after a meal. The tablets were to be swallowed whole and were not to be crushed or broken. Participants received study treatment until disease progression, death, unacceptable adverse event, withdrawal of consent, or physician decision. Participants who withdrew due to an adverse event or disease progression were followed for survival."
NCT01313663,Phase 2,7/1/12,NA,NA,163161,0.222222222,2,9,Participants were analyzed from the time the first dose of study treatment was administered until 28 days following discontinuation of study treatment regardless of initiation of a new cancer therapy or transfer to hospice (up to Study Week 55).,"Serious adverse events (SAEs) and non-serious AEs were collected in the Safety Population, comprisedof all participants who were randomized and took at least one dose of study medication. This population was based on the actual treatment received, if it differed from that to which the participant was randomized.",Pemetrexed 500 mg/m^2,"Participants received an intravenous (IV) infusion of pemetrexed (500 mg per meters squared [mg/m^2]) over 10 minutes on Day 1 of each 21-day cycle. Participants received study treatment until disease progression, death, unacceptable adverse event, withdrawal of consent, or physician decision. Participants who withdrew due to an adverse event or disease progression were followed for survival."
NCT01313884,Phase 2,7/1/14,Study did not reach primary objective; study didn't accrue enough patients.,Study did not reach primary objective; study did not accrue enough patients.,162979,0.333333333,1,3,All adverse events (related and unrelated) occurring during the study (from the time the patient receives the first dose of study drug) and up to 30 days after the last dose of study medication were reported.,Patients were asked about adverse events at every clinic visit.,Combination Therapy,"Regimen A alternate with Regimen B every 21 daysRegimen A:Cytoxan=1200mg/m2 Doxorubicin=75mg/m2 (Maxiumum allowed dose 450mg/m2) Vincristine=2mg/m2 (capped at 2mg total dose)Regimen B:Irinotecan=50 mg/m2/day x 5 days Temozolomide=100 mg/m2/day x 5 days followed by two weeks of treatment-free period.Irinotecan: 50 mg/m2/day x 5 daysVincristine: 2 mg/m2 (capped at 2mg total do)Temozolomide: 100 mg/m2/day x 5 daysDoxorubicin: 75 mg/m2Cytoxan: 1200 mg/m2Pegfilgrastim: 6 mgMesna: 240 mg/m2 in 50 ml NS"
NCT01331109,Phase 2,8/1/12,"This study was terminated early, resulting in a small number of patients analyzed. Only descriptive statistics were presented.",NA,158700,0.035087719,2,57,"Adverse Event data was collected during a 14-month period from July, 2011 to August, 2012.",NA,Milnacipran,"oral administration, twice daily dosingMilnacipran : maximum tolerated dose (50, 75, or 100 mg/day tablets); for 52 weeks."
NCT01343823,Phase 2,6/1/12,"The study was determined to be inadequately powered to detect a statistically significant difference between ecallantide and placebo for the primary efficacy endpoint, and therefore terminated early.",Interim analysis suggested a trend favoring ecallantide; observed response rate to placebo was   substantially higher than described in medical literature.,155254,0.277777778,5,18,NA,NA,Placebo,NA
NCT01343823,Phase 2,6/1/12,"The study was determined to be inadequately powered to detect a statistically significant difference between ecallantide and placebo for the primary efficacy endpoint, and therefore terminated early.",Interim analysis suggested a trend favoring ecallantide; observed response rate to placebo was   substantially higher than described in medical literature.,155256,0.421052632,8,19,NA,NA,Ecallantide 30 mg,NA
NCT01343823,Phase 2,6/1/12,"The study was determined to be inadequately powered to detect a statistically significant difference between ecallantide and placebo for the primary efficacy endpoint, and therefore terminated early.",Interim analysis suggested a trend favoring ecallantide; observed response rate to placebo was   substantially higher than described in medical literature.,155257,0.3,6,20,NA,NA,Ecallantide 10 mg,NA
NCT01343823,Phase 2,6/1/12,"The study was determined to be inadequately powered to detect a statistically significant difference between ecallantide and placebo for the primary efficacy endpoint, and therefore terminated early.",Interim analysis suggested a trend favoring ecallantide; observed response rate to placebo was   substantially higher than described in medical literature.,155255,0.421052632,8,19,NA,NA,Ecallantide 60 mg,NA
NCT01348087,Phase 2,9/1/14,"The sponsor decided to terminate this study prematurely, as the study treatment failed to demonstrate efficacy in target population in two other clinical studies: CAFQ056B2214 (NCT01357239) and CAFQ056A2212 (NCT01253629).",Study treatment AFQ056 failed to demonstrate efficacy in the adult patient with Fragile X   Syndrome in 2 other clinical studies (CAFQ056B2214 and CAFQ056A2212),154040,0.044444444,6,135,NA,NA,AFQ056 100 mg Bid,AFQ056 100 mg bid
NCT01348087,Phase 2,9/1/14,"The sponsor decided to terminate this study prematurely, as the study treatment failed to demonstrate efficacy in target population in two other clinical studies: CAFQ056B2214 (NCT01357239) and CAFQ056A2212 (NCT01253629).",Study treatment AFQ056 failed to demonstrate efficacy in the adult patient with Fragile X   Syndrome in 2 other clinical studies (CAFQ056B2214 and CAFQ056A2212),154039,0.047297297,7,148,NA,NA,AFQ056 Total,NA
NCT01348087,Phase 2,9/1/14,"The sponsor decided to terminate this study prematurely, as the study treatment failed to demonstrate efficacy in target population in two other clinical studies: CAFQ056B2214 (NCT01357239) and CAFQ056A2212 (NCT01253629).",Study treatment AFQ056 failed to demonstrate efficacy in the adult patient with Fragile X   Syndrome in 2 other clinical studies (CAFQ056B2214 and CAFQ056A2212),154043,0.006802721,1,147,NA,NA,AFQ056 25 mg Bid,AFQ056 25 mg bid
NCT01348087,Phase 2,9/1/14,"The sponsor decided to terminate this study prematurely, as the study treatment failed to demonstrate efficacy in target population in two other clinical studies: CAFQ056B2214 (NCT01357239) and CAFQ056A2212 (NCT01253629).",Study treatment AFQ056 failed to demonstrate efficacy in the adult patient with Fragile X   Syndrome in 2 other clinical studies (CAFQ056B2214 and CAFQ056A2212),154041,0.007092199,1,141,NA,NA,AFQ056 75 mg Bid,AFQ056 75 mg bid
NCT01359254,Phase 2,6/1/12,NA,did not accrue enough patients.,151328,1,1,1,100 days,NA,"Fludarabine, Melphalan, and ATG","Arm I contains fludarabine, melphalan, and antithymocyte globulin (ATG)Melphalan: Melphalan is given daily for 2 days, overlapping with the completion of fludarabine.Fludarabine: Fludarabine is given through the vein daily for 5 days.Antithymocyte Globulin (ATG): ATG is given every other day for 4 days."
NCT01034657,Phase 2,8/1/12,NA,The study was terminated due to lack of efficacy of single agent LBH589 in the 4 month open   label core phase and due to enrollment difficulties.,249953,1,1,1,NA,NA,Not Randomized,"Participant, who was eligible for randomization, was not randomized. The participant had stable disease and should have been randomized, but in error, was considered a responder and therefore continued on single agent LBH589."
NCT01365910,Phase 2,6/1/13,NA,Interim analysis determined the study did not meet criteria to proceed,149700,0.533333333,16,30,NA,NA,Treatment (Enzyme Inhibitor),"Patients receive linifanib PO QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.linifanib: Given PO"
NCT01369888,Phase 1/Phase 2,5/1/14,NA,Closed this protocol due to autoimmune toxicity.,148602,1,1,1,NA,NA,IL-15 Following Young TIL (0.25 mcg),"0.25 mcg/kg/day x 10Cyclophosphamide: 60 mg/m^2, intravenous (IV) (in the vein) x 2 daysFludarabine: 25 mg/m^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days (days -5 to -1)Tumor Infiltrating Lymphocytes: IV over 30 minutes on day 0IL-15: IV over 30 minutes, daily for 10 days, starting 3-4 hours after the TIL infusion. (day 0 to day 9). Doses will be increased every 3-6 patients."
NCT01374451,Phase 2,2/1/15,"A planned primary analysis was completed with data cut of 02-Apr-2014. The study did not meet its primary objective, which was based on progression-free survival as per local radiology assessment and was prematurely terminated.",The study was stopped for not meeting the primary endpoint for PFS.,147340,0.604938272,49,81,NA,NA,Everolimus,everolimus 10 mg once daily po alone
NCT01388647,Phase 1/Phase 2,9/1/14,"Although MTD of eribulin with carboplatin & trastuzuamb as neoadjuvant therapy was determined by protocol definitions, study closed early due to increased hematologic toxicity & possible reduced efficacy. Phase II of this trial was not initiated.",Closed early due to increased hematologic toxicity and possible reduced efficacy,144593,0.5,3,6,Adverse events were collected beginning at the start of study treatment until 21 days after the subject's last study treatment,NA,Eribulin 1.1 mg/m2,Subjects assigned to receive a starting dose of eribulin 1.1 mg/m2
NCT01388647,Phase 1/Phase 2,9/1/14,"Although MTD of eribulin with carboplatin & trastuzuamb as neoadjuvant therapy was determined by protocol definitions, study closed early due to increased hematologic toxicity & possible reduced efficacy. Phase II of this trial was not initiated.",Closed early due to increased hematologic toxicity and possible reduced efficacy,144592,0.5,3,6,Adverse events were collected beginning at the start of study treatment until 21 days after the subject's last study treatment,NA,Eribulin 1.4 mg/m2,Subjects assigned to receive a starting dose of eribulin 1.4 mg/m2
NCT01389076,Phase 2,6/1/16,This trial was abandoned prematurely due to the withdrawal of Bexxar by the manufacturer and failure to find another supplier.,Bexxar isn't being produced by the manufacturer as of Feb. 2014,144475,0.181818182,4,22,NA,NA,Methotrexate and Bexxar,"Low dose methotrexate and Bexxar (tositumomab)Patients will begin taking methotrexate 7.5 mg orally once weekly 3 weeks prior to initiating I-131 tositumomab, with additional weekly doses once I-131 tositumomab therapy has begun for a total of 10 doses.On Study Day 0, patients will receive the IV administration of 450 mg unlabeled tositumomab followed by the IV administration of the dosimetric dose (5 mCi of Iodine I 131 tositumomab)."
NCT01400451,Phase 1,12/1/13,"In Phase 1 of the study, MTD was not reached because more than 2 of 6 treated participants experienced DLTs with the combination therapy. Enrollments in Phase 1 were terminated and Phase 2 was not started so only overall safety was summarized.",More than 2 of 6 patients treated experienced dose limiting toxicities.,141694,0.333333333,2,6,"From the first vemurafenib dose in the Lead In Period to the last dose of combination drugs in the Treatment Period + 90 days, up to last patient, last visit, approximately 2 years.",Final safety follow-up was 23 December 2013.,Lead-In Period 960 mg Vemurafenib,"Lead In Period: 28 Days of 960 mg vemurafenib orally twice daily (starting Day -27 or -13).Events between the first vemurafenib dose and the day prior to the first ipilimumab dose."
NCT01400451,Phase 1,12/1/13,"In Phase 1 of the study, MTD was not reached because more than 2 of 6 treated participants experienced DLTs with the combination therapy. Enrollments in Phase 1 were terminated and Phase 2 was not started so only overall safety was summarized.",More than 2 of 6 patients treated experienced dose limiting toxicities.,141692,0.5,1,2,"From the first vemurafenib dose in the Lead In Period to the last dose of combination drugs in the Treatment Period + 90 days, up to last patient, last visit, approximately 2 years.",Final safety follow-up was 23 December 2013.,Lead- In Period 720 mg Vemurafenib Alone,"These participants were receiving 720 mg vemurafenib in the Lead in Period prior to starting ipilimumab but after the DLTs were identified, ipilimumab was not started. Due to disease stabilization, they continued on 720 mg vemurafenib alone orally twice daily."
NCT01400451,Phase 1,12/1/13,"In Phase 1 of the study, MTD was not reached because more than 2 of 6 treated participants experienced DLTs with the combination therapy. Enrollments in Phase 1 were terminated and Phase 2 was not started so only overall safety was summarized.",More than 2 of 6 patients treated experienced dose limiting toxicities.,141693,0.25,1,4,"From the first vemurafenib dose in the Lead In Period to the last dose of combination drugs in the Treatment Period + 90 days, up to last patient, last visit, approximately 2 years.",Final safety follow-up was 23 December 2013.,Lead-In Period 720 mg Vemurafenib,"Lead In Period: 28 Days of 720 mg vemurafenib orally twice daily (starting Day -27 or -13).Events between the first vemurafenib dose and the day prior to the first ipilimumab dose."
NCT01420081,Phase 2,12/1/15,NA,See termination reason in detailed description.,138347,0.526315789,10,19,"Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.","All causality AEs and SAEs are included in this section. The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",PF-05212384 154 mg (PI3K Activated),"Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K activated). Participants received PF-05212384 154 mg by 30 minute infusion at the study site, QW until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death."
NCT01420081,Phase 2,12/1/15,NA,See termination reason in detailed description.,138344,0.333333333,1,3,"Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.","All causality AEs and SAEs are included in this section. The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",LIC PF-05212384 (154 mg),"Participants who were enrolled in the PF-05212384 LIC began dosing with PF-05212384 154 mg at least 4 days (but no more than 10 days) prior to Cycle 1 Day 1 and continued taking PF-05212384 until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death."
NCT01420081,Phase 2,12/1/15,NA,See termination reason in detailed description.,138352,0.6,3,5,"Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.","All causality AEs and SAEs are included in this section. The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",PF-04691502 8 mg (PI3K Basal),"Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal). Participants self-administered PF-04691502 8 mg orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death. Dose of the participants were reduced to 6 mg if they were on 8 mg dose."
NCT01420081,Phase 2,12/1/15,NA,See termination reason in detailed description.,138351,1,1,1,"Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.","All causality AEs and SAEs are included in this section. The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",PF-04691502 6 mg (PI3K Basal),"Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal). Participants self-administered PF-04691502 6 mg orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death."
NCT01420081,Phase 2,12/1/15,NA,See termination reason in detailed description.,138349,0.333333333,1,3,"Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.","All causality AEs and SAEs are included in this section. The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",PF-04691502 6 mg (PI3K Activated),"Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K activated). Participants self-administered PF-04691502 6 mg orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death."
NCT01420081,Phase 2,12/1/15,NA,See termination reason in detailed description.,138346,0.333333333,1,3,"Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.","All causality AEs and SAEs are included in this section. The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",Lead-in-cohort (LIC) PF-04691502 (4 mg),"Participants who were enrolled in the PF-04691502 LIC began dosing with PF-04691502 4 mg at least 4 days (but no more than 10 days) prior to Cycle 1 Day 1 and continued taking PF-05691502 until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death."
NCT01420081,Phase 2,12/1/15,NA,See termination reason in detailed description.,138348,0.142857143,3,21,"Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.","All causality AEs and SAEs are included in this section. The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",PF-05212384 154 mg (PI3K Basal),"Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K basal). Participants received PF-05212384 154 mg by 30 minute infusion at the study site, QW (Quaque [Once Weekly]) until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death."
NCT01420081,Phase 2,12/1/15,NA,See termination reason in detailed description.,138350,0.777777778,7,9,"Maximum of treatment duration (i.e., 21 to 169 days for the PF 04691502 [PI3K basal and activated], 29 to 345 days for PF 05212384 PI3K basal and 1 to 400 days for PF 05212384 PI3K activated) + 28 days across all participants.","All causality AEs and SAEs are included in this section. The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",PF-04691502 8 mg (PI3K Activated),"Eligible participants were categorized by PI3K pathway activation status (i.e. PI3K activated). Participants self-administered PF-04691502 8 mg orally, QD until they experienced unacceptable toxicity, disease progression, significant deviation, withdrawal of consent or death. Dose of the participants were reduced to 6 mg if they were on 8 mg dose."
NCT01424501,Phase 2,4/1/14,"Due to a safety signal found at a planned interim safety review, further conduct of this safety study is not recommended hence the study was terminated.","Due to a safety signal found at a planned interim safety review, further conduct of this   safety study is not recommended hence the study was terminated.",137458,0.08,2,25,"Solicited AEs: during the 7 day (Days 0-6), after each vaccine dose; Unsolicited AEs: during the 30 day (Days 0-29), after vaccination; SAEs: Up to day 210.","Results presented per group consist of a summary of the events (SAEs and AEs other than SAEs, respectively) reported, compiling overall number of subjects with events across the different periods of assessment.",TB Treated Saline Group,"Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who in this study received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1."
NCT01424501,Phase 2,4/1/14,"Due to a safety signal found at a planned interim safety review, further conduct of this safety study is not recommended hence the study was terminated.","Due to a safety signal found at a planned interim safety review, further conduct of this   safety study is not recommended hence the study was terminated.",137457,0.025,1,40,"Solicited AEs: during the 7 day (Days 0-6), after each vaccine dose; Unsolicited AEs: during the 30 day (Days 0-29), after vaccination; SAEs: Up to day 210.","Results presented per group consist of a summary of the events (SAEs and AEs other than SAEs, respectively) reported, compiling overall number of subjects with events across the different periods of assessment.",TB Naive GSK 692342 Group,Subjects unaffected by tuberculosis who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.
NCT01424501,Phase 2,4/1/14,"Due to a safety signal found at a planned interim safety review, further conduct of this safety study is not recommended hence the study was terminated.","Due to a safety signal found at a planned interim safety review, further conduct of this   safety study is not recommended hence the study was terminated.",137459,0.083333333,2,24,"Solicited AEs: during the 7 day (Days 0-6), after each vaccine dose; Unsolicited AEs: during the 30 day (Days 0-29), after vaccination; SAEs: Up to day 210.","Results presented per group consist of a summary of the events (SAEs and AEs other than SAEs, respectively) reported, compiling overall number of subjects with events across the different periods of assessment.",TB Treated GSK 692342 Group,"Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who during this study received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1."
NCT01425190,Phase 1,3/1/13,NA,The US FDA and the EU CHMP provided guidance indicating preference for intereferon-free   regimens in pediatric studies of HCV infection.,137216,0.0625,1,16,Nonserious adverse events (AEs) and serious AEs (SAEs) were collected during the time of boceprevir administration until the final PK sample was collected on Day 1.,AEs were monitored in the All Subjects as Treated (all boceprevir-treated participants) population.,Cohort 1: Children 17 to ‰ä´13 Years,"Participants were administered a single dose of boceprevir powder mixed in a suitable vehicle such pudding or applesauce. The first 4 participants were treated with a 11.4 mg/kg dose of boceprevir powder. The dose/weight ratio may be adjusted for the next 12 participants based on the evaluation of the PK, safety, and tolerability data from the first 4 participants."
NCT01034657,Phase 2,8/1/12,NA,The study was terminated due to lack of efficacy of single agent LBH589 in the 4 month open   label core phase and due to enrollment difficulties.,249955,0.166666667,1,6,NA,NA,LBH589 - Randomized Phase,"During the randomized phase, participants randomized to LBH589 + Epoetin Alfa (ESA) received oral LBH589 40mg/30mg + ESA 30000 international units (IU)/week injected subcutaneously for 4 months."
NCT01440283,Phase 2,3/1/15,"The study was closed to accrual in January 2014 due to the principal investigator leaving St. Jude. It was expected to re-open to accrual, however, in September 2015, the decision was made to permanently close the trial to participant enrollment.",NA,133732,0.142857143,2,14,"Adverse events were collected from the initiation of radiation therapy until completion of study, removal from study, or disease recurrence, up to 2 years after the last participant enrollment.",The therapy delivered on protocol was standard of care (standard indications for radiation and standard radiation doses) and was not expected to generate unexpected toxicities related to abdominal radiation.,Treatment,"Patients with high-risk abdominal neuroblastoma who receive any high-risk neuroblastoma treatment regimen were eligible to enroll prior to surgical resection of the primary tumor. Following implantation of fiducial markers within the tumor bed and autologous hematopoietic rescue, patients began the planning process for abdominal irradiation.Intensity Modulated Radiation Therapy (IMRT) delivery followed current conventional volume-targeting guidelines, however, appropriate application within the abdomen was determined by ascertaining intra-abdominal organ motion and the potential for reducing normal tissue dose, while simultaneously increasing dose delivered to target tissues, particularly when dose escalation for gross residual disease was required."
NCT01451723,Phase 2,2/1/13,The study was halted prematurely because of the high incidence of liver function abnormalities,Unusual high frequency of elevated liver function tests.,131241,0.166666667,1,6,1 year,NA,Polyphenon E 400mg Twice a Day,"Two capsules of Polyphenon E containing 200mg of EGCG each taken twice a day with food.Polyphenon E: Polyphenon E is a standardized green tea extract. For this study we will use capsules of Polyphenon E containing 200 mg of EGCG per capsule. Subjects will take two capsules twice a day with food."
NCT01452347,Phase 2,6/1/13,This study was terminated prematurely due to safety concerns arising during conduct of the trial.,NA,131095,0.123595506,11,89,From first intake of study drug until last intake of study drug plus 6 days (Up to 101 days).,"There were 8 patients who switched from dabigatran etexilate to warfarin during the study, and hence these patients are counted in the denominator of both arms. Any AEs which occurred in these patients are only presented under the treatment that the patient was taking at the time of the event.",Warfarin,"Oral administration of Warfarin 1mg, 3mg and 5 mg according to target international normalised ratio (INR), as recommended in guidelines, and deemed appropriate by investigator"
NCT01452347,Phase 2,6/1/13,This study was terminated prematurely due to safety concerns arising during conduct of the trial.,NA,131096,0.117283951,19,162,From first intake of study drug until last intake of study drug plus 6 days (Up to 101 days).,"There were 8 patients who switched from dabigatran etexilate to warfarin during the study, and hence these patients are counted in the denominator of both arms. Any AEs which occurred in these patients are only presented under the treatment that the patient was taking at the time of the event.",Dabigatran Etexilate,"Oral administration of 1 capsule of 150 mg (150 mg), 2 capsules of 110 mg (220 mg), or 2 capsules of 150 mg (300 mg) twice daily"
NCT01453595,Phase 1/Phase 2,4/1/14,"Given the number of toxicities seen and the difficulty with patient retention in the dose escalation portion, the sponsor decided to close the trial.","Given the number of toxicities seen and the difficulty with patient retention in the dose   escalation portion, the sponsor decided to close the trial.",130737,0.5,1,2,NA,NA,Cohort -1a: BEZ235 300mg,Cohort -1a: BEZ235 300mg by mouth twice daily
NCT01453595,Phase 1/Phase 2,4/1/14,"Given the number of toxicities seen and the difficulty with patient retention in the dose escalation portion, the sponsor decided to close the trial.","Given the number of toxicities seen and the difficulty with patient retention in the dose   escalation portion, the sponsor decided to close the trial.",130738,0.166666667,1,6,NA,NA,Cohort -1: BEZ235 200mg,Cohort -1: BEZ235 200mg by mouth twice daily
NCT01467076,Phase 2,6/1/12,NA,The study was halted due to futility concerns based on the unmet benchmarks as specified in   the pilot study protocol.,126930,0.666666667,2,3,Enrolled infants were monitored continuously throughout study aerosol administration and through 48 hours post study aerosol discontinuation for possible adverse effects of PGE1.,"Monitored adverse events (AEs) include arrhythmia, hypotension, seizures, bleeding tendency, diarrhea, and seizures. 2 AEs reported; neither was attributed to study aerosol. One infant in control group developed transient, self-resolved mild fever within 5 minutes of starting study aerosol, and completely resolved within 6 hours of onset. One infant in control group developed moderate hypotension 66 hours after initiation of study aerosol, which completely resolved within an hour of onset.",Control,Aerosolized saline
NCT01474434,Phase 2,6/1/14,"The study was terminated based on the interim analysis on Part A, Cohort 1 after patients completed Part A. Part B was not conducted. Not all the planned assessments were completed due to the termination",The study was terminated based on interim analysis. See detailed description.,124935,0.041666667,1,24,NA,The safety analysis set included all patients who received at least one dose of study drug.,"Part A, Cohort 2: Placebo",Cohort 2 consisted of patients with stable asymptomatic non-obstructive coronary artery disease or coronary heart disease risk equivalents and mild to moderate hypertriglyceridemia. All randomized patients who received matching placebo in either of 2 treatment period
NCT01475253,Phase 2,12/1/12,"As per protocol, efficacy analyses were not performed for the Sham Cytoscopic Procedure-Randomized Study Arm/Group. Only safety analyses were completed.",This study was not enrolled completely and was terminated.,124618,0.043478261,2,46,Adverse Events (AEs) and Serious Adverse Events (SAEs) reporting was collected from the time of Day of insertion through the duration of study participation (Randomized and Open Label phases).[Up to 18 Weeks],"The Intent-to-treat population, all enrolled participants for whom the study insertion procedure was initiated, was used for all safety analyses and was used to determine the number of participants at risk for Serious Adverse Events and Adverse Events.",LiRISå¨ Placebo - Randomized Study,"LiRISå¨ Placebo, the matching placebo for the LiRIS investigational product containing lactose as the drug surrogate, was inserted into the bladder using a standard cystoscopic procedure on Baseline Study Day 0 and was removed from the bladder on Day 14."
NCT01475253,Phase 2,12/1/12,"As per protocol, efficacy analyses were not performed for the Sham Cytoscopic Procedure-Randomized Study Arm/Group. Only safety analyses were completed.",This study was not enrolled completely and was terminated.,124619,0.02173913,1,46,Adverse Events (AEs) and Serious Adverse Events (SAEs) reporting was collected from the time of Day of insertion through the duration of study participation (Randomized and Open Label phases).[Up to 18 Weeks],"The Intent-to-treat population, all enrolled participants for whom the study insertion procedure was initiated, was used for all safety analyses and was used to determine the number of participants at risk for Serious Adverse Events and Adverse Events.",LiRISå¨ 400 mg - Randomized Study,"LiRISå¨ 400 mg, a non-resorbable intravesical drug-device combination investigational product that contains 400 mg of lidocaine, was inserted into the bladder using a standard cystoscopic procedure on Baseline Study Day 0 and was removed from the bladder on Day 14."
NCT01478360,Phase 2,11/1/14,NA,"Further investigations would require changes in study design; the use of different endpoints,   a different IL-17 antibody or a different patient population.",123704,0.032258065,1,31,NA,NA,AIN457 10 mg/kg,AIN457 10 mg/kg
NCT01478360,Phase 2,11/1/14,NA,"Further investigations would require changes in study design; the use of different endpoints,   a different IL-17 antibody or a different patient population.",123703,0.133333333,2,15,NA,NA,Placebo,Placebo
NCT01034657,Phase 2,8/1/12,NA,The study was terminated due to lack of efficacy of single agent LBH589 in the 4 month open   label core phase and due to enrollment difficulties.,249956,0.323529412,11,34,NA,NA,LBH589 - Core Phase,"During the core phase, all participants received oral LBH589 40 mg (30 mg after a protocol amendment) for 4 months. During the randomization phase, participants with hematological improvement of the erythropoetic system (HI-E) and participants with stable disease, who were randomized to single agent LBH589, continued on single agent LBH589 40mg/30mg for an additional 4 months."
NCT01485536,Phase 2,11/1/15,"Although the study surpassed the first futility endpoint for DLBCL cohort, it was terminated early due to limited responses and significant toxicities witnessed in the entire cohort of the study.",Study halted early due to limited response.,122335,0.2,4,20,Adverse event data were collected through each four week cycle up to 12 cycles (48 weeks).,NA,AUY922,"AUY922 starting dose 70 mg/m2 intravenous on Days 1, 8, 15, and 22 of 28 day cycle."
NCT01491633,Phase 2,5/1/13,Due to the toxicity of the study agent no subjects were evaluable for response,Safety issues/concerns per DF/HCC PI,120886,0.4,2,5,NA,NA,Dasatinib,"Dasatinib 140 mg by mouth each dayDasatinib: 140 mg orally, daily in 28 day cycles"
NCT01499355,Phase 2,12/1/15,"Study was terminated based on the review of results following the prespecified, blinded futility analysis, which did not demonstrate sufficient efficacy to warrant continuation of the study. Study was not terminated based on safety considerations.",Results from pre-specified criteria did not demonstrate sufficient efficacy to warrant   continuation of the study.,119125,0.111111111,7,63,AEs: Run-in Day 1 through Week 64 +/- 5 days. SAEs: Screening through Week 64 +/- 5 days.,NA,Placebo,"Placebo intravenous (IV) infusion on Day 1, Week 2, Week 4, Week 8, and every 4 weeks thereafter through Week 48, plus background therapy including oral steroids (prednisone or equivalent) and MMF."
NCT01499355,Phase 2,12/1/15,"Study was terminated based on the review of results following the prespecified, blinded futility analysis, which did not demonstrate sufficient efficacy to warrant continuation of the study. Study was not terminated based on safety considerations.",Results from pre-specified criteria did not demonstrate sufficient efficacy to warrant   continuation of the study.,119123,0.161290323,10,62,AEs: Run-in Day 1 through Week 64 +/- 5 days. SAEs: Screening through Week 64 +/- 5 days.,NA,BIIB023 20 mg/kg,"BIIB023 20 mg/kg IV on Day 1, Week 2, Week 4, Week 8, and every 4 weeks thereafter through Week 48 plus background therapy including oral steroids (prednisone or equivalent) and MMF."
NCT01499355,Phase 2,12/1/15,"Study was terminated based on the review of results following the prespecified, blinded futility analysis, which did not demonstrate sufficient efficacy to warrant continuation of the study. Study was not terminated based on safety considerations.",Results from pre-specified criteria did not demonstrate sufficient efficacy to warrant   continuation of the study.,119126,0.101449275,28,276,AEs: Run-in Day 1 through Week 64 +/- 5 days. SAEs: Screening through Week 64 +/- 5 days.,NA,Run-in Period,"At Run-in Day 1, participants entering the study received oral corticosteroid (prednisone or equivalent) starting at 0.75 mg/kg/day (maximum allowed dose of 60 mg/day) for 2 weeks and subsequently tapered over an 8-week period to 10 mg/day by Run-in Week 10. Following confirmation of eligibility, subjects also received MMF starting at Run-in Day 1 at a total dose of 1 g/day and titrated to a target dose of 2 g/day by Run-in Week 2."
NCT01499355,Phase 2,12/1/15,"Study was terminated based on the review of results following the prespecified, blinded futility analysis, which did not demonstrate sufficient efficacy to warrant continuation of the study. Study was not terminated based on safety considerations.",Results from pre-specified criteria did not demonstrate sufficient efficacy to warrant   continuation of the study.,119124,0.174603175,11,63,AEs: Run-in Day 1 through Week 64 +/- 5 days. SAEs: Screening through Week 64 +/- 5 days.,NA,BIIB023 3 mg/kg,"BIIB023 3 mg/kg IV on Day 1, Week 2, Week 4, Week 8, and every 4 weeks thereafter through Week 48 plus background therapy including oral steroids (prednisone or equivalent) and MMF."
NCT01505881,Phase 2,6/1/13,This study was terminated prematurely due to safety concerns arising during conduct of the trial.,NA,118350,0.06779661,4,59,From first intake of study drug until last intake of study drug plus 6 days (Up to 272 days),"Patients are presented according to the treatment they received except for 2 patients, who mistakenly switched to study warfarin during the study. These patients are presented under the Dabigatran columns only.",Warfarin,"Oral administration of Warfarin 1mg, 3mg and 5 mg according to target international normalised ratio (INR), as recommended in guidelines, and deemed appropriate by investigator"
NCT01505881,Phase 2,6/1/13,This study was terminated prematurely due to safety concerns arising during conduct of the trial.,NA,118351,0.03030303,3,99,From first intake of study drug until last intake of study drug plus 6 days (Up to 272 days),"Patients are presented according to the treatment they received except for 2 patients, who mistakenly switched to study warfarin during the study. These patients are presented under the Dabigatran columns only.",Dabigatran Etexilate,"Oral administration of 1 capsule of 150 mg (150 mg), 2 capsules of 110 mg (220 mg), or 2 capsules of 150 mg (300 mg) twice daily"
NCT01506726,Phase 2,11/1/14,NA,Study drug expiration and supply shortage,118258,0.4,2,5,All non-serious adverse events and serious adverse events will be collected from the time of randomization through the subject‰Ûªs final study visit up to 6 months.,Adverse events and serious adverse events will be collected for subjects who terminate early from the study until the time of their withdrawal.,Placebo Arm,"Subjects randomized to the placebo arm will receive a matching placebo pill (one pill) twice a day (am and pm) for one month. After one month the dose will be increased to 2 matching placebo pills twice a day (if the one pill dose was tolerated) for a further 5 months. Total treatment time is 6 months.Placebo: Placebo tablet - one pill twice daily for one month, followed by 2 pills twice daily for a further 5 months. Total duration of treatment is 6 months"
NCT01506726,Phase 2,11/1/14,NA,Study drug expiration and supply shortage,118259,0.5,3,6,All non-serious adverse events and serious adverse events will be collected from the time of randomization through the subject‰Ûªs final study visit up to 6 months.,Adverse events and serious adverse events will be collected for subjects who terminate early from the study until the time of their withdrawal.,Active Drug - Oral Salsalate,"Subjects randomized to active drug arm will receive 750mg of salsalate (one pill) twice a day (am and pm) for one month. After one month the dose will be increased to 1500mg (2 pills) twice a day (if the 750mg dose was tolerated) for a further 5 months. Total treatment time is 6 months.Salsalate: Salsalate 750mg tablet 1 pill bid for one month followed by Salsalate 750mg tablets 2 pills (1500mg) twice a day for a further 5 months (total duration of treatment will be 6 months)"
NCT01511107,Phase 2,10/1/15,NA,The primary objective of the study was met.,117180,0.011673152,3,257,"Parents were interviewed at each scheduled study visit (Day 1, Day 12-14, Day 16-30, 6 week), at the Day 4-6 phone call, at interim illness visits through May 31st, and at the final September visit to determine if their child had any adverse events.","Staff reviewed child's medical records since their last study visit for any adverse events (AEs). A medical condition that was present at the time that the child was screened was considered baseline and not reported as an AE. If the severity of any pre-existing medical condition increased at any time during the study, it was reported as an AE.","Amoxicillin-Clavulanate, 10 Days",Amoxicillin-clavulanate administered at a dosage of 90/6.4mg/kg/day in 2 divided doses for 10 days.
NCT01511107,Phase 2,10/1/15,NA,The primary objective of the study was met.,117179,0.019379845,5,258,"Parents were interviewed at each scheduled study visit (Day 1, Day 12-14, Day 16-30, 6 week), at the Day 4-6 phone call, at interim illness visits through May 31st, and at the final September visit to determine if their child had any adverse events.","Staff reviewed child's medical records since their last study visit for any adverse events (AEs). A medical condition that was present at the time that the child was screened was considered baseline and not reported as an AE. If the severity of any pre-existing medical condition increased at any time during the study, it was reported as an AE.","Amoxicillin-Clavulanate, 5 Days",Amoxicillin-clavulanate administered at a dosage of 90/6.4mg/kg/day in 2 divided doses for Days 1-5 followed by placebo in 2 divided doses for Days 6-10.
NCT01513317,Phase 2,9/1/12,NA,The study was stopped after the interim analysis based on lack of sufficient efficacy. There   were no safety concerns.,116725,0.2,10,50,Adverse events are reported for the time period between the first dose of study medication through 30 days after the last dose.,Safety was analyzed for all randomized participants who received at least 1 dose of study medication.,Siltuximab,15 mg/kg of siltuximab administered as a 1-hour infusion every 4 weeks + best supportive care (BSC)
NCT01513317,Phase 2,9/1/12,NA,The study was stopped after the interim analysis based on lack of sufficient efficacy. There   were no safety concerns.,116724,0.307692308,8,26,Adverse events are reported for the time period between the first dose of study medication through 30 days after the last dose.,Safety was analyzed for all randomized participants who received at least 1 dose of study medication.,Placebo,Placebo administered as a 1-hour infusion every 4 weeks + best supportive care (BSC)
NCT01517984,Phase 2,5/1/15,"After meeting protocol stopping rules, this trial was closed to new enrollment and randomization. No additional prespecified withdrawal of tacrolimus was allowed. Those already enrolled or randomized were followed for up to 24 months post-transplant.",Absence of equipoise on the basis of predetermined stopping rules.,115840,0.076923077,2,26,Transplantation through end of study (up to 24 months),NA,"Transplanted, But Not Randomized","These participants were enrolled into the study and received a living-donor kidney allograft transplant. Participants were given an induction therapy with rabbit antithymocyte globulin (1.5-2.0 mg/kg daily for 5 days) and treated with a regimen of mycophenolate mofetil (target dose of 1000 mg twice daily), prednisone (no less than 5 mg/day or 10 mg every other day) and tacrolimus (0.1 mg/kg twice daily, adjusted to target trough levels of 8-12 ng/ml in first 3 months post-transplant, 5-8 ng/ml thereafter). Participants were followed for up to 8 months and deemed ineligible for randomization or terminated for other reasons."
NCT01517984,Phase 2,5/1/15,"After meeting protocol stopping rules, this trial was closed to new enrollment and randomization. No additional prespecified withdrawal of tacrolimus was allowed. Those already enrolled or randomized were followed for up to 24 months post-transplant.",Absence of equipoise on the basis of predetermined stopping rules.,115839,0.285714286,4,14,Transplantation through end of study (up to 24 months),NA,Randomized to Tacrolimus Withdrawal,"These participants were enrolled into the study and received a living-donor kidney allograft transplant. Participants were given an induction therapy with rabbit antithymocyte globulin (1.5-2.0 mg/kg daily for 5 days) and treated with a regimen of mycophenolate mofetil (target dose of 1000 mg twice daily), prednisone (no less than 5 mg/day or 10 mg every other day) and tacrolimus (0.1 mg/kg twice daily, adjusted to target trough levels of 8-12 ng/ml in first 3 months post-transplant, 5-8 ng/ml thereafter). Participants were followed for 6-8 months then randomized to tacrolimus withdrawal. Following randomization these participants had their dose of tacrolimus withdrawn gradually over three to four months, with complete withdrawal occurring no later than four months. Participants were followed up to 18 months after being randomized."
NCT01518153,Phase 2,8/1/14,NA,Objectives not met.,115808,1,4,4,"Adverse events (AEs) were collected from the start of preparative regimen up to discontinuation of study treatment. Overall collection period: March 30, 2012 to April 15, 2014.",NA,High Dose Donor T-Cells,"Fludarabine 40 mg/m^2 intravenous (IV) administered from Day -6 to -3, Melphalan 140 mg/m^2 IV on Day -2 and Alemtuzumab 50 mg IV on Day -1. Day 0 Stem Cell infusion: Fresh or cryopreserved peripheral blood progenitor cells infused. Planned Donor Lymphocyte Infusion CD3+ cells: 3*10^6 CD3+ cells/kg between Day +56 & +64. Tacrolimus 0.015 mg/kg IV as continuous infusion daily to achieve therapeutic level of 5-15 ng/ml (target 10 ng/ml). Tacrolimus changed to oral dosing, tapering approximately Day +35 to off by Day +42. Methotrexate 5 mg/m^2 administered IV days +1, +3, +6. G-CSF 5 mcg/kg/day subcutaneously beginning Day +7, continuing until absolute neutrophil count (ANC)> 500*10/L for 3 consecutive days."
NCT01518153,Phase 2,8/1/14,NA,Objectives not met.,115810,1,9,9,"Adverse events (AEs) were collected from the start of preparative regimen up to discontinuation of study treatment. Overall collection period: March 30, 2012 to April 15, 2014.",NA,Stem Cell Infusion,"Fludarabine 40 mg/m^2 intravenous (IV) administered from Day -6 to -3, Melphalan 140 mg/m^2 IV on Day -2 and Alemtuzumab 50 mg IV on Day -1. Day 0 Stem Cell infusion: Fresh or cryopreserved peripheral blood progenitor cells infused."
NCT01518153,Phase 2,8/1/14,NA,Objectives not met.,115809,0.666666667,2,3,"Adverse events (AEs) were collected from the start of preparative regimen up to discontinuation of study treatment. Overall collection period: March 30, 2012 to April 15, 2014.",NA,Low Dose Donor T-Cells,"Fludarabine 40 mg/m^2 intravenous (IV) administered from Day -6 to -3, Melphalan 140 mg/m^2 IV on Day -2 and Alemtuzumab 50 mg IV on Day -1. Day 0 Stem Cell infusion: Fresh or cryopreserved peripheral blood progenitor cells infused. Planned Donor Lymphocyte Infusion CD3+ cells: 1*10^6 CD3+ cells/kg between Day +56 & +64. Tacrolimus 0.015 mg/kg IV as continuous infusion daily to achieve therapeutic level of 5-15 ng/ml (target 10 ng/ml). Tacrolimus changed to oral dosing, tapering approximately Day +35 to off by Day +42. Methotrexate 5 mg/m^2 administered IV days +1, +3, +6. G-CSF 5 mcg/kg/day subcutaneously beginning Day +7, continuing until absolute neutrophil count (ANC)> 500*10/L for 3 consecutive days."
NCT01521143,Phase 2,3/1/15,NA,The study was terminated due to company restructuring and changes in drug development   priorities.,114729,0.25,5,20,NA,"Part A - Safety population: All randomized participants who received at least 1 dose of Cvac or placebo.Part B - Safety population: All randomized participants who received at least 1 dose of Cvac (Cvac group) or were evaluated at least once (observational standard of care group).",Part A - Cvac,"Participants received intradermal injections of Cvac given at 4-week intervals for the first 3 doses, and then every 12 weeks for 3 additional doses, for a total of 6 doses over 44 weeks. Each injection had an approximate concentration of 60 ÌÑ 10^6 viable dendritic cells/mL."
NCT01521143,Phase 2,3/1/15,NA,The study was terminated due to company restructuring and changes in drug development   priorities.,114728,0.35,7,20,NA,"Part A - Safety population: All randomized participants who received at least 1 dose of Cvac or placebo.Part B - Safety population: All randomized participants who received at least 1 dose of Cvac (Cvac group) or were evaluated at least once (observational standard of care group).",Part A - Placebo,"Participants received intradermal injections of placebo given at 4-week intervals for the first 3 doses, and then every 12 weeks for 3 additional doses, for a total of 6 doses over 44 weeks."
NCT01530399,Phase 2,11/1/12,NA,Safety,112983,0.2,2,10,30 (+5) days post treatment,NA,MDCO 4,"MDCO-2010 Dose 4: MDCO-2010 will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with MDCO-2010. MDCO 4: load 90 ë_g/kg; infusion 180 ë_g/kg/h; CPB prime 0.65 ë_g/mL priming volume"
NCT01530399,Phase 2,11/1/12,NA,Safety,112985,0.25,2,8,30 (+5) days post treatment,NA,MDCO 2,"MDCO-2010 Dose 2: MDCO-2010 will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with MDCO-2010. MDCO 2: load 30 ë_g/kg; infusion 60 ë_g/kg/h; CPB prime 0.22 ë_g/mL priming volume"
NCT01530399,Phase 2,11/1/12,NA,Safety,112986,0.285714286,2,7,30 (+5) days post treatment,NA,MDCO 1,"MDCO-2010 Dose 1: MDCO-2010 will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with MDCO-2010. MDCO 1: load 15 ë_g/kg; infusion 30 ë_g/kg/h; CPB prime 0.11 ë_g/mL priming volume"
NCT01530399,Phase 2,11/1/12,NA,Safety,112984,0.142857143,1,7,30 (+5) days post treatment,NA,MDCO 3,"MDCO-2010 Dose 3: MDCO-2010 will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with MDCO-2010. MDCO 3: load 60 ë_g/kg ; infusion 120 ë_g/kg/h; CPB prime 0.44 ë_g/mL priming volume"
NCT01534143,Phase 2,5/1/13,Data was not collected.,Data was not collected.,112324,1,1,1,NA,NA,"Treatment (Chemotherapy, Enzyme Inhibitor)","CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -7 to -3, busulfan IV on days -6 to -3, and bortezomib IV on day -2.GVHD PROPHYLAXIS: Patients receive thymoglobulin IV on days -3 to -1, sirolimus PO on day -3, and tacrolimus IV on day -3. Patients undergo allogeneic HSCT on day 0.anti-thymocyte globulin : Given IVpharmacological study : Correlative studiesfludarabine phosphate : Given IVbusulfan : Given IVbortezomib : Given IVallogeneic hematopoietic stem cell transplantation : Undergo allogeneic HSCTtacrolimus : Given IVlaboratory biomarker analysis : Correlative studiessirolimus : Given PO"
NCT01577381,Phase 2,10/1/13,"The study was terminated early due to an organizational decision, which was not based on safety or efficacy concerns. As only 10 participants enrolled at the time of termination, there were not enough subjects or data to perform meaningful analyses.",See termination reason in detailed description.,104180,0.5,1,2,NA,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as non-serious in another subject, or one subject may have experienced both a serious and non-serious event during the study.",PF-04382923 2.5 mg/kg,PF-04382923 (RN6G) at 2.5 milligrams per kilogram (mg/kg) was administered as an intravenous (IV) infusion over 30 minutes every 28 days for 11 doses.
NCT01592773,Phase 2,3/1/14,NA,Terminated because primary efficacy parameter failed to demonstrate statistically significant   difference between memantine and placebo in controlled trials,100720,0.010709505,8,747,Adverse Event data was collected from October 2012 to February 2014 at 106 sites in the US and 15 other countries.,"Safety results are based on the safety population (ie, all patients who took at least one dose of investigational product).",Memantine,"To maintain the blind of the preceding study, patients who participated in MEM-MD-68 began this study with 6 weeks of double blind dosing during which all patients were either titrated to or remained on their maximum target dosages. This was followed by up-to 42 weeks of open-label dosing.Patients who took open-label memantine in the preceding study, MEM-MD-67 or MEM-MD-91, received up to 48 weeks of open-label memantine at their maximum tolerated weight based target dosage."
NCT01603121,Phase 1/Phase 2,5/1/13,Early termination due to difficulty recruiting subjects.,Unable to enroll sufficient number of subjects,98891,1,1,1,NA,"Adverse events were assessed for through investigator assessment during the treatment period, and planned phone calls with patient following treatment periods.",Lisofylline Intravenous,"Lisofylline 9 mg/kg as a continuous intravenous infusion over a 10 hours periodLisofylline: Lisofylline single dose of 9 mg/kg continuous intravenous infusion over a 10 hour period, and lisofylline single dose of 12 mg/kg continuous subcutaneous infusion over a 10 hour period during the alternate period 1 week apart."
NCT01604941,Phase 2,7/1/14,This study was terminated due to treatment stop resulting in an inability to draw conclusions from the data. Evaluation of nonclinical rat findings is ongoing.,This study was terminated due to treatment stop resulting in an inability to draw conclusions   from the data. Evaluation of nonclinical rat findings is ongoing.,98591,0.166666667,2,12,NA,"All safety analyses, including analyses of AEs, were based on the Safety Set, which included participants in the 50mg/kg/day BID and 75mg/kg/day BID dosing groups who had taken at least 1 BID dose of investigational product. Participants in the QD only dosing groups were not included in the Safety Set.",SPD602 50mg/kg/Day,Participants received SPD602 50mg/kg/day oral dosing BID either as originally randomized or as a re-enrolled participant.
NCT01604941,Phase 2,7/1/14,This study was terminated due to treatment stop resulting in an inability to draw conclusions from the data. Evaluation of nonclinical rat findings is ongoing.,This study was terminated due to treatment stop resulting in an inability to draw conclusions   from the data. Evaluation of nonclinical rat findings is ongoing.,98590,0.285714286,2,7,NA,"All safety analyses, including analyses of AEs, were based on the Safety Set, which included participants in the 50mg/kg/day BID and 75mg/kg/day BID dosing groups who had taken at least 1 BID dose of investigational product. Participants in the QD only dosing groups were not included in the Safety Set.",SPD602 75mg/kg/Day,Participants received SPD602 75mg/kg/day oral dosing BID either as originally randomized or as a re-enrolled participant.
NCT01609062,Phase 2,11/1/14,NA,NA,97457,0.2,2,10,"Study Period, up to 192 weeks or ETV",All Adverse Events,BMN 110 Weekly at 4.0 mg/kg/Week,BMN 110: Weekly IV infusions of BMN 110 at 4.0 mg/kg/week over a period of approximately 4 hours per infusion in the primary phase.
NCT01609062,Phase 2,11/1/14,NA,NA,97458,0.2,3,15,"Study Period, up to 192 weeks or ETV",All Adverse Events,BMN 110 Weekly at 2.0 mg/kg/Week,BMN 110: Weekly IV infusions of BMN 110 at 2.0 mg/kg/week over a period of approximately 4 hours per infusion in the primary phase.
NCT01615822,Phase 1,4/1/13,NA,Decision taken to halt progression of mefloquine as a potential partner for OZ439 as a single   dose cure due to low probability of success,96158,0.125,1,8,Up to Day 42 post-dose,All subjects who received at least one dose of study drug were included in the safety analysis set. Adverse events were collected irrespective of whether or not the patients had received OZ439 alone or in combination with MQ.,Cohort 1,"Period 1: OZ439 100mg single dose oral suspensionPeriod 2: Single dose OZ439 100mg oral suspension in combination with single dose MQ 250mg tablet"
NCT01627002,Phase 1,4/1/13,Part B of the study was terminated early which led to a small number of subjects analyzed. Pharmacokinetic parameters were not calculated for Part A 0.3mg and 10 mg PA401,NA,94663,0.5,1,2,Up to 14 days post dose,Adverse events were monitored by the clinical staff asking non-leading questions during the period of confinement to the clinic.,Part A PA401 10 mg,NA
NCT01628913,Phase 2,9/1/14,Trial terminated based on the results of a pre-planned interim analysis of the primary OM ( which demonstrated BEX235 not having improved PFS (progression free survival) vs everolimus)..The secondary OM analyses were not conducted,This trial was terminated based on an interim analysis as BEZ235 did not demonstrate a   progression free survival advantage to everolimus treatment.,94252,0.290322581,9,31,NA,NA,Everolimus,"Patients received Everolimus 10 mg qd p.o. (by mouth, daily)"
NCT01628913,Phase 2,9/1/14,Trial terminated based on the results of a pre-planned interim analysis of the primary OM ( which demonstrated BEX235 not having improved PFS (progression free survival) vs everolimus)..The secondary OM analyses were not conducted,This trial was terminated based on an interim analysis as BEZ235 did not demonstrate a   progression free survival advantage to everolimus treatment.,94253,0.35483871,11,31,NA,NA,BEZ235,"Patients received BEZ235 400 mg bid p.o. (by mouth, twice daily)"
NCT01631630,Phase 2,9/1/15,"This study was terminated early, so the number of subjects analyzed is small.",The study was closed to recruitment due to feasibility problems.,93950,0.25,2,8,Adverse event data were collected throughout the 31 days of the inpatient stay for each subject,NA,Pioglitazone,"Subjects received pioglitazone, 15mg/day for 3 days; 30mg day for 3 days; 45mg/day thereafter, for a minimum total of 13 days"
NCT01634360,Phase 2,6/1/08,"Due to early termination, no subjects completed this open-label extension study.",Due to termination of clinical program for Parkinson's Disease,93283,0.270833333,13,48,"Treatment emergent adverse events (TEAE) are those that start on or after the first day of dosing with study medication in the open label extension study, and no later than 30 days after the last day of dosing with study medication.",NA,Perampanel (Placebo During Core Study),"Subjects entered this open-label extension study from the double-blind core study (E2007-E044-204). Subjects started on perampanel 1mg once daily for 4 weeks, followed by 2mg once daily for 2 weeks; if they did not tolerate the 1 mg dose, subjects were withdrawn from the study. Subjects could be up-titrated to 3 or 4 mg in a sequential manner. There were at least 2 weeks between each titration to assess safety and tolerability, and the subjects attended a clinic visit for safety review and dispensing of more medication. Subjects could be down-titrated at any time to either 3, 2 or 1 mg in a sequential manner."
NCT01634360,Phase 2,6/1/08,"Due to early termination, no subjects completed this open-label extension study.",Due to termination of clinical program for Parkinson's Disease,93282,0.291044776,39,134,"Treatment emergent adverse events (TEAE) are those that start on or after the first day of dosing with study medication in the open label extension study, and no later than 30 days after the last day of dosing with study medication.",NA,"Perampanel (Perampanel 0.5, 1, or 2 mg During Core Study)","Subjects entered this open-label extension study from the double-blind core study (E2007-E044-204). Subjects started on perampanel 1mg once daily for 4 weeks, followed by 2mg once daily for 2 weeks; if they did not tolerate the 1 mg dose, subjects were withdrawn from the study. Subjects could be up-titrated to 3 or 4 mg in a sequential manner. There were at least 2 weeks between each titration to assess safety and tolerability, and the subjects attended a clinic visit for safety review and dispensing of more medication. Subjects could be down-titrated at any time to either 3, 2 or 1 mg in a sequential manner."
NCT01668173,Phase 2,5/1/15,Early termination leading to small numbers of subjects analyzed.,patient safety,86245,0.428571429,3,7,NA,NA,All Patients,"HSP90 Inhibitor, AUY922, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET"
NCT01671111,Phase 2,7/1/14,"This study was terminated early due to non-clinical safety results. Not all participants completed the study. The available efficacy data were analyzed as specified in the statistical analysis plan; however, no efficacy conclusions were drawn.",This study was terminated due to treatment stop resulting in an inability to draw conclusions   from the data. Evaluation of nonclinical rat findings is ongoing.,85670,0.066666667,2,30,From start of study treatment up to the end of study (1 week after the end of treatment),An adverse event (AE) that occurred during the study was considered a treatment-emergent AE (TEAE) if it had a start date and time on or after the study treatment or if it had a start date before the date and time of the study treatment but increased in intensity on or after the date and time of the study treatment.,SSP-004184AQ,"Participants received SSP-004184AQ (magnesium salt of free acid or active form, that is, SSP-004184 [SPD602, FBS0701]) capsules orally at a total daily dose of 8-75 mg/kg/day (equivalent to SSP-004184 7-68 mg/kg/day) either once daily or twice daily at the discretion of investigator for up to a maximum of 3 years or until the sponsor decided to stop the study."
NCT01688882,Phase 2,3/1/15,NA,This study was stopped after Part 1 completed and was terminated because the predefined   criteria of efficacy was not reached ( >50% better then placebo),82101,0.285714286,2,7,NA,NA,Placebo,Placebo to Match Q2W s.c.
NCT01688882,Phase 2,3/1/15,NA,This study was stopped after Part 1 completed and was terminated because the predefined   criteria of efficacy was not reached ( >50% better then placebo),82099,0.181818182,2,11,NA,NA,Follow-up Period: QGE031,Follow-up Period after completion of Part 1 QGE031 240 mg Q2W s.c.
NCT01688882,Phase 2,3/1/15,NA,This study was stopped after Part 1 completed and was terminated because the predefined   criteria of efficacy was not reached ( >50% better then placebo),82102,0.461538462,6,13,NA,NA,QGE031,QGE031 240 mg Q2W s.c
NCT01688882,Phase 2,3/1/15,NA,This study was stopped after Part 1 completed and was terminated because the predefined   criteria of efficacy was not reached ( >50% better then placebo),82100,0.25,1,4,NA,NA,Open Label QGE031,Open Label QGE031 Q2W s.c.
NCT01697319,Phase 2,10/1/14,NA,NA,80608,0.466666667,7,15,Study Period,All Adverse Events,BMN 110 at 2.0 mg/kg/Week,Weekly IV infusions of BMN 110 at 2.0 mg/kg/week over a period of approximately 4 hours per infusion for an initial treatment phase of 48 weeks and an extension treatment phase of up to an additional 96 weeks.
NCT01704599,Phase 1/Phase 2,5/1/14,Early termination due to high amount of combination of side effects and poor outcomes leading to small numbers of subjects analyzed.,side effect and poor clinical outcome,79068,0.125,1,8,2010-2013,"On Humira alone: WBC elevation, Non specific st-t wave change and Left axis deviation. .",Humira Then Humira Plus 3 B Vitamins,Pneumonia while on adaimumab and before the adalimumab plus B vitamins were begun.prior to vitamins
NCT01705496,Phase 2,11/1/13,NA,The sensitivity and specificity were not able to be assessed in this study due to the poor   image quality.,78949,0.045454545,1,22,NA,NA,[124I]FIAU,"Single dose study of [124I]FIAU in patients presenting with pain in a prosthetic knee or hip joint who will undergo PET-CT scanning.[124I]FIAU: This is a single dose study of 5 mCi [124I]FIAU in subjects presenting with pain in a prosthetic knee or hip joint. Subject will receive two PET-CT scans after [124I]FIAU injection."
NCT01706159,Phase 2,7/1/13,The trial was terminated earlier than planned as the hypothesis of a correlation between low levels of FXIII and disease activity of UC could not be confirmed.,Trial screening data did not support the medical hypothesis,78896,0.076923077,1,13,Adverse events reported by the investigator from the first trial-related activity after the subject is exposed to the trial drug until the end of trial visit (Week 10).,Safety analysis set was identical to the FAS which included all randomised and treated subjects.,rFXIII,Recombinant factor XIII (rFXIII) was administered as intravenous (i.v.) injections (at an approximate rate of 1-2 mL/min) at a dose of 35 IU/kg. The doses were administered once every second week for a total of 4 doses.
NCT01750346,Phase 2,5/1/15,NA,NA,70266,0.333333333,1,3,NA,NA,0.05% AH-8,"Participants in the 0.05% AH-8 arm received the higher dose of the study drug, Acetyl Hexapeptide 8 (AH-8), which is sold under the band name, Argireline.Topical acetyl hexapeptide-8"
NCT01750346,Phase 2,5/1/15,NA,NA,70264,0.333333333,1,3,NA,NA,Placebo,"Participants in the Placebo arm received the placebo.Topical acetyl hexapeptide-8"
NCT01754623,Phase 2,10/1/14,"The study only accrued 9 (of planned 35) participants. It was not possible to collect adequate pre-treatment tissue for radiosensitivity index (RSI) analysis, pre-treatment. The study was terminated before planned completion.",Lack of pre-treatment tissue to make the study plan feasible.,69760,0.444444444,4,9,"1 year, 5 months",NA,Chemotherapy Followed by Radiation Treatment,"Gemcitabine, Taxotere, Xeloda (GTX): 21 day cycle x 3 Gemcitabine 750mg/m^2 on days 4 and 11 Taxotereå¨ (docetaxel) 30 mg/m^2 on days 4 and 11 Xelodaå¨ (capecitabine) 750 mg/m^2 on days 1-14 Radiation: stereotactic body radiation therapy stereotactic body radiation therapy (SBRT).After radiation, participants will be re-evaluated for surgery."
NCT01764919,Phase 2,2/1/14,NA,No correlation between FIAU uptake and bone biopsy results.,67648,0.25,1,4,NA,NA,[124I]FIAU,"Single intravenous injection of [124I]FIAU in patients with diabetic foot infection[124I]FIAU: A single intravenous injection of 5 mCi[124I]FIAU in patients with diabetic foot infection who will undergo 2 PET-CT scanning."
NCT01766336,Phase 2,8/1/15,NA,NA,67184,0.193333333,29,150,Adverse events were recorded for each patient starting from the time the consent form was signed until the completion of the study.,NA,ELND005/ELND005,Patients who received ELND005 in AG201 and received ELND005 in this extension study AG251
NCT01766336,Phase 2,8/1/15,NA,NA,67183,0.178082192,26,146,Adverse events were recorded for each patient starting from the time the consent form was signed until the completion of the study.,NA,Placebo/ELND005,Patients who received Placebo in AG201 and received ELND005 in this extension study AG251
NCT01792635,Phase 2,5/1/14,"Part B of the study was terminated due to the safety issue. Due to the low number of participants who completed the study, there are no conclusions for PK or PD in Part B. The prioritization of Part A endpoints was done by inputs from team.",The study was terminated prematurely on 16 May 2014 due to a safety concern.,63160,0.142857143,1,7,Baseline up to follow-up (up to approximately 3 days after the last clamp procedure in Part A and up to approximately 10 to 14 days after the last study drug administration in Part B),"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",PF-05175157 200 mg Twice a Day - Part B,"Participants received PF-05175157 200 mg twice a day at approximately 08:00 immediately before the morning meal, and at approximately 18:00 before the dinner meal. The treatment period was 6 weeks."
NCT01807156,Phase 2,2/1/15,NA,Primary endpoint not met,61676,0.142857143,1,7,NA,NA,Tivozanib,"Patients would receive Tivozanib 1.0 mg/day orally, 3 weeks on, one week off, for one cycle starting day 1. If no adverse event is encountered, patients will continue subsequent cycles of Tivozanib 1.5 mg/day orally; 3 weeks on/1 week off, dosing schedule. Patients will continue on treatment until disease progression, unacceptable toxicity, or patient withdrawal from the study.Tivozanib: Oral medication given daily. No placebo."
NCT01808950,Phase 1/Phase 2,8/1/13,NA,safety issues,61226,0.333333333,1,3,NA,NA,0.06% Resiquimod Gel - B,"100 mg gelOnce daily prior to normal sleeping hours5x within 1 week (Monday to Friday) for 4 weeks (at maximum) or until clinical manifestation of skin erosion/crust formation0.06% Resiquimod Gel - B"
NCT01810302,Phase 2,1/1/14,"This single center study was terminated early due to inability to maintain an adequate drug supply; therefore, statistical analysis of the 2 participants was not done.",Unable to secure drug.,60921,1,1,1,Adverse event monitoring began at the initiation of study procedures and continued until post-hemorrhage day 17.,NA,Nicardipine Hydrochloride,"Nicardipine hydrochloride 4mg by intrathecal administration twice a day until post-hemorrhage day 10.Nicardipine hydrochloride: Nicardipine hydrochloride 4mg by intrathecal administration twice a day until post-hemorrhage day 10."
NCT01813019,Phase 2,11/1/14,NA,Study was prematurely terminated at the time of the first Interim Analysis (IA) as the study   did not meet its primary efficacy objective.,60502,0.038461538,1,26,NA,NA,AFQ056,"AFQ056 b.i.d up-titration of 50mg,100mg, 150mg and 200 mg for 4 weeks then AFQ056 200mg b.i.d for 12 weeks and then a down-titration of AFQ056 100mg, 50mg and 25mg b.i.d for 3 weeks"
NCT01813019,Phase 2,11/1/14,NA,Study was prematurely terminated at the time of the first Interim Analysis (IA) as the study   did not meet its primary efficacy objective.,60503,0.083333333,2,24,NA,NA,Placebo,Matching Placebo b.i.d. dosing
NCT01838499,Phase 2,10/1/14,The trial terminated early due to lack of efficacy. An interim analysis was conducted after the first 61 subjects at 12 weeks and showed no evidence of MEDI8968 activity in reducing (HS) severity or pain over that seen with placebo.,"At the planned IA for decision making, no evidence was demonstrated of MEDI8968 activity in   reducing (HS) severity or pain over that seen with placebo.",57168,0.036363636,2,55,"24 weeks. However, if a subject withdraws from treatment for any reason prior to week 24, the subject should continue to be seen up to 16 weeks after his/her last dose.","In the tables below all the SAEs are presented. In the Other Adverse events tables please note that a Frequency Threshold of 5% has been applies to reporting the AEs and associated summaries. If, within a treatment group the frequency >= 5%, the associated information has been presented for both treatment arms.",MEDI8968,SC injection
NCT01838499,Phase 2,10/1/14,The trial terminated early due to lack of efficacy. An interim analysis was conducted after the first 61 subjects at 12 weeks and showed no evidence of MEDI8968 activity in reducing (HS) severity or pain over that seen with placebo.,"At the planned IA for decision making, no evidence was demonstrated of MEDI8968 activity in   reducing (HS) severity or pain over that seen with placebo.",57167,0.037037037,2,54,"24 weeks. However, if a subject withdraws from treatment for any reason prior to week 24, the subject should continue to be seen up to 16 weeks after his/her last dose.","In the tables below all the SAEs are presented. In the Other Adverse events tables please note that a Frequency Threshold of 5% has been applies to reporting the AEs and associated summaries. If, within a treatment group the frequency >= 5%, the associated information has been presented for both treatment arms.",Saline,SC injection
NCT01838642,Phase 2,1/1/16,NA,Recruiting halted prematurely and will not resume. New study to open soon.,57058,0.666666667,2,3,17 months and 19 days,No participants were enrolled in the RET mutation negative group; study closed prematurely.,RET Mutation Positive Participants,"Rearranged during transfection) (RET)Ponatinib: Ponatinib tablets will be administered orally, continually, once daily at a dose of 30 mg. A cycle of ponatinib is defined as 28 consecutive days starting with the first day of the treatment cycle. Treatment will be administered primarily in an outpatient setting."
NCT01848756,Phase 1/Phase 2,6/1/15,NA,Business reasons,55917,0.533333333,8,15,"From patient screening to removal from study, average time on study 49+/-16 days",Regular Investigator Assessment including patient volunteered reports,SNX-5422,"Open-label administration of SNX-5422 capsules to total 100 mg/m2 every other day for 21 days (total = 11 doses), out of a 28-day treatment cycle. Subjects will continue treatment on a 28-day cycle at the discretion of the principal investigator based on safety.SNX-5422: Capsule(s) dosed every other day for 21 days (total = 11 doses), out of a 28-day treatment cycle."
NCT01861301,Phase 2,3/1/15,NA,NA,54001,0.166666667,3,18,NA,NA,Treatment (Tivantinib),Patients receive tivantinib 360 PO BID. Treatment continues in the absence of disease progression or unacceptable toxicity.
NCT01874340,Phase 2,4/1/14,Due to early termination this trial was not powered for efficacy no statistical analysis was performed,Study terminated early based upon development of another anti-IL17 fully human monoclonal   antibody with better potential for treating MS patients,52923,0.125,1,8,NA,The safety set consists of all subjects who received at least one dose of study medication. Subjects were analyzed according to the treatment received.,AIN457 7 mg/kg,"AIN457 will be administered intravenously at day1, Week 2, week 4 and every 4 weeks therafter."
NCT01880437,Phase 2,11/1/14,This study was prematurely terminated because of lower-than-expected efficacy observed in interim data analyses.,NA,52070,0.75,3,4,From screening until study completion or early termination visit (Up to 14 months),NA,FLT-3 Mutation Positive,"Participants with relapsed/refractory AML or relapsed/refractory high-risk MDS falling under 'FLT-3 mutation positive' subgroup received oral 150 mg dose of vismodegib capsule once daily until disease progression, intolerable toxicity most probably attributable to vismodegib, or participant withdrawal of consent."
NCT01880437,Phase 2,11/1/14,This study was prematurely terminated because of lower-than-expected efficacy observed in interim data analyses.,NA,52071,0.666666667,10,15,From screening until study completion or early termination visit (Up to 14 months),NA,Poor Risk Cytogenetics,"Participants with relapsed/refractory AML or relapsed/refractory high-risk MDS falling under 'poor risk cytogenetics' subgroup received oral 150 mg dose of vismodegib capsule once daily until disease progression, intolerable toxicity most probably attributable to vismodegib, or participant withdrawal of consent."
NCT01880437,Phase 2,11/1/14,This study was prematurely terminated because of lower-than-expected efficacy observed in interim data analyses.,NA,52069,0.684210526,13,19,From screening until study completion or early termination visit (Up to 14 months),NA,Neither Poor Risk Cytogenetics Nor FLT-3,"Participants with relapsed/refractory AML or relapsed/refractory high-risk MDS falling neither under 'poor risk cytogenetics' nor 'FLT-3 mutation positive' subgroup were included in this group and received oral 150 mg dose of vismodegib capsule once daily until disease progression, intolerable toxicity most probably attributable to vismodegib, or participant withdrawal of consent."
NCT01888965,Phase 2,10/1/14,NA,Adverse Event issues.,51275,0.555555556,5,9,1 year,NA,Dovitinib,"Dovitinib 500 mg orally daily for 5 days followed by 2 days off (7 day cycles) for up to 2 yearsDovitinib: All patients in the study will receive Dovitinib, 500 mg orally daily for 5 days followed by 2 days off (7 day cycles) for up to 2 years."
NCT01912404,Phase 2,8/1/15,"Since the study was stopped early, no conclusions regarding efficacy can be made.",Due to concern for high systemic drug levels that could exceed levels in toxicology studies.,48241,1,2,2,6 Months,NA,Placebo,Matching Placebo capsules twice daily for 28 days
NCT01912404,Phase 2,8/1/15,"Since the study was stopped early, no conclusions regarding efficacy can be made.",Due to concern for high systemic drug levels that could exceed levels in toxicology studies.,48242,1,3,3,6 Months,NA,IDN-6556,"IDN-6556 capsules, 25 mg twice daily for 28 days"
NCT01930890,Phase 2,1/1/16,"Study was terminated based on the pre-specified, blinded futility analysis of Study 211LE201 (NCT01499355), which did not demonstrate sufficient efficacy to warrant continuation of the studies. Study was not terminated based on safety considerations.",Results from pre-specified criteria in study NCT01499355 (211LE201) did not demonstrate   sufficient efficacy to warrant continuation of the study,46040,0.071428571,1,14,Up to Week 108,NA,Placebo (211LE201) to BIIB023 3 mg/kg (211LE202),Participants who received placebo Q4W plus MMF and oral corticosteroids in 211LE201 and received BIIB023 3 mg/kg IV Q4W plus MMF and oral corticosteroids through Week 100 in 211LE202.
NCT01930890,Phase 2,1/1/16,"Study was terminated based on the pre-specified, blinded futility analysis of Study 211LE201 (NCT01499355), which did not demonstrate sufficient efficacy to warrant continuation of the studies. Study was not terminated based on safety considerations.",Results from pre-specified criteria in study NCT01499355 (211LE201) did not demonstrate   sufficient efficacy to warrant continuation of the study,46038,0.307692308,4,13,Up to Week 108,NA,Placebo (211LE201) to BIIB023 20 mg/kg (211LE202),Participants who received placebo every Q4W plus MMF and oral corticosteroids in 211LE201 and received BIIB023 20 mg/kg IV Q4W plus MMF and oral corticosteroids through Week 100 in 211LE202.
NCT01930890,Phase 2,1/1/16,"Study was terminated based on the pre-specified, blinded futility analysis of Study 211LE201 (NCT01499355), which did not demonstrate sufficient efficacy to warrant continuation of the studies. Study was not terminated based on safety considerations.",Results from pre-specified criteria in study NCT01499355 (211LE201) did not demonstrate   sufficient efficacy to warrant continuation of the study,46039,0.212121212,7,33,Up to Week 108,NA,BIIB023 3 mg/kg (211LE201) to BIIB023 3 mg/kg (211LE202),Participants who received BIIB023 3 mg/kg Q4W plus MMF and oral corticosteroids in 211LE201 and received BIIB023 3 mg/kg IV Q4W plus MMF and oral corticosteroids through Week 100 in 211LE202.
NCT01930890,Phase 2,1/1/16,"Study was terminated based on the pre-specified, blinded futility analysis of Study 211LE201 (NCT01499355), which did not demonstrate sufficient efficacy to warrant continuation of the studies. Study was not terminated based on safety considerations.",Results from pre-specified criteria in study NCT01499355 (211LE201) did not demonstrate   sufficient efficacy to warrant continuation of the study,46037,0.111111111,3,27,Up to Week 108,NA,BIIB023 20 mg/kg (211LE201) to BIIB023 20 mg/kg (211LE202),Participants who received BIIB023 20 mg/kg Q4W plus MMF and oral corticosteroids in 211LE201 and received BIIB023 20 mg/kg IV Q4W plus MMF and oral corticosteroids through Week 100 in 211LE202.
NCT01937130,Phase 2,2/1/15,Study was terminated early.,Data needs met,45510,0.6,3,5,Adverse events data were collected for a period of 18 months.,NA,IDN-6556 50 mg,"Dosed twice dailyIDN-6556"
NCT01937130,Phase 2,2/1/15,Study was terminated early.,Data needs met,45512,0.6,3,5,Adverse events data were collected for a period of 18 months.,NA,IDN-6556 5 mg,"Dosed twice dailyIDN-6556"
NCT01937130,Phase 2,2/1/15,Study was terminated early.,Data needs met,45509,0.5,2,4,Adverse events data were collected for a period of 18 months.,NA,Placebo,"Dosed twice dailyPlacebo"
NCT01937130,Phase 2,2/1/15,Study was terminated early.,Data needs met,45511,0.857142857,6,7,Adverse events data were collected for a period of 18 months.,NA,IDN-6556 25 mg,"Dosed twice dailyIDN-6556"
NCT01939548,Phase 2,10/1/14,The study was terminated prematurely as a pre-planned interim analysis indicated the study was unlikely to meet the pre-specified efficacy criteria. The decision was not based on any safety concerns.,A pre-planned interim analysis indicated the trial was unlikely to meet the pre-specified   efficacy criteria. The decision was not based on any safety concerns.,44566,0.025641026,2,78,NA,"All treated participants were analyzed for AEs. The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",PF-02545920 5 mg BID,"Participants received 1 placebo tablet and 2 PF-02545920 1 mg tablets twice daily (BID) from Days 1-7, followed by 2 placebo tablets and 1 PF-02545920 5 mg tablet BID from Days 8-84 (treatment phase). Study drug was self-administered orally BID by the participants based on instructions given at the sites. Participants took a total of 6 tablets per day (3 each in the morning and evening)."
NCT01939548,Phase 2,10/1/14,The study was terminated prematurely as a pre-planned interim analysis indicated the study was unlikely to meet the pre-specified efficacy criteria. The decision was not based on any safety concerns.,A pre-planned interim analysis indicated the trial was unlikely to meet the pre-specified   efficacy criteria. The decision was not based on any safety concerns.,44564,0.075,6,80,NA,"All treated participants were analyzed for AEs. The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",Placebo,Participants received 3 placebo tablets from Days 1-84 (treatment phase). Study drug was self-administered orally BID by the participants based on instructions given at the sites. Participants took a total of 6 tablets per day (3 each in the morning and evening).
NCT01954160,Phase 2,12/1/14,Data Safety Monitoring Board (DSMB) terminated trial based upon noted lack of efficacy in manufacturers pivotal trials. Endpoint data not collected or analyzed.,DSMB decision based upon noted lack of efficacy in manufacturers pivotal trials.,42164,0.25,1,4,up to one year post randomization,NA,Early Renal Denervation,"Subjects undergo renal denervation within 2 weeks of baseline visitSymplicity Renal Denervation System"
NCT01958060,Phase 1,4/1/14,"Due to a drug-related Serious Adverse event in the first subject of 100 mg BI 1034020 single iv dose group, the trial was prematurely terminated. No further iv dosing was performed and no planned sc dosing scheme was performed in this trial.",NA,41558,1,1,1,"from the first drug administration to end of trial, up to 50 days",NA,BI 1034020 (100 mg/25 mL - iv),Single dose administration of BI 1034020 (5 mg) diluted with 25mL solution for intravenous (iv) infusion in the morning.
NCT01972776,Phase 2,5/1/15,Part 2 was terminated after 21 patients were enrolled. Three of the 21 patients experienced moderate to severe (up to 17-fold) asymptomatic and reversible elevation of liver transaminase levels after 3 weeks of treatment with QBM076 150 mg bid.,Part 1 was completed. Part 2 was terminated for safety reasons.,39409,0.142857143,1,7,NA,NA,Part 1: Placebo,Part 1: Placebo
NCT01972776,Phase 2,5/1/15,Part 2 was terminated after 21 patients were enrolled. Three of the 21 patients experienced moderate to severe (up to 17-fold) asymptomatic and reversible elevation of liver transaminase levels after 3 weeks of treatment with QBM076 150 mg bid.,Part 1 was completed. Part 2 was terminated for safety reasons.,39408,0.142857143,2,14,NA,NA,Part 2: QBM076 B.I.D 150 mg,Part 2: QBM076 B.I.D 150 mg
NCT01994291,Phase 2,8/1/15,NA,NA,36889,0.070707071,7,99,Baseline to Week 12,NA,PF-04634817 200 mg QD,Participants received 50 mg tablets of PF-04634817 and masked sham therapy.
NCT02007252,Phase 2,10/1/15,NA,The results of a third interim analysis (ad hoc) indicated a lack of efficacy and futility in   continuing the trial.,35690,0.064516129,2,31,NA,NA,ACZ885,Participants received ACZ885 150 mg subcutaneously (s.c.) once per month for 12 months.
NCT02029417,Phase 2,12/1/15,Due to the study's early termination and low accrual no statistical inference of the primary aims were carried forth.,Major revisions needed in study,33247,1,2,2,NA,NA,"Treatment (Cytarabine, Omacetaxine Mepesuccinate, Decitabine)","INDUCTION CHEMOTHERAPY: Patients receive cytarabine SC BID and omacetaxine mepesuccinate SC BID on days 1-14. Treatment for induction therapy repeats every 28 days for up to 4 courses or until patients achieve CR in the absence of disease progression or unacceptable toxicity.CONSOLIDATION THERAPY: Patients alternate courses between decitabine and OAG. Patients receive decitabine IV on days 1-5. Patients alternate with OAG courses, comprising cytarabine SC BID on days 1-7 and omacetaxine mepesuccinate SC BID on days 1-7. Treatment repeats every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity.cytarabine: Given SComacetaxine mepesuccinate: Given SCdecitabine: Given IVlaboratory biomarker analysis: Correlative studies"
NCT02159040,Phase 2,6/1/15,"No conclusion pertaining to efficacy and/or safety was drawn, only one patient was randomized to the study and their study participation was terminated prematurely due to fatal outcome of SAE.Only one patient in trial.No analysis will ever be done.",Only one patient in trial. Stopped for Safety. No analysis will ever be done.,21192,1,1,1,NA,NA,Azacitidine,75mg/m2 7days/28 day cycle
NCT02172755,Phase 1,8/1/02,NA,occurrence of a serious adverse event,20104,0.071428571,1,14,NA,NA,Elderly Subjects,"14 Elderly subjects aged 65 years or more; During the whole study, subjects were to receive a single 600 mg dose of BIA 2-093 (Phase A) followed by 600 mg BIA 2-093 once daily for 8 days in Phase B. Phase B was to begun 96 hours post-Phase A dose.BIA 2-093: During the whole study, subjects were to receive a single 600 mg dose of BIA 2-093 (Phase A) followed by 600 mg BIA 2-093 once daily for 8 days in Phase B. Phase B was to begun 96 hours post-Phase A dose."
NCT02187029,Phase 1,12/1/14,NA,B7911002 was prematurely discontinued due to a safety concern that led to decision to   terminate the study on 10 Nov 2014,19182,0.090909091,1,11,Baseline up to 28 days after last study drug administration.,"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another, or 1 participant may have experienced both an AE and SAE during the study. All treated participants were included in the analysis.",Cohort 2: PF-06743649 5 mg,Participants received PF-06743649 5 mg tablets QD for 2 days before the study was terminated for safety reasons. This cohort was stopped after acute kidney injury was reported in 1 participant.
NCT02201524,Phase 2,9/1/15,The study was terminated early due to changes in the prioritization of the drug development portfolio and the early termination was not safety related.,Study terminated 26 June 2015 due to changes in the drug development portfolio. This study was   not terminated for reasons of safety and/or efficacy,18205,0.071428571,1,14,NA,"The same event may appear as both an AE and a serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.",Placebo,Participants received placebo matched to PF-04965842 tablets orally from Day 1 to 28.
NCT02222207,Phase 2,6/1/15,"As the study was prematurely terminated since pre-defined proof of concept (PoC) criteria were not met in Part A, hence part B was not initiated. Part B related end points and data were not reported since it is not conducted.",NA,16614,0.058823529,3,51,From the start of study treatment until 30 days after last dose of study drug treatment (up to Week 16).,NA,Part A Regorafenib,"Participants self-administered 30 mg/mL, 25 mcL, 1 drop of regorafenib eye drops, topically thrice daily (TID) to the study eye for 12 weeks."
NCT02254551,Phase 2,10/1/15,Early termination of study during dose-escalation did not support continuation of study.,Safety lead-in data did not support continuation of study.,14694,0.285714286,2,7,Treatment-emergent adverse events were collected on Days 1 and 8 of every 21-day cycle for up to 48 weeks (plus 30 days for end of treatment visit).,All patients who received at least one dose of LDE225 plus bortezomib.,Cohort 1: LDE225 400mg/m^2,"Cohort 1 will receive LDE225 orally on a daily basis, at 400mg/m^2 every 21 days.Bortezomib will be administered by subcutaneous injection (SQ) at a fixed dose of 1.3 mg/m2 on days 1, 4, 8, and 11 of each 21 day cycle."
NCT02439138,Phase 2,4/1/16,This study was terminated early due to safety concerns from the previously untreated CLL experience. All participants who remained on study at that time were permanently removed from protocol therapy. The median time on protocol therapy was 1 cycle,Safety issues from trials in CLL,6265,0.8,4,5,"Adverse events were collected from the time of screening until 30 days post treatment discontinuation, up to 16 weeks (median 4 weeks).",NA,GS-1101,"After the screening procedures confirms eligibility to participate in the research study. Treatment will be administered on an outpatient basis.-- Idelalisib (GS-11-01) orally, predetermined dose twice daily per cycle for up to 6 cycles. After this initial 6 month period, for Cycles 7 and beyond, Idelalisib will be administered once a day until disease progression.GS-1101"
NCT02480010,Phase 2,9/1/05,The study was terminated at the time of interim analysis since none of the participants showed a PSA response.,The study was terminated at the time of interim analysis since none of the participants showed   a PSA response.,4937,0.181818182,6,33,Adverse Events were recorded from the date of Screening until 7 weeks after the last infusion of study treatment.,NA,Pertuzumab 1050 mg - Cohort B,Participants in Cohort B received 1050 mg pertuzumab as an IV infusion on Day 1 of each 3-week cycle for a maximum of 36 cycles or until study termination.
NCT02480010,Phase 2,9/1/05,The study was terminated at the time of interim analysis since none of the participants showed a PSA response.,The study was terminated at the time of interim analysis since none of the participants showed   a PSA response.,4938,0.257142857,9,35,Adverse Events were recorded from the date of Screening until 7 weeks after the last infusion of study treatment.,NA,Pertuzumab 420 mg - Cohort A,"Participants in Cohort A received an IV loading dose of 840 mg pertuzumab on Day 1 of Cycle 1 (3-week cycles); from Cycle 2 onwards, participants received IV infusions of 420 mg on Day 1. Treatment continued for a maximum of 36 cycles or until study termination."
NCT02512679,Phase 2,2/1/14,De-escalation was not ensued. All enrolled subjects engrafted without toxicity for dose level one.,Optimal dose obtained for engraftment and minimizing toxicity,3863,0.1,2,20,"Adverse event data was collected throughout the course of the study up to 2 years post transplantation. Subjects were evaluated for post transplant complications related to conditioning, such as VOD, GVHD, infections and engraftment failure.",NA,Cyclophosphamide Dose Level 1,"Cyclophosphamide given by Intravenous (IV) at a total dose of 105 mg/kg, to be divided into three doses of one 35 mg/kg dose per day, for 3 days on the first level.Drug to be given in combination of Busulfan, Campath and FludarabineCyclophosphamide Dose Level 1: given by IV at a total dose of 105 mg/kg, to be divided into three doses of one 35 mg/kg dose per day, for 3 days on the first level. After ten patients the de-escalation will begin if the stopping rule is not met."